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ABSTRACT 
 
Zhixia Yan 
 
Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and 
Simulations to Characterize the Disposition of Orally-Active Antiparasitic Prodrugs and 
Metabolites: Prediction of the Dose-Exposure Relationship in Humans 
 
 (Under the direction of Mary F. Paine, R.Ph., Ph.D. and Kim L.R. Brouwer, Pharm.D., Ph.D.) 
 
Prediction of the disposition and selection of the appropriate dosage regimen of drug 
candidates prior to clinical studies presents a major challenge in drug development. In this 
dissertation project, a multiexperimental approach, including Caco-2 cells, rat isolated 
perfused livers (IPLs), rat and human sandwich-cultured hepatocytes (SCH), a 
plasma/tissue binding assay, and pharmacokinetic modeling was employed to 1) examine 
mechanisms underlying differences in systemic exposure of two active metabolites 
(furamidine and CPD-0801) of respective antiparasitic prodrugs (pafuramidine and CPD-
0868), and 2) quantitatively integrate preclinical and clinical data to elucidate the dose-
plasma/exposure relationship in humans using pafuramidine/furamidine as a model 
prodrug/active metabolite pair. 
Pafuramidine and CPD-0868 exhibited similar permeability properties in Caco-2 
monolayers when the basolateral compartment was supplemented with 4% bovine serum 
albumin, suggesting that the difference in systemic exposure of active metabolites was not 
due to the difference in intestinal permeabilities between the prodrugs. Hepatic 
accumulation of both active metabolites was extensive (>95% of total formed) in rat IPLs 
and SCH. Compared to furamidine, the extent of formation and perfusate/medium exposure 
of CPD-0801 was greater, by ≤2.5- and ≥7-fold, respectively. The unbound fraction of both
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active metabolites in rat liver (fu,L) was lower than that in plasma and perfusate by ≥24-fold; 
fu,L of CPD-0801 was 5-fold higher than that of furamidine (1.6 versus 0.3%). These 
observations suggested that intrahepatic binding influences the disposition of these active 
metabolites. A higher fu,L mostly explained the enhanced perfusate exposure of CPD-0801 
compared to furamidine in rat IPLs. A strong concordance between rat IPL and SCH data 
substantiated SCH as a useful tool to study the hepatobiliary disposition of these 
compounds.  
Pafuramidine/furamidine preclinical and clinical data were used as a training set to 
develop whole-body semi-physiologically-based pharmacokinetic (PBPK) models for rats 
and humans. The PBPK models suggested that the intestine may contribute to pre-systemic 
furamidine formation. Based on the prodrug dose-plasma/exposure relationship predicted by 
the human model, a dosage regimen of pafuramidine, 40 mg/day, was proposed. This 
dissertation project, through integration of preclinical and clinical data with pharmacokinetic 
modeling and simulations, provided a framework to guide dose-ranging studies in humans 
for next-in-class antiparasitic compounds. 
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INTRODUCTION 
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A. HUMAN AFRICAN TRYPANOSOMIASIS  
 
 
A.1.      Overview 
Human African trypanosomiasis (HAT), one of four neglected tropical diseases 
identified by the World Health Organization (WHO) (WHO, 2010a), is transmitted through 
infected tsetse flies. HAT in west and central Africa is primarily a chronic disease caused by 
the protozoan parasite Trypanosoma brucei (T. b.) gambiense; HAT in east and southern 
Africa is primarily an acute and virulent disease caused by T. b. rhodesiense (Barrett et al., 
2007).  HAT has afflicted hundreds of thousands of people in rural areas of sub-Saharan 
Africa. Because of improved HAT control over the past decade, the number of new cases 
reported to WHO in 2009 has decreased to historically low level (<10,000) in 50 years 
(WHO, 2010b). However, political unrest, declining contributions by nongovernmental 
organizations, demographic evolution, climate changes, and reduced funding for HAT 
control all can lead to resurgence of HAT cases, as occurred in the 1980s (Simarro et al., 
2011).  As such, close surveillance and continued research of the disease and treatment 
options must be maintained.  
HAT consists of two stages. The first stage of infection begins when parasites are 
restricted in the hemolymphatic system, accompanied with generalized symptoms, including 
fever, headache, and joint pain. If untreated, the symptoms progress to endocrine, cardiac, 
renal, and/or anemic disorders. Second stage infection occurs when the parasites extend 
their distribution to the central nervous system (CNS), leading to severe neurological 
dysfunction, with the characteristic symptom of breakdown in the sleep-wake patterns, 
hence the more common term for this disease: “sleeping sickness”. Without treatment, the 
disease is 100% fatal, progressing from neurological and psychiatric disorders to coma, and 
ultimately to death (Barrett, 2010). 
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HAT treatment is crucial for reducing the trypanosome reservoir in humans and, 
consequently, for controlling the disease. However, infected individuals often live in 
resource-deficient and insecure areas of Africa with limited access to health care. Disease 
control and management, therefore, are extremely challenged by logistical issues, lack of 
optimal control tools and insufficient financial support for research and development.  
 
A.2.      Current Chemotherapy 
An effective vaccine has not yet been developed for this deadly disease. In addition, 
only four licensed compounds are used currently to treat HAT, the choice of which depends 
on the causative subspecies and disease progression stages (Barrett, 2010). There have 
been no therapeutic advances in more than 40 years. Chemotherapy for both stages of HAT 
has been limited to pentamidine and suramin for first stage infection and melarsoprol, 
eflornithine, and a combination of eflornithine and nifurtimox for second stage infection.  
 
A.2.1.   Chemotherapy for First Stage HAT 
Pentamidine, an aromatic diamidine (Fig. 1.1), was introduced in the early 1940s and 
remains the primary therapy for prophylaxis and treatment of Pneumocystis jirovecii 
pneumonia, several forms of American cutaneous leishmaniasis, and first stage of T. b. 
gambiense HAT (Dorlo and Kager, 2008). The diamidine structure of pentamidine has been 
shown to be essential for antimicrobial activity (Dorlo and Kager, 2008). Despite efficacy 
against the aforementioned infections, pentamidine has a number of untoward effects, 
including severe hypo- or hyper-glycemia, severe hypotension, and nephrotoxicity.  
Suramin, a sulfonated naphthylamine (Fig. 1.1), was introduced in the early 1920s 
and, to date, remains the drug of choice for treatment of the first stage of T. b. rhodesiense 
HAT. Suramin is associated with severe side effects, including collapse, nausea, 
nephrotoxicity and anemia (Bouteille et al., 2003). However, no significant resistance has 
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been observed in preclinical and clinical isolates, which could be due to its ability to inhibit 
multiple pharmacological targets (Fairlamb, 2003) 
Due to the highly hydrophilic nature of both pentamidine and suramin, they have 
poor oral absorption and must be given parenterally; neither drug crosses the blood brain 
barrier in sufficient concentrations to act against the organisms that invade the CNS. 
Therefore, both drugs are only effective against first stage HAT.  
 
A.2.2.   Chemotherapy for Second Stage HAT 
Invasion of parasites into the CNS poses a major challenge in drug development for 
second stage HAT due to the limited ability of many compounds to cross the blood brain 
barrier. To date, the only antitrypanosomal compounds that can reach therapeutic 
concentrations in the central nervous system are melarsoprol and eflornithine, both of which 
have been used for treatment of second stage HAT for many decades (Fairlamb, 2003).  
Melarsoprol, an old organic arsenical compound (Fig. 1.1), has been the drug of 
choice for second stage HAT caused by either T. b. gambiense or T. b. rhodesiense since 
1949 (Fairlamb, 2003). Melarsoprol is a highly lipophilic compound that crosses the blood 
brain barrier by passive diffusion (Nok, 2003). However, because of poor water solubility, 
melarsoprol must be administered intravenously after being dissolved in propylene glycol, 
which is highly irritating to tissues (Nok, 2003). Administration of melarsoprol, therefore, is 
very painful. The standard melarsoprol treatment regimen, which consists of 26-day 
consecutive injections, is protracted and associated with severe adverse effects; up to 10% 
of patients die during treatment from drug-induced reactive encephalopathy (Pepin and 
Milord, 1994). A newer short-course (10-day) alternative regimen demonstrated comparable 
efficacy, but a similar incidence of reactive encephalopathy (Burri et al., 2000).  
Eflornithine (DFMO),  an irreversible inhibitor of ornithine decarboxylase (Fig. 1.1), 
was introduced in the 1970s (Fairlamb, 2003). Eflornithine exhibits excellent penetration into 
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the CNS in humans and is effective against both stages of HAT caused by T. b. gambiense. 
Eflornithine is not recommended for T. b. rhodesiense infection due to innate tolerance of 
this strain to the drug (Iten et al. 1995). Compared to melarsoprol, eflornithine is relatively 
nontoxic with tolerable side effects such as gastrointestinal disturbances and anemia. 
However, the dosage regimen, which consists of 400 mg/kg per day in four daily infusions 
over 2 h for at least ten days, is burdensome and costly because it requires in-patient 
hospitalization. All of these factors limit the widespread use of eflornithine in rural areas of 
Africa with limited resources (Bouteille et al., 2003).  
Nifurtimox, a nitroheterocyclic compound (Fig. 1.1), originally was developed for 
treatment of American trypanosomiasis (Chaga’s disease). The major advantage of 
nifurtimox is that it is orally active. Common side effects include neurological dysfunction 
and gastrointestinal tract disorders (Bouteille et al., 2003). Nifurtimox has been used as a 
companion drug to treat second stage HAT when other treatments (melarsoprol or 
eflornithine) have failed.  
Nifurtimox-Eflornithine Combination Therapy (NECT) was included in the WHO 
Essential List of Medicines as a new treatment option for second stage T. b. gambiense 
HAT in 2009 (WHO, 2009). Eflornithine combined with nifurtimox offers a more feasible 
treatment regimen, by significantly reducing the frequency and number of eflornithine 
infusions from four times daily for 2 weeks to twice daily for one week combined with 
nifurtimox administered orally three times daily for 10 days; this combination has shown 
equivalent effectiveness without increased side effects compared with eflornithine alone 
(Barrett, 2010).  Furthermore, this combination may decrease the emergence of resistance 
to monotherapy and avoid the risk of severe adverse events associated with melarsoprol 
(encephalopathy). Despite these advantages, NECT has a number of limitations: it is less 
effective against T. b. rhodesiense HAT and requires administration of two drugs (IV and 
oral) for 7-10 days, which is a relatively complicated regimen.  
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In conclusion, although all of the current treatments for both stages of HAT have 
been used for decades, none of them are satisfactory.  Increasing rates of treatment failures 
due to parasite resistance, inconvenient regimens, painful formulations, significant adverse 
events, costly regimens, and involvement of specialized health personnel are all limitations 
of current therapies. Parenteral administration due to poor oral bioavailability poses 
significant challenges in remote regions of Africa where this disease is prevalent. Limitations 
of current chemotherapies highlight the desirable features of new drugs for HAT treatment 
(DNDi, 2009), which include: 1) low toxicity; 2) oral activity; 3) efficacy towards both stages 
of HAT; 4) a broad spectrum against both T. b. gambiense and rhodesiense; 5) short 
treatment duration; 6) product stability over long-term storage; and 7) affordability. Without 
question, an orally-active drug with a convenient treatment regimen and a low potential for 
toxicity would have great clinical benefit in the treatment of both stages of HAT.  
 
B. ORALLY-ACTIVE PENTAMIDINE ANALOGUES 
Pentamidine (Fig. 1.1) has been used clinically since 1939 and remains an important 
agent to treat first stage HAT despite a loss of activity when administered orally and toxicity 
when administered intravenously. The diamidine structure of pentamidine has been shown 
to be essential for antimicrobial activity, which is assumed to result from binding to the minor 
groove of DNA at AT-rich regions (Barrett et al., 2007). The exact mechanism of action of 
pentamidine is currently unknown. Of the many structurally related compounds that have 
been synthesized and tested to date, the dicationic agent, 2,5-bis(4-amidinophenyl)furan 
(furamidine; Fig. 1.2) has emerged as the most promising agent in terms of efficacy and 
toxicity when administered intravenously.  However, like pentamidine, furamidine has the 
diamidine moiety (pKa ≈10), which carries positive charges at physiological pH and limits the 
ability of furamidine to cross the intestinal epithelia when administered orally. As such, a 
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prodrug strategy that focuses on attempting to mask these positive charges with O-alkyl 
moieties was devised to improve the oral bioavailability of diamidine. 
 
B.1.      Pafuramidine  
Pafuramidine (Fig. 1.2) (Boykin et al., 1996), a methylamidoxime prodrug of 
furamidine, exhibits enhanced intestinal permeability and oral activity in mouse and monkey 
models (Zhou et al., 2002). To date, pafuramidine is the only orally available agent that has 
shown promise in clinical trials for the treatment of first stage HAT (Paine et al., 2010). In a 
multi-center phase III trial conducted from 2005 to 2007, 273 patients were enrolled and 
randomized to treatment with pafuramidine (100 mg oral, twice daily for 10 days) or 
pentamidine (4 mg/kg intramuscular, once daily for 7 days). Pafuramidine demonstrated 
promising efficacy, comparable to pentamidine; the 24-month post-treatment efficacy was 
84% and 89%, respectively (Paine et al., 2010). As requested by the U.S. Food and Drug 
Administration, an expanded phase I safety study was initiated in late 2007 involving healthy 
indigenous African volunteers, and the treatment regimen was extended from 10 to 14 days. 
During this study, approximately 25% of subjects developed transiently elevated liver 
transaminases five days after completion of the 14-day dosage regimen. This adverse event 
placed pafuramdine development program on clinical hold 
(www.immtechpharma.com/documents/news_022208.pdf) (Paine et al., 2010). Mechanisms 
responsible for pafuramidine-induced elevated hepatic signals currently are being 
investigated in preclinical models. 
Bioactivation of pafuramidine to the active metabolite, furamidine, is believed to 
occur primarily in the liver. The metabolic pathway involves sequential oxidative O-
demethylation reactions catalyzed by multiple cytochrome P450 enzymes (notably, 
CYP4F2/3B) and reductive N-dehydroxylation reactions catalyzed by cytochrome b5/NADH 
cytochrome b5 reductases (Fig. 1.3) (Saulter et al., 2005; Wang et al., 2006). In rats 
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administered a single oral dose (10 mg/kg) of 14C-pafuramidine, total radioactivity, largely as 
furamidine, accumulated in the liver at substantially higher concentrations (~1300 fold) than 
those measured in plasma 24 hr post-administration; radioactivity was still measurable in the 
liver after seven days (Midgley et al., 2007). Validation of a rat toxicity model currently is 
being undertaken by our collaborators at the Hamner Institute for Health Sciences (RTP, 
NC). Preliminary results showed that pafuramidine demonstrated dose-dependent elevation 
of liver transaminases in rats (unpublished observations). Furamidine is generated primarily 
in the liver, where accumulation of furamidine increases with increment of pafuramidine 
dose.  Whether furamidine accumulates in livers of humans in vivo is not known.   
 
B.2.      2, 5-Bis [5-(N-methoxyamidino)-2-pyridyl] furan (CPD-0868) 
Drug treatment for second stage infection still relies on the old monotherapy 
(melarsoprol or eflornithine) and newly approved combination therapy (NECT), all of which 
require complicated/protracted treatment and inconvenient parenteral administration. Both 
pafuramidine and furamidine were unsuccessful for treatment of second stage infection 
because of limited access of furamidine to the brain (Mdachi et al., 2009). Structural analogs 
currently are being tested in various in vitro and in vivo systems, one of which is 2, 5-bis (5-
amidino)-2-pyridyl) furan (CPD-0801; Fig. 1.2).  
In vitro IC50 studies indicated that CPD-0801 was highly potent against both T. b. 
gambiense and rhodesiense, similar to furamidine and pentamidine. In vivo studies with a 
second stage mouse model administered CPD-0801 (20 mg/kg intraperitoneal, once daily 
for 10 days) demonstrated 100% cure; infected mice survived for more than 180 days after 
infection without showing a parasitemia relapse (Wenzler et al., 2009). Under the same 
experimental conditions, neither furamidine nor pentamidine showed efficacy against 
second stage infection in mice (Wenzler et al., 2009). An acetate salt of CPD-0801 (CPD-
0802) is currently under consideration for clinical testing in the treatment of second stage 
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HAT (Paine et al., 2010). Despite promising efficacy, CPD-0801 is an aromatic diamidine 
and exhibits poor oral activity due to inherent hydrophilic properties. Therefore, its methoxy 
prodrug, 2, 5-bis [5-(N-methoxyamidino)-2-pyridyl] furan (CPD-0868; Fig. 1.2), was 
synthesized.  
CPD-0868, a structural analog of pafuramidine, differs from pafuramidine by a single 
nitrogen incorporated into both phenyl rings. CPD-0868 was shown to be effective against 
both first and second stage infection in mice (Wenzler et al., 2009). Despite the remarkable 
structural similarity, CPD-0868 demonstrated a much higher cure rate compared to 
pafuramidine (4/5 versus 1/5) when administered at a oral dose of 50 mg/kg once daily for 
10 days in a second stage mouse model (Wenzler et al., 2009). Systemic exposure of the 
corresponding active metabolite (CPD-0801) was higher than that of furamidine, the active 
metabolite of pafuramidine (Wu et al., 2007). Higher systemic concentrations of CPD-0801 
could lead to enhanced brain exposure of this active metabolite, and hence, adequate 
therapeutic concentrations to kill the parasites in the brain. These results supported the 
hypothesis that CPD-868 may be a promising prodrug for treatment of second stage HAT.  
 
C. INTEGRATION OF PRECLINICAL AND MATHEMATICAL MODELS TO OPTIMIZE 
PRODRUG DOSE-SELECTION STRATEGY 
 
Successful completion of proof-of-concept phase II and multi-center phase III trials of 
pafuramidine were promising milestones in the development of this orally-active agent for 
patients who are suffering from this devastating disease without proper treatment. However, 
the transiently elevated liver transaminases observed in the subsequent safety study 
involving indigenous African healthy volunteers suspended the development of this 
promising agent (www.immtechpharma.com/documents/news_022208.pdf) (Paine et al., 
2010).  Although pafuramidine is no longer under development, there are many promising 
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compounds currently under preclinical evaluation,  including CPD-0868, a lead candidate for 
both first and second stages of HAT (Wenzler et al., 2009).  
Drug-induced toxicity is the primary cause of attrition of compounds during drug 
development and post-marketing withdrawals in recent years. Approximately 6.7% of 
hospitalized patients suffer serious adverse drug reactions, defined as those resulting in 
hospitalization or causing disability or death; adverse drug reactions are the sixth leading 
cause of death in the United States (Lazarou et al., 1998). It is important to realize that 
absolute toxicity is rare. Relative toxicity is more common and may be influenced by many 
factors such as disease processes, dose/frequency/duration of treatment regimens, ADME 
properties, and drug/diet-drug interactions. In the case of orally-active antiparasitic agents, 
suspension of the pafuramidine program during late stage clinical studies was not attributed 
to a lack of efficacy, but to an overt drug-induced adverse event. Based on tissue 
distribution studies in rats administered a single oral dose of pafuramidine (10 mg/kg), 
furamidine was sequestered significantly in the liver (Midgley et al., 2007). Whether or not 
extensive accumulation of furamidine in the liver triggered pafuramidine-induced elevation of 
liver transaminases in human subjects remains unclear.  As mentioned previously, CPD-
0868 demonstrated a higher efficacy and an enhanced systemic exposure of derived active 
metabolite, CPD-0801, compared to pafuramidine/furamidine in a second stage mouse 
model (Wu et al., 2007; Wenzler et al., 2009).  In rats administered a single oral dose of 
CPD-0868 or pafuramidine (30 μmol/kg), CPD-0801 exhibited 7- and 40-fold less kidney 
retention compared to furamidine, six hours and eight days post administration of respective 
prodrug, respectively (Goldsmith, 2011). These observations emphasized the need to gain 
an improved understanding of the relationship between dose and systemic or tissue 
exposure, as well as their interrelation to efficacy and safety profiles of these antiparasitic 
prodrugs and active metabolites. 
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Drug efficacy results from the complex interplay of several pharmacokinetic 
processes, including intestinal absorption, distribution into blood and tissues, phase I and/or 
II metabolism, and renal and/or fecal drug excretion, which act in concert to provide 
pharmacologically active concentrations at the site of the respective target, e.g., the parasite 
in the brain during second stage HAT. After oral administration, the prodrugs pafuramidine 
and CPD-0868 must first traverse the intestinal epithelium and reach the bioactivation site 
(gut and/or liver) where they are metabolized to the respective active compounds, 
furamidine and CPD-0801, through complicated metabolic pathways (Fig. 1.3) (Zhou et al., 
2004; Generaux, 2010). The fact that insertion of a single nitrogen into each phenyl ring of 
pafuramidine led to improved efficacy of CPD-0868 towards second stage infection and 
enhanced systemic exposure of the corresponding active metabolite (CPD-0801) may be 
reflected by the differences in the intestinal and hepatobiliary disposition between the two 
prodrug/active metabolite pairs.  
To address these important issues, careful selection of relevant and predictive model 
systems is critical to quantify the impact of both intestinal/hepatic transport and metabolism 
on the overall disposition of these prodrugs/metabolites. Coupled with mathematical 
modeling, this integrated approach can provide valuable insight into the intestinal and 
hepatobiliary disposition of these compounds by assigning significance to each process and 
identifying the key step(s) that governs the systemic/tissue exposure of these active 
metabolites. 
 
C.1.      Preclinical Models 
A compound will not be an effective drug, regardless of the extent of 
pharmacological activity, unless it is well absorbed, distributed to the target site, metabolized 
and eliminated in a suitable manner. The ideal antiparasitic prodrug should be rapidly and 
almost completely absorbed from the gut, and reach the primary bioactivation site in the liver, 
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where it is efficiently converted to the active metabolite.  Once formed, the active metabolite 
should be efficiently excreted from the liver and reach sufficient concentrations in the 
systemic circulation to kill the parasites in the hemolymphatic system (first stage), or in the 
brain to elicit antitrypanosomal effects in the central nervous system (second stage). It is 
also important that prodrugs and derived active metabolites do not accumulate to a toxic 
level in the target organs. In order to identify compounds that possess the aforementioned 
desirable ADME features, proper selection of in vitro and in vivo model systems with 
descriptive and predictive capabilities is imperative.  
 
C.1.1.   Intestinal Absorption Models 
 Transport of compounds across the intestinal membrane is a complex and dynamic 
process, and dictated by various influx and efflux mechanisms via transcellular (passive 
diffusion or carrier/transporter-mediated process) and paracellular (via the tight junctions 
between the enterocytes) routes (Artursson et al., 2001). Many techniques have been 
developed and utilized to evaluate the intestinal permeability of drug candidates during early 
drug discovery (Miret et al., 2004; Penzotti et al., 2004). The commonly used methodologies 
include: in vitro systems, such as animal tissue-based Ussing chamber and membrane 
vesicles, human colon adenocarcinoma cell line (Caco-2) and Mardin-Darby canine kidney 
(MDCK), parallel artificial membrane permeability assay (PAMPA) and immobilized artificial 
membranes (IAM);  in situ intestine perfusion; in vivo animal studies; and in silico methods 
(Balimane et al., 2000; Lennernas, 2007). Artificial membrane-based systems and 
computer-based models are high-throughput screening tools, but the lack of mechanistic 
basis of these methods often causes less predictive results; although more predictive, in situ 
and in vivo studies are animal- and labor-intensive. As such, in vitro models, which are 
balanced between predictability and throughput, are the method of choice for permeability 
assessment in both academic and industrial settings. 
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Among all the in vitro models, the Caco-2 cell monolayer permeability assay is the 
most popular and well-recognized model in drug permeability studies (Artursson and 
Karlsson, 1991). Upon culture, Caco-2 cells differentiate and become confluent to form 
monolayers with tight junctions and polarized apical (A; gut lumen) and basolateral (B; blood) 
membranes that are structurally and functionally similar to those of enterocytes in vivo (Sun 
et al., 2008). Multiple uptake and efflux transporters, such as breast cancer resistance 
protein (BCRP), P-glycoprotein (P-gp), multidrug resistance protein (MRP), organic anion-
transporting polypeptide (OATP), and organic cation transporter (OCT) also are expressed 
and functional in Caco-2 cells (Hirohashi et al., 2000; Kobayashi et al., 2003; Muller et al., 
2005; Sun et al., 2008). In addition, phase II drug metabolizing enzymes, such as 
sulfotransferases and glutathione S-transferases reside in the Caco-2 cells (Peters and 
Roelofs, 1989; Sun et al., 2008). Although some phase I enzymes, particularly CYP3A4, are 
lacking in Caco-2 cells, medium supplemented with 1α,25-dihydroxy-vitamin-D3 (1α,25-
(OH)2-D3) can induce the CYP3A4 enzyme levels in a dose-dependent manner (Schmiedlin-
Ren et al., 1997). In addition to CYP3A4 enzyme, expression and activity of various 
transporters including P-gp, MRP1, and MRP2 also are significantly increased (p<0.05) in 
1α,25-(OH)2-D3-treated Caco-2 cells (Fan et al., 2009). These characteristics of Caco-2 cells 
allow for studying both intestinal metabolism and transport in a single cell-based system.  
Previous studies showed that absorptive permeability coefficient (Papp,A→B) of drugs 
derived in Caco-2 cell monolayers correlates well with the fraction of compound absorbed (fa) 
measured in humans in a sigmoidal shape (Artursson and Karlsson, 1991; Keldenich, 2009). 
According to Artursson and Karlsson, compounds that have Papp,A→B greater than 1 × 10-6 
cm/s in Caco-2 cells may be absorbed completely from the small intestine in humans. 
Another report showed that only drugs that have Papp,A→B greater than 7 × 10-6 cm/s are 
considered to be highly permeable (fa ≈ 100%) (Keldenich, 2009). It is well known that the 
main limitation of Caco-2 is the inter-laboratory variability (Stewart et al., 1995; Dressman et 
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al., 2008); the thresholds for permeability classification are, therefore, assay-specific and 
may differ from lab to lab. Papp,A→B value may not accurately predict fa when drugs are 
absorbed primarily via a paracellular route or transporters due to the narrower tight junctions 
and over- or under-expression of transporters in Caco-2 cells, respectively (Chong et al., 
1996; Collett et al., 1996; Yee, 1997). 
In addition to the permeability across the intestinal membrane, formulations and 
physicochemical properties including molecular weight, solubility, lipophilicity, pKa also are 
important determinants in the prediction of fa in humans (Keldenich, 2009). Following oral 
administration, the compound must be released from the dosage form, dissolved in the 
gastrointestinal (GI) fluids to be available in solution form at the sites of absorption (i.e., 
intestine). The Biopharmaceutical Classification System (BCS), provided by U.S. Food and 
Drug Administration, categorizes compounds into one of the four biopharmaceutical classes 
based on their water solubility and membrane permeability and allows the prediction of the 
rate-limiting step in the intestinal absorption process following oral administration (Polli et al., 
2008). In addition, food components also can play a role in the oral absorption of drugs, 
especially for poorly water-soluble but highly permeable compounds, absorption of which is 
usually bolstered when drugs are administered with food (Welling, 1996). Therefore, results 
with Caco-2 cells need to be considered within the context of other factors in the estimation 
of fa in humans.  
 
C.1.2.   Hepatobiliary Models 
After oral administration and absorption through the GI tract, drugs reach the primary 
clearing organ, the liver, where compounds can be metabolized by phase I or II enzymes, 
sequestered in the liver, excreted into bile, and/or effluxed back to the systemic circulation. 
Hepatobiliary disposition may play an important role in the overall therapeutic and/or 
toxicologic profile of a drug. For this reason, preclinical hepatic models that can accurately 
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resemble in vivo disposition of drug candidates in the liver can provide a mechanistic 
understanding of the hepatic disposition of a compound at an early developmental stage. 
Several in vitro or ex vivo hepatic models have been developed in the past few decades, 
including microsomes, cytosol, S9 fraction, cell lines, primary hepatocytes, liver slices, and 
perfused liver (Brandon et al., 2003). Model selection depends on the purpose of the study 
(e.g. phenotyping, biotransformation pathways, drug-drug interactions, hepatic uptake, 
and/or biliary excretion). In order to accurately investigate the overall hepatobiliary 
disposition of compounds, polarized whole-cell model systems must be utilized.  
Isolated perfused livers (IPLs) are the most physiologically-relevant ex vivo hepatic 
model because this model most closely approximates the whole liver in vivo (Brouwer and 
Thurman, 1996). Depending on the study objectives, IPLs can be performed in a either 
single-pass or recirculating manner; corresponding surgical procedures and experimental 
conditions have been described (Xiong et al., 2000; Ward et al., 2001; Zamek-Gliszczynski 
et al., 2006).  In contrast to in vitro models including microsomes, isolated/cultured 
hepatocytes, and liver slices, IPLs preserve hepatic architecture, cell polarity, and bile flow 
in the absence of the influences from in vivo non-hepatic and neural-hormonal effects 
(Gores et al., 1986). Besides, IPLs allow repeated sampling of perfusate, permit easy 
exposure of the liver to different concentrations of “victim” (test substrate) and “perpetrators” 
(inhibitors or inducers of metabolism and transport), and are amenable to alterations in 
physiology (blood flow and/or disease state) that would not be tolerated or feasible in vivo 
(Brouwer and Thurman, 1996). These advantages make IPLs a valuable model to elucidate 
the impact of the physiologic, pathologic, and pharmacologic factors on the hepatobiliary 
disposition of xenobiotics. Despite all these advantages, there are a number of reasons why 
IPLs are not used routinely, especially in the industry setting. The availability of viable 
human livers is limited due to ethical reasons, and livers from preclinical species may not be 
a useful predictor of drug disposition in humans. Furthermore, IPLs are labor intensive, 
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require delicate surgical procedures, and the functional integrity of metabolic systems and 
biliary excretion typically is limited to 2 h (Brouwer and Thurman, 1996). 
Sandwich-cultured hepatocytes (SCH) represent an alternative in vitro model to 
study the hepatobiliary disposition of xenobiotics (Dunn et al., 1989). Primary hepatocytes 
from animals or humans cultured between two layers of gelled collagen form extensive bile 
canalicular networks (LeCluyse et al., 1994). When hepatocytes are cultured in a collagen-
sandwich configuration, the cells differentiate, allowing for sinusoidal and canalicular 
transport protein localization to the proper domain.  SCH may represent a useful tool for 
investigating the hepatobiliary disposition of compounds. However, a major limitation of SCH 
is the decrease in cytochrome P450 enzyme activities observed over days in culture (Hoen 
et al., 2000; Boess et al., 2003). Medium supplemented with inducers such as phenobarbital 
and dexamethasone  (DEX) can reverse the decline in enzyme expression and maintain the 
enzyme levels comparable to in vivo conditions, as determined by gene expression and 
enzyme activity analysis (Kienhuis et al., 2007).  
Because of the presence of complete phase I/II metabolizing enzymes and cofactors, 
SCH are an appropriate system for metabolite identification and metabolic stability 
evaluation. These applications are supported by numerous reports on the similarity in 
metabolite profiles between SCH and in vivo models (Ansede and Brouwer, 2008; Wolf et al., 
2008; Yan et al., 2011). A handful of literature reports demonstrated that SCH also are 
capable of  studying drug-drug interactions at the levels of both hepatic uptake/efflux and 
metabolic processes (Annaert and Brouwer, 2005; Hewitt et al., 2007a; Lengyel et al., 2008; 
Jackson et al., 2009). Another advantage of SCH is its ability to differentiate the contribution 
of transporters via RNA interference (RNAi) of single or multiple transport proteins, 
particularly when probe substrates or inhibitors are not available. This technique showed 
success in specifically knocking down Bcrp/BCRP and Oatp/OATP in rat and human SCH 
(Yue et al., 2009; Liao et al., 2010).  
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Drug-induced liver injury (DILI) is the most common reason for safety-related drug 
marketing withdrawals and is a primary toxicological cause of attrition during drug 
development. Many hepatotoxic compounds are not recognized in preclinical species until 
later clinical studies, indicating that tolerability to toxic substances varies between animals 
and humans. Therefore, a human-derived in vitro model that can accurately predict DILI at 
early preclinical stage is highly needed.  Bosentan, an endothelin receptor antagonist for the 
treatment of pulmonary arterial hypertension, demonstrated hepatotoxicity in humans, but 
not in rats (Fattinger et al., 2001; Cohen et al., 2004). Using rat and human SCH, the 
mechanism of bosentan-induced preferential hepatotoxic effect in humans was explained by 
a differential inhibition of Na+-dependent taurocholate cotransporting polypeptide 
(Ntcp/NTCP) between the two species, resulting a greater extent of intrahepatic 
accumulation of bile acid in humans (Leslie et al., 2007). Studies on hepato-protective effect 
of DEX against trabectedin-mediated cytotoxicity further substantiated SCH as a useful in 
vitro model to assess and predict the hepatotoxicity of xenobiotics (Lee et al., 2008).  
SCH, cultured in different formats (6- to 96-well plates), are widely utilized in both 
industrial and academic research settings because of the versatility of this in vitro system to 
address a variety of scientific questions and applications. Compared to ex vivo (e.g. IPLs) 
and in vivo models, SCH represent a higher-throughput and more cost-effective system by 
significantly reducing the number of animals and amount of compounds required for 
experimentation. In addition, SCH from humans offer significant advantages over existing 
methodologies (e.g. liver microsomes and suspended/conventionally-cultured hepatocytes) 
to characterize and predict human biotransformation and transport processes. 
 
C.2.      PBPK Modeling-Based Dose-Selection Strategy 
Once the differential influence of ADME factors on the overall disposition of prodrugs 
and active metabolites is elucidated, translation of these results together with previously 
 18
generated preclinical data to make them therapeutically meaningful is warranted. This 
translational step is crucial to fill the gap between scientific research at the preclinical stage 
and the application of this information to the clinical setting.  
Selection of an appropriate dosage regimen is essential in clinical drug development 
of drug candidates that have shown therapeutic promise in preclinical evaluations. If too 
high of a dose is selected, immediate toxicity and early termination of the drug candidate 
may occur.  If too low of a dose is selected, it will add unnecessary testing and expense to 
the dose-ranging studies (Peck and Cross, 2007). Estimating the starting dose is a 
complicated and important task, and yet there is little uniformity or standardization of 
approaches. Dose calculations are performed in many different ways, often using empirical 
methods (Poulin and Theil, 2002). The approach used often depends on the training and 
experience of the scientists involved, and/or clinically used dosing regimens of structurally 
similar analogs. A mechanism-based approach is needed to select the right dose on a less 
empirical, more rational basis. Integration of the pharmacokinetic and pharmacodynamic 
properties of drug candidates utilizing mathematical model-based drug-development 
techniques would provide a sound scientific strategy for efficient dose optimization (Zhang et 
al., 2006; Lalonde et al., 2007; Wetherington et al., 2010). 
Empirical allometric scaling, based on body weight, is a commonly used method for 
extrapolating doses from animals to humans (Ito and Houston, 2005). Although many drugs 
are well predicted in humans from animal data using this method, some fail in the scaling 
exercise. For compounds that are distributed by passive distribution and that are mainly 
eliminated through hepatic metabolism or glomerular filtration, allometric scaling can provide 
relatively good predictions in pharmacokinetics for humans. In contrast, such method have 
proven to be of limited value for compounds that show large interspecies differences in the 
distribution and excretion processes (Mahmood, 2000).  
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Physiologically-based pharmacokinetic (PBPK) modeling, initially used in the areas 
of environmental toxicology and human health risk assessment, has been increasingly 
accepted and utilized in drug development over the years, primarily as a means to 
extrapolate pharmacokinetic behaviors from animals to humans (Andersen and Krishnan, 
1994; Bjorkman et al., 2001; Germani et al., 2005; Chiu et al., 2007; Germani et al., 2007).   
Unlike empirical allometric scaling, PBPK modeling includes specific tissue compartments 
involved in exposure, toxicity, metabolism, and biliary/renal excretory processes associated 
with blood flow (Fig. 1.4). Because compartments and blood flows are described using 
physiologically-relevant parameters, extrapolation between species can be performed by 
altering these physiological parameters (Rowland et al., 2004).  
In most cases, tissues are considered as “well-stirred” compartments, where the 
distribution of compounds between organs and blood is determined only by the flow rate of 
blood perfusing the organ (flow-limited kinetics); on the subtissue level, tissue blood and 
intracellular space can be further separated when diffusion across physiological membrane 
barriers becomes the rate-limiting step in the distribution of compounds within tissues 
(diffusion-limited kinetics) (von Kleist and Huisinga, 2007; Evans et al., 2008). Tissue-to-
plasma partition coefficient (Kp) is a key parameter to describe the rate and extent of 
distribution of a compound between the two compartments. Kp is often measured by either in 
vivo animal studies under the steady-state conditions or in vitro equilibrium dialysis (Kousba 
and Sultatos, 2002). However, this measurement process is elaborate, limiting the 
widespread use of PBPK modeling. It has become increasingly popular and accepted to 
estimate Kp based on physicochemical properties of compounds such as lipophilicity and 
pKa (Poulin and Theil, 2000; Rodgers and Rowland, 2006). However, when active transport 
processes are involved, Kp of compounds needs to be determined experimentally.  
Hepatic clearance (ClH) also is a very important parameter that dictates the overall 
disposition of compounds. Methods for predicting human in vivo ClH from in vitro systems 
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(e.g., hepatocytes and microsomes) and in vivo animal models have been described in 
detail (Obach, 1999; Luttringer et al., 2003; Ito and Houston, 2005; Lipscomb and Poet, 
2008). Through the incorporation of these drug-specific ADME properties derived from in 
silico, in vitro, ex vivo, and in vivo systems into the model, PBPK modeling is capable of 
extrapolating between routes of exposure (intravenous versus oral), species (rat versus 
human), and dosage regimens (single versus multiple dose).  For this reason, dosage 
regimens can be selected based upon model simulations on plasma/tissue concentration-
time profiles and anticipated therapeutic and safety margins of compounds (Parrott et al., 
2005). 
Dose selection for antiparasitic drugs traditionally has relied on correlations between 
plasma concentrations in animal models and humans. Clinically-used dosage regimen of 
pafuramidine also was selected based on this method.  However, the relationship between 
pafuramidine dose and furamidine plasma/tissue exposure is not known. This prodrug/active 
metabolite pair has been studied in multiple preclinical species (mice, rats, and monkeys) 
and humans by different collaborative labs and institutes involved in the Consortium for 
Parasitic Drug Development (CPDD). A large body of pafuramidine/furamidine 
pharmacokinetic and efficacy/safety data exists in various in vitro and in vivo model systems. 
The mechanistic and physiologic nature of PBPK modeling served as an ideal platform to 
combine all the preclinical/clinical results in an integrated manner to predict the dose-
plasma/tissue exposure relationship. In this dissertation project, additional preclinical models 
(in vitro and ex vivo) were selected and implemented in the mechanistic investigations of the 
intestinal and hepatobiliary disposition of pafuramidine and CPD-0868 and respective active 
metabolites, furamidine and CPD-0801. With the aid of PBPK models developed in this 
project, concentration-time profiles of furamidine in plasma and tissue (liver and kidney) 
were simulated under various dosing scenarios in humans. The dose-plasma/exposure 
relationship was predicted for the model antiparasitic prodrug/active metabolite pair, 
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pafuramidine and furamidine. This PBPK modeling-based strategy could be applied to next-
in-class compounds to guide dose-ranging studies in humans. 
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D.        OVERVIEW OF PROJECT 
Human dose projection is a key component of preclinical development before 
initiation of the first-in-human study. Selection of a first-in-human dose plays an important 
role in the anticipation of therapeutic-safety index, allowing for early discrimination of 
selection of potential drug candidates for later phase II/III trials. An appropriate dosage 
regimen should allow the drug candidate to achieve therapeutic concentrations at the site of 
action for a suitable duration of time, while maintaining these concentrations associated with 
a desirable safety profile. Therefore, preclinical studies should not only focus on the 
evaluation of efficacy, safety, and PK profiles in various preclinical models, but also the 
prediction of clinical outcomes via  quantitative integration of preclinical data.  
In this dissertation project, pafuramidine, a prodrug of furamidine, and CPD-0868, a 
prodrug of CPD-0801, were selected as model prodrug/active metabolite pairs for 
investigation of these aforementioned issues. Pafuramidine was the only orally-active agent 
that entered clinical trials for treatment of first stage HAT (Paine et al., 2010). However, 
clinical development of pafuramidine was suspended due to transiently elevated liver 
transaminases observed in an expanded phase I safety study 
(http://www.immtechpharma.com/documents/news_022208.pdf) (Paine et al., 2010). 
Furamidine exhibited extensive hepatic retention in rats following a single oral dose of 
pafuramidine (Midgley et al., 2007). CPD-0868, a lead candidate for oral treatment of 
second stage HAT, currently is under preclinical development. The active metabolite, CPD-
0801 exhibited a greater systemic exposure than furamidine, despite remarkable structural 
similarity between these two active metabolites (Wu et al., 2007). An improved mechanistic 
understanding of the disposition and the dose-exposure relationship of these prodrugs and 
metabolites is needed. These unaddressed important issues serve as the foundation for the 
central hypothesis and aims of this dissertation.  
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Central Hypothesis: Integration of preclinical data and mechanism-based 
pharmacokinetic modeling can elucidate mechanisms underlying the difference in 
systemic/tissue exposure between the two antiparasitic active metabolites, and provide a 
framework for prediction of the disposition and the dose-plasma/tissue exposure relationship 
of prodrugs/metabolites in humans. 
To test this hypothesis, a multiexperimental approach, which included the human 
intestinal cell line Caco-2, rat isolated perfused livers (IPLs), rat and human sandwich-
cultured hepatocytes (SCH), a plasma/tissue binding assay, and pharmacokinetic 
(compartmental/noncompartmental and PBPK) modeling, was employed as outlined in the 
following specific aims: 
AIM #1. CHARACTERIZE AND COMPARE THE INTESTINAL DISPOSITION OF THE 
PRODRUGS PAFURAMIDINE AND CPD-0868 USING THE HUMAN INTESTINAL CELL LINE CACO-2.  
 
Hypothesis: The improved efficacy of the prodrug CPD-0868 compared to 
pafuramidine is due to superior permeability through the intestinal epithelium, which results 
in increased hepatic exposure to CPD-0868. 
1.a. Determine the permeability coefficient (Papp) of pafuramidine and CPD-0868 
across Caco-2 cell monolayers (A→B and B→A) under serum-free conditions. 
1.b. Determine the permeability coefficient (Papp) of pafuramidine and CPD-0868 
across Caco-2 cell monolayers (A→B) under “sink” conditions (addition of 4% BSA into the 
B compartment) 
 1 c. Evaluate the accumulation of pafuramidine and CPD-0868 in Caco-2 cells. 
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AIM #2. ELUCIDATE MECHANISMS UNDERLYING THE DIFFERENCE IN SYSTEMIC 
EXPOSURE OF ACTIVE METABOLITES, FURAMIDINE AND CPD-0801, BY COMPARING THE 
HEPATOBILIARY DISPOSITION OF RESPECTIVE PRODRUGS AND DERIVED METABOLITES IN TWO 
PRECLINICAL HEPATIC MODELS. 
 
Hypothesis: The enhanced systemic exposure of CPD-0801 compared to 
furamidine reflects superior hepatobiliary disposition characteristics, including a greater 
extent of conversion, less intrahepatic sequestration, and/or more efficient excretion of CPD-
0801 from hepatocytes into the systemic circulation. 
2.a. Quantify in recirculating isolated perfused livers (IPLs) from rats the extent of 
conversion of each prodrug to the corresponding active metabolite and the hepatocellular 
accumulation, biliary excretion and basolateral efflux of each prodrug and derived 
metabolites. 
2.b. Quantify in sandwich-cultured hepatocytes (SCH) from rats the extent of 
conversion of each prodrug to the corresponding active metabolite and the hepatocellular 
accumulation, biliary excretion and basolateral efflux of each prodrug and derived 
metabolites. 
2.c. Utilize the data generated from AIMS 2a and 2b and compartmental 
pharmacokinetic modeling to compare the hepatobiliary disposition of pafuramidine and 
CPD-0868 and derived metabolites, and elucidate the predominant process(es) that govern 
the hepatic disposition of respective active metabolites. 
2.d. Compare the data generated in rat SCH with rat IPL data. 
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AIM #3. DESIGN A SYSTEMATIC STRATEGY FOR DOSE SELECTION VIA PBPK MODELING 
AND SIMULATION USING PAFURAMIDINE/FURAMIDINE AS A MODEL PRODRUG/ACTIVE 
METABOLITE PAIR. 
Hypothesis: Incorporation of preclinical data into a PBPK model can be used to 
predict the disposition and the dose-plasma/tissue exposure relationship of 
pafuramidine/furamidine in humans. 
3.a. Develop a whole-liver rat semi-PBPK model for pafuramidine/furamidine using 
rat IPL data generated from Aim 2a. 
3.b. Develop a whole-body rat semi-PBPK model for pafuramidine/furamidine with 
integration of the IPL model and data from in vivo studies, tissue partitioning and renal 
excretion; examine the accuracy of the prediction by comparing with in vivo plasma data.  
3.c. Develop a whole-body human semi-PBPK model for pafuramidine/furamidine to 
1) predict the plasma/tissue and excretion profiles, and 2) predict the dose-exposure 
relationship in humans.  
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Figure 1.1. Chemical structures of drugs for treatment of first stage (left) and second stage 
(right) human African trypanosomiasis. 
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Figure 1.2. Chemical structures of orally-active pentamidine analogues, pafuramidine and 2, 
5-bis [5-(N-methoxyamidino)-2-pyridyl] furan (CPD-0868), and corresponding active 
metabolites, furamidine and 2, 5-bis (5-amidino)-2-pyridyl) furan (CPD-0801).  Arrows 
denote sequential metabolic pathways involved in the conversion of prodrugs to respective 
active metabolites.  
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Figure 1.3. Biocoversion of the prodrug pafuramidine to the active metabolite furamidine in 
human liver microsomes. M1-M4 represent four intermediate phase I metabolites. 
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Figure 1.4. Scheme for a generic physiologically-based pharmacokinetic (PBPK) model.
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CHAPTER 2 
 
 
 
 
 
 
 
 
 
COMPARISON OF THE INTESTINAL ABSORPTION OF TWO ANTIPARASITIC PRODRUGS 
USING CACO-2 CELL MONOLAYERS 
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A. ABSTRACT  
A successful oral prodrug should have sufficient permeability to traverse the gut wall 
and reach major site(s) of bioactivation to the active metabolite. Pafuramidine, a prodrug of 
furamidine, exhibited potent trypanocidal activity against first stage human African 
trypanosomiasis (HAT). 2, 5-Bis [5-(N-methoxyamidino)-2-pyridyl] furan (CPD-0868), a 
prodrug of 2, 5-bis (5-amidino)-2-pyridyl) furan (CPD-0801), showed improved efficacy and 
enhanced systemic exposure to the active metabolite (CPD-0801) compared to 
pafuramidine/furamidine in a second stage mouse model of HAT. To test the hypothesis that 
the superiority of CPD-0868 in terms of efficacy and systemic exposure is due in part to a 
greater extent of absorption, the human intestinal cell line Caco-2 was utilized to elucidate 
and compare the intestinal absorption properties of pafuramidine and CPD-0868. The 
similar absorptive and exsorptive permeability, in the absence of basolateral serum protein, 
suggested that both prodrugs are absorbed across the intestinal epithelium by passive 
diffusion. Application of 4% bovine serum albumin (BSA) to the basolateral compartment 
increased absorptive permeability of pafuramidine (by ~5-fold), but not CPD-0868, 
suggesting that portal plasma protein binding has a more significant impact on pafuramidine 
absorption. Comparable permeability coefficients of both prodrugs under this more 
physiologic condition suggested that the extent of absorption between pafuramidine and 
CPD-0868 may be similar in vivo.  
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B. INTRODUCTION 
Human African trypanosomiasis (HAT), also known as “sleeping sickness”, is a life-
threatening disease if untreated (Barrett et al., 2003). First stage infection is characterized 
by restriction of parasites to the hemolymphatic system; second stage infection occurs once 
parasites enter the central nervous system (CNS) (Checchi and Barrett, 2008). Current 
treatments for HAT are limited to four drugs as monotherapy: pentamidine or suramin for 
first stage infection, and melarsoprol or eflornithine for second stage infection.  All of these 
agents are associated with toxicities and increasing clinical failure and require parenteral 
administration (intravenous or intramuscular), posing challenges in rural areas of Africa 
where HAT is most prevalent (Checchi and Barrett, 2008). Orally-active drugs are, therefore, 
preferred as an alternative route to parenteral administration in resource-constrained 
settings. 
Pentamidine (Fig 2.1), was discovered in 1941 and still remains the drug of choice 
for the treatment of first stage HAT, regardless of adverse effects (Dorlo and Kager, 
2008). Of many structural analogs of pentamidine, furamidine (Fig. 2.1), synthesized in the 
early 1970s, showed promise, comparable to pentamidine, in animal models of first stage 
infection (Boykin et al., 1996). However, like pentamidine, furamidine carries positive 
charges at physiologic pH due to the diamidine moiety (pKa ≈ 10), which contributes to poor 
oral absorption (Zhou et al., 2002). Consequently, furamidine must be administered 
parenterally to achieve sufficient systemic trypanocidal concentrations at the target site.  An 
approach to improve oral bioavailability of furamidine focused on masking the cationic 
groups. Accordingly, pafuramidine (Fig. 2.1), an O-methylamidoxime prodrug of furamidine, 
was synthesized (Boykin et al., 1996). Pafuramidine exhibited improved oral activity in 
mouse and monkey infection models and was the only orally-active agent that had shown 
efficacy in the treatment of first stage HAT (Paine et al., 2010). However, pafuramidine was 
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not successful for the treatment of second stage (CNS) infection in a monkey model 
(Wenzler et al., 2009).   
Structural modifications to pafuramidine currently are being evaluated. To date, the 
most potent analogue is 2, 5-bis [5-(N-methoxyamidino)-2-pyridyl] CPD-0868 (Fig. 2.1), a 
prodrug of 2, 5-bis (5-amidino)-2-pyridyl) furan CPD-0801 (Fig. 2.1), which differs from 
pafuramidine by substitution of the phenyl rings with pyridines.  CPD-0868 demonstrated a 
higher cure rate  (4/5  vs. 1/5 at 50 mg/kg p.o. for 10 days) compared to pafuramidine in a 
second stage mouse model of infection (Wenzler et al., 2009); systemic exposure to CPD-
0801 was >2-fold higher than that to furamidine in mice given the same dose of respective 
prodrugs (Wu et al., 2007). 
These observations led to the hypothesis that the improved efficacy of the prodrug 
CPD-0868 and enhanced systemic exposure to the active metabolite CPD-0801, compared 
to pafuramidine/furamidine, is due to superior permeability of CPD-0868 through the 
intestinal epithelium. Following oral administration, pafuramidine or CPD-0868 must traverse 
the intestinal epithelium before reaching the portal circulation. Accurate prediction of human 
intestinal absorption can facilitate selection of candidates with optimal absorption properties 
for further development as oral drugs. The aims of this study were to 1) ascertain the means 
of absorption of pafuramidine and CPD-0868; and 2) compare the intestinal permeability 
between these two prodrugs using the well-characterized human intestine-derived cell line 
Caco-2.   
Caco-2 cells resemble morphologically and functionally the enterocytes of the human 
small intestine (Artursson, 1999). Caco-2 cells have been used widely as an in vitro tool to 
predict human drug absorption and elucidate transport mechanisms of drug molecules. The 
spontaneous differentiation process in cell culture leads to formation of tight junctions and 
development of cell polarity. Various phase I and phase II drug metabolizing enzymes as 
well as  uptake and efflux transporters including the breast cancer resistance 
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protein (BCRP), P-glycoprotein (P-gp), multidrug resistance protein (MRP), organic anion-
transporting polypeptide (OATP), and organic cation transporter (OCT) also are expressed 
and functional in Caco-2 cells (Muller et al., 2005; Sun et al., 2008). In many respects, 
Caco-2 cells mimic the human intestinal epithelium. One functional difference between 
enterocytes and Caco-2 cells is the relative lack of expression of cytochrome P450 (CYP) 
enzymes, particularly CYP3A4, which is expressed normally at high levels in the intestine 
(Sun et al., 2008). However, addition of 1α,25-dihydroxy-vitamin-D3 (1α,25-(OH)2-D3) to the 
culture medium can induce CYP3A4 expression and activity in a dose-dependent manner 
(Schmiedlin-Ren et al., 1997).  
Caco-2 monolayers were employed (Fig. 2.2) to evaluate both absorption and 
exsorption of pafuramidine and CPD-0868 by adding the test compound to either the apical 
(A) compartment (luminal side) or the basolateral (B) compartment (blood side); the A→B 
and B→A permeability coefficients (Papps) were calculated and compared to elucidate 
means of absorption (passive diffusion versus transporter-mediated pathways). In addition, 
the A→B translocation of prodrugs was evaluated further under “sink” conditions, when the 
B compartment was supplemented with 4% bovine serum albumin (BSA) to mimic the 
physiologic situation.  
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C. METHODS 
Materials and chemicals.  BioCoatTM control cell culture inserts (4.2 cm2, 1 µm pore 
size) and murine laminin were purchased from BD Biosciences Labware (Bedford, MA).  
Dulbecco’s modified Eagle’s medium (DMEM) (containing 25 mM D-glucose and L-glutamine) 
and nonessential amino acids (NEAA) were purchased from Invitrogen (Carlsbad, CA).  
Fetal bovine serum (FBS) was purchased from Thermo Scientific HyClone (Logan, UT).  
Vitamin E, zinc sulfate, sodium selenite, gentamicin, and BSA were purchased from Sigma-
Aldrich (St. Louis, MO).  Pafuramidine, CPD-0868, and internal standards (deuterium-
labeled prodrugs, d8-pafuramidine and d6-CPD-0868) were synthesized in the laboratory of 
Dr. David W. Boykin (Georgia State University, Atlanta, GA) (Boykin et al., 1996; Ismail et al., 
2003). All other chemicals and reagents were of analytical grade and were used without 
further purification. 
Caco-2 Cell Culture Conditions. Cell culture inserts were coated with murine 
laminin (5 µg/cm2) prior to seeding with the Caco-2 cell clone P27.7 (Schmiedlin-Ren et 
al.,1997) (passage 24) at a density of ~5 x 105 cells/cm2.  The cell cultures were maintained 
in growth medium (consisting of DMEM, 20% FBS, 0.1 % (v/v) NEAA, 50 µg/ml gentamicin, 
and 45 nM vitamin E) until reaching confluence, as determined by transepithelial electrical 
resistance (TEER) values of ≥250 Ω-cm2.  Cell monolayers were then treated with 
differentiation medium (consisting of DMEM, 5% heat-inactivated FBS, 0.1 % (v/v) NEAA, 50 
µg/ml gentamicin, 45 nM vitamin E, 0.1 µM sodium selenite, and 3 µM zinc sulfate) for 21 
days as described previously (Paine et al., 2005). 
Disposition of Pafuramidine and CPD-0868 in Caco-2 cells. Serum-Free 
Conditions.  To evaluate the absorptive (A→B) and exsorptive (B→A) translocation (Fig. 2.2), 
1.5 ml of incubation medium (differentiation medium devoid of FBS) containing pafuramidine 
or CPD-0868 (1 µM; 0.01% DMSO) was added to the donor compartment, followed by 1.5 
ml of drug-free incubation medium to the receiver compartment. Aliquots (25 µl) were 
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collected from the A and B compartments at 0, 10, 20, 30, 40, and 60 min. Cells were 
collected at the end of the experiment by scraping into 200 µl of cold incubation medium, 
after which acetonitrile (600 µl) was added. Cellular supernatants were collected followed by 
vortex-mixing and centrifugation at 1800 g for 10 min. TEER values were measured before 
and after the experiment to assess effects of test compounds on cell monolayer integrity. 
Sink Conditions. The experimental procedure for evaluation of A→B translocation of 
prodrugs under sink conditions was similar as described above, only the incubation medium 
in the B compartment was supplemented with 4% BSA. Samples from the donor and 
receiver compartments and cellular supernatants were stored at -80°C pending analysis for 
prodrugs by LC-MS/MS. The dosing concentration (1 µM) was based on prodrug solubility in 
the incubation medium and assay sensitivity to quantify prodrug in the receiver compartment. 
Sample Preparation and LC-MS/MS Analysis. Donor samples were diluted 10-fold 
by adding 12.5 µl to 112.5 µl of acetonitrile (ACN). Receiver samples were diluted 5-fold by 
adding 25 µl to 100 µl of ACN.  The internal standards (d8-pafuramidine and d6-CPD-0868) 
were prepared by diluting the stock solution (100 µM in 100% DMSO) to generate a working 
solution (600 nM in 99.4% ACN and 0.6% DMSO), 25 µl of which was added to 125 µl of 
donor, receiver, and cell samples. After vortex-mixing and centrifugation at 1800 g for 10 
min, the supernatant (100 µl) was transferred to HPLC vials and quantified for pafuramidine 
and CPD-0868 on an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, 
Foster City, CA) equipped with a Turbo IonSpray interface (MDS Sciex, San Francisco, CA). 
Analytes were separated with an Aquasil C18 HPLC column (2.1 mm × 50 mm, 5 µm) 
(Thermo Electron, Waltham, MA) and a high-pressure linear gradient program consisting of 
0.1% formic acid in HPLC-grade water (A) and 0.1% formic acid in HPLC-grade methanol (B) 
delivered by a Shimadzu pumping system (Shimadzu, Kyoto, Japan) at a flow rate of 0.75 
ml/min as follows: after a 0.5-min initial hold at 10% B, mobile phase composition was 
increased from 10% to 90% B over 3.5 min, and held at 90% B for 0.5 min; the column was 
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re-equilibrated for 0.5 min before the next injection. The mass spectrometer was operated in 
positive ion mode using multiple reaction monitoring: pafuramidine, 365.1→334.1 m/z; d8-
pafuramidine, 373.1→342.2 m/z; CPD-0868, 367.1→336.1 m/z; d6- CPD-0868, 
373.1→342.1 m/z; furamidine, 305.3 288.1 m/z; CPD-0801,  307.3 290.1 m/z. Although 
not quantified, the active metabolites (furamidine and CPD-0801) were monitored for peaks 
of the respective m/z ratios. Calibration curves were prepared in appropriate matrices 
(medium and cell supernatant) and were linear over 5-2000 nM (R2 > 0.99).  
LogP Calculation. The log octanol-to-water partition coefficients (logP) for 
pafuramidine and CPD-0868 were calculated using ACD/ChemSketch (Advanced Chemistry 
Development Inc., Toronto, Canada). 
Data Analysis. The apparent permeability coefficients (Papp) of both absorptive 
(A→B) and exsorptive (B→A) transport were calculated according to the following equation 
(Artursson, 1990):  
Papp = (dQ/dt)/(A•C0)     (Eqn 1) 
where dQ/dt is the appearance rate of prodrug in the receiver compartment, 
calculated by regression of the linear portion of concentration-time profiles; A is the surface 
area of the culture insert (4.2 cm2); and C0 is the initial concentration of the test compound 
added to the donor compartment (1 µM). 
The ratio of the exsorptive to absorptive permeability coefficient was calculated to 
obtain information regarding any asymmetry in the translocation of the test compound. Thus, 
efflux ratios were calculated as the ratio of Papp, B→A to Papp, A→B. Recoveries following apical 
and basolateral dosing were determined as the sum of amounts recovered in the apical, 
basolateral, and cellular compartments at 60 min as a percentage of the initial amount 
added. Cellular accumulation was calculated based on the amount recovered in cell 
scrapings as a percentage of the initial amount added. 
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Statistical Analysis.  Data are expressed as mean ± SD of triplicate culture inserts. 
Statistical significant differences between Papp values and between cellular accumulation at 
60 min, were determined by the unpaired Student’s t-test (p < 0.05). 
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D. RESULTS 
Effects of Prodrugs on Monolayer Integrity.  Under all conditions, the TEER 
measurements exceeded 250 Ω-cm2 and varied <15% over the 60-min experiment, 
indicating that membrane integrity remained intact as a function of prodrug/BSA treatments 
and time. 
Disposition of Pafuramidine and CPD-0868 in Caco-2 cells under Serum-Free 
Conditions.  Translocation. For both pafuramidine and CPD-0868, translocation through 
Caco-2 cell monolayers in the A→B direction was nearly superimposable with that in the 
B→A direction (Fig. 2.3), resulting in similar apparent permeability coefficients (Papp) 
measured in both directions and efflux ratios near unity (Table 2.1).  Corresponding Papp 
(A→B and B→A) of CPD-0868 were significantly higher than those of pafuramidine, differing 
by approximately 3- to 4-fold (Table 2.1). At the end of the experiment, almost 100% of both 
prodrugs were recovered except that pafuramidine recovery was <80% when added into the 
B compartment (Table 2.1). Cellular Accumulation. The cellular accumulation of 
pafuramidine at 60 min averaged 33% following apical administration; there was a 
significant decrease (2-fold) in cellular accumulation of pafuramidine under the same 
conditions following basolateral dosing (Fig. 2.4). In comparison to pafuramidine, the cellular 
accumulation of CPD-0868 at 60 min was significantly lower following the same 
administration route (33 versus 6% for apical dose and 17 versus 4% for basolateral dose) 
(Fig. 2.4). Metabolism. Neither of the active metabolites (furamidine or CPD-0801) was 
detected throughout the experiment regardless of whether the prodrug was dosed into the A 
or B compartment. 
Disposition of Pafuramidine and CPD-0868 in Caco-2 Cells under Sink 
Conditions. Translocation. When the B compartment was supplemented with 4% BSA, the 
A→B translocation of both prodrugs became nearly superimposable (Fig. 2.5). In addition, 
the Papp, A→B value of pafuramidine increased by ~5-fold in the presence relative to the 
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absence of BSA (Table 2.1); no significant difference in Papp, A→B associated with BSA was 
observed for CPD-0868 (Table 2.1). As a consequence, A→B permeability of pafuramidine 
and CPD-0868 became comparable (Table 2.1). Cellular Accumulation. In the presence of 
BSA, cellular accumulation of pafuramidine following apical dosing was significantly reduced, 
by approximately 2-fold, compared to the absence of BSA (33 versus 16%). Nevertheless, 
cellular accumulation of pafuramidine was still much higher than that of CPD-0868 (16 
versus 4%) (Fig. 2.4). Metabolism. Neither of the active metabolites (furamidine or CPD-
0801) was detected throughout the experiment. 
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E. DISCUSSION 
Current treatments for both the first and second stage of HAT require inconvenient 
parenteral administration, which limits widespread use of these drugs in areas affected by 
HAT. Prodrugs are one approach to enhance drug absorption of low permeability 
compounds. Pafuramidine, a lipophilic prodrug of furamidine, has greatly improved oral 
potency, compared to the hydrophilic active metabolite (furamidine), towards first stage HAT 
(Boykin et al., 1996).  Despite its improved intestinal permeability, pafuramidine was not 
effective against second stage HAT.  The structural analog, CPD-0868, may represent an 
alternative for second stage infection, as evidenced by a higher cure rate and improved 
systemic exposure of derived active metabolite (CPD-0801) in a second stage (CNS) mouse 
model (Wu et al., 2007; Wenzler et al., 2009). To investigate whether intestinal absorption 
plays a role in the observed difference in efficacy and pharmacokinetics between 
pafuramidine and CPD-0868, a well-characterized in vitro model of the intestinal epithelium, 
Caco-2 cells, was utilized to assess permeability and transport characteristics of both 
prodrugs. 
A previous study showed that the prodrug pafuramidine crossed the intestinal 
epithelium predominantly via a transcellular route (Zhou et al., 2002). Masking the cationic 
functionalities of furamidine by O-methylamidoxime moieties greatly enhanced the 
lipophilicity of the prodrug, pafuramidine, by increasing the LogD value from -3 to 4.3 (Zhou 
et al., 2002). At physiologic pH, passive diffusion would be expected to represent the major 
pathway for the uncharged (pKa ≈ 4) and lipophilic prodrug, pafuramidine, to traverse the 
intestinal epithelium. The nearly superimposable translocation profiles (Fig. 2.3) and similar 
Papp values (Table 2.1) for both pafuramidine and CPD-0868 after apical and basolateral 
dosing in Caco-2 cells (without serum in the medium) support the aforementioned 
postulation. Although both prodrugs crossed cell monolayers by passive diffusion, in the 
absence of serum in the medium, both absorptive and exsorptive permeability coefficients of 
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CPD-0868 were more than 3-fold higher than those of pafuramidine (Table 2.1), which could 
be attributed to the much lower cellular accumulation compared to pafuramidine (Fig. 2.4).  
As reported previously, the presence of BSA significantly increased absorptive Papp 
values of only the most lipophilic (logP > 3.0) and highly protein bound (fu < 5%) compounds 
(chlorpromazine and nelfinavir) by reducing cellular drug accumulation and non-specific 
binding to plastic wells (Aungst et al., 2000). Another study also demonstrated that addition 
of 4% BSA into the receiver compartment increased the absorptive permeability of a highly 
lipophilic compound, Sch-Y (logP = 4.0), by 5-fold, but the Papp values of a relatively less 
lipophilic compound, Sch 56592 (logP = 2.4), remained unchanged (Saha and Kou, 2002). 
Consistent with these previous results, when 4% BSA was added into the basolateral 
compartment to mimic plasma protein binding in the portal circulation, the cellular 
accumulation of the highly lipophilic prodrug, pafuramidine (LogP = 4.0; Table 2.1), 
decreased significantly (Fig. 2.4).  As a consequence, the permeability of pafuramidine 
increased by 5-fold, comparable to CPD-0868 (Table 2.1). This observation indicated that 
BSA served as a “sink” for pafuramidine to reduce backward flux and cellular accumulation 
of this prodrug. In contrast, little difference in permeability and cellular accumulation of the 
relatively less lipophilic prodrug, CPD-0868 (LogP = 2.2; Table 2.1), was observed in the 
absence and presence of BSA (Table. 2.1 and Fig. 2.4). Consistent with the relative 
lipophilicity between these two prodrugs, the unbound fraction (fu) of pafuramidine in human 
plasma was 35-fold less than that of CPD-0868 (Table 2.1). If BSA is the major protein that 
both prodrugs are bound to in the human plasma, the fu of CPD-0868 in 4% BSA would be 
expected to be much higher than that of pafuramidine, which could explain the fact that 
binding to BSA in the B compartment has a much lower impact on the permeability of CPD-
0868 across Caco-2 cell monolayers compared to pafuramidine.  
Both pafuramidine and CPD-0868 are poorly water-soluble compounds, thus, the 
dosing solutions of both prodrugs need to be prepared in a hydrophobic solvent, such as 
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DMSO. According to the Biopharmaceutical Classification System (BCS), pafuramidine and 
CPD-0868 can be classified as low solubility–high permeability class II compounds (Polli et 
al., 2008). Therefore, the extent of absorption of these prodrugs, expressed as the fraction 
of absorbed (fa), would be expected to be limited by the solubility rather than the 
permeability. In addition to the inherent physicochemical properties, local solubility of 
compounds in the gastrointestinal tract also can be influenced by a variety of factors, such 
as, surfactants, pH, buffer capacity, and food components (Dressman and Reppas, 2000). 
Numerous reports showed that the presence of food, particularly consisting of fat 
components, can greatly increase the extent of absorption of class II compounds (Welling, 
1996; Dressman and Reppas, 2000; Dressman et al., 2008). In the case of these 
antiparasitic prodrugs, administration accompanied by plenty of water and a high fat meal 
would be expected to enhance the fa, and in turn, the portal exposure for biotransformation 
to the active metabolites in the liver. 
In the current study, both prodrugs exhibited near complete recoveries in the Caco-2 
model, except for pafuramidine when dosed in the basolateral compartment. Considering 
the higher lipophilicity and more extensive binding of pafuramidine, the incomplete recovery 
of this prodrug when dosed into the B compartment may have reflected a greater extent of 
non-specific binding to the larger surface area of culture well/insert. In addition, no active 
metabolite formation was observed for either prodrug over the 60-min transport study. A 
previous study using human intestinal microsomes showed that human enteric CYP4F may 
play a role in the pre-systemic biotransformation of pafuramidine (Wang et al., 2007). 
Studies using human liver microsomes showed that CYP3A4 may be also involved in the 
sequential metabolism of pafuramidine to form furamidine (Wang et al., 2006). The 
activity/expression levels of some phase I metabolizing enzymes, particularly CYP3A4, in 
Caco-2 cells are considerably lower than those detected in human intestinal epithelium (Sun 
et al., 2008). The expression/activity levels of enzymes involved in biotransformation of 
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these prodrugs (e.g., CYP4F/CYP3A4) may not be adequate in Caco-2 cells to predict and 
study the metabolism of these compounds in the small intestine.  
In conclusion, no apparent difference in the Papp, A→B of these two prodrugs was 
observed under more physiologically-relevant conditions in the Caco-2 model, suggesting 
that the permeability of pafuramidine and CPD-0868 through the intestinal epithelium may 
be similar in vivo, hence, the intestinal permeability of prodrugs may have little impact on the 
difference in the systemic exposure of respective active metabolites observed in vivo. This 
study further demonstrated the utility of Caco-2 model to characterize the translocation of 
compounds in the gut and highlighted the importance of BSA in accurate assessment of 
Papp,A→B and permeability ranking of highly lipophilic compounds. The method used in this 
study can facilitate selection of lead candidates with desirable intestinal permeability 
properties for oral treatment of HAT. 
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F. TABLES 
 
Table 2.1 Comparison of pafuramidine and CPD-0868 translocation across Caco-2 cell 
monolayers.  
 
 
aCalculated based on equation (1); comparisons between pafuramidine and CPD-0868 Papp values 
were made using the two-tailed Student’s t-test. #p<0.05 versus the absence of BSA in the 
basolateral compartment.  *p<0.05 versus pafuramidine in the same translocation direction. Values 
denote mean ± SD of 3 culture inserts. 
 
bDetermined as the ratio of the Papp value in the B → A direction to that in the A → B direction. 
 
cCalculated as the sum of amount of prodrug recovered in the A and B compartments and cells as a 
percentage of initial amount of prodrug added to the donor compartment. 
 
dCalculated as described in Materials and Methods. 
 
efu denotes unbound fraction of pafuramidine or CPD-0868 in human plasma, which was determined 
using a method described in a previous study (Yan et al., 2011). 
 
fIncubation medium in the B compartment was supplemented with 4% BSA. 
 
gNot applicable. 
Prodrug Translocation Direction 
Papp  
(10-6 
cm/s)a    
Efflux 
Ratiob 
Recovery 
at  
60 min 
(%)c 
LogPd 
fu (%) in 
Human 
Plasmae 
A → B 8.0 ± 0.3 98 ± 8 
B → A 7.0 ± 0.2
0.9 ± 0.1
73 ± 1 Pafuramidine 
A → B 
 (w/ BSA)f 44 ± 3
# N.A.g 100 ± 4 
4.0 ± 0.7 0.2 ± 0.02 
A → B 27 ± 2* 100 ± 5 
B → A 27 ± 3* 
1.0 ± 0.1
96 ± 2 CPD-0868 
A → B 
 (w/ BSA) 33 ± 1 N.A. 100 ± 1 
2.2 ± 0.7 7 ± 0.6 
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Figure 2.1 Chemical structures of pentamidine, pafuramidine, furamidine, CPD-0868, and 
CPD-0801.  Arrows denote sequential metabolic pathways involved in the conversion of 
prodrugs to respective active metabolites. 
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Figure 2.2 Schematic representation of the Caco-2 permeability assay. 
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Figure 2.3 Translocation of pafuramidine and CPD-0868 (1 µM) across Caco-2 cell 
monolayers. Symbols and error bars denote means and SDs, respectively, of triplicate 
culture inserts.  
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Figure 2.4 Cellular accumulation of pafuramidine or CPD-0868 in Caco-2 cells at the end of 
the 60-min experiment. Black, white, and gray bars represent the amount of each prodrug 
recovered in the cell scrapings as a percentage of initial amount added to the apical (A) or 
basolateral (B) compartment or apical compartment with 4% BSA in the B compartment 
containing 4% BSA. *p <0.05 versus CPD-0868 under the same dosing condition; **p <0.05 
versus A dose w/BSA (Student’s t-test). 
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Figure 2.5 Apical-to-basolateral translocation of pafuramidine and CPD-0868 (1 µM) across 
Caco-2 cell monolayers in the presence of 4% BSA in the basolateral compartment. 
Symbols and error bars denote means and SDs, respectively, of triplicate culture inserts.  
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A.        ABSTRACT 
Selection of in vitro models that accurately characterize metabolite systemic and 
hepatobiliary exposure remains a challenge in drug development. In the present study, 
mechanisms underlying differences in systemic exposure of two active metabolites, 
furamidine and 2, 5-bis (5-amidino)-2-pyridyl) furan (CPD-0801), were examined using two 
hepatic models from rats: isolated perfused livers (IPLs) and sandwich-cultured hepatocytes 
(SCH).  Pafuramidine, a prodrug of furamidine, and 2, 5-bis [5-(N-methoxyamidino)-2-pyridyl] 
furan (CPD-0868), a prodrug of CPD-0801, were selected for investigation because CPD-
0801 exhibits greater systemic exposure than furamidine, despite remarkable structural 
similarity between these two active metabolites.  In both IPLs and SCH, the extent of 
conversion of CPD-0868 to CPD-0801 was consistently higher than that of pafuramidine to 
furamidine over time (at most 2.5-fold); area under the curve (AUC) of CPD-0801 in IPL 
perfusate and SCH medium was at least 7-fold higher than that of furamidine. 
Pharmacokinetic modeling revealed that the rate constant for basolateral (liver to blood) net 
efflux (kA_net efflux) of total formed CPD-0801 (bound+unbound) was 6-fold higher than that of 
furamidine. Hepatic accumulation of both active metabolites was extensive (>95% of total 
formed); hepatic unbound fraction (fu,L) of CPD-0801 was 5-fold higher than that of 
furamidine (1.6 versus 0.3%). Incorporation of fu,L into the pharmacokinetic model resulted in 
comparable kA_net efflux,u between furamidine and CPD-0801.  In conclusion, intrahepatic 
binding markedly influenced the disposition of these active metabolites. A higher fu,L 
explained, in part, the enhanced perfusate AUC of CPD-0801 compared to furamidine in 
IPLs. SCH predicted the disposition of prodrug/metabolite in IPLs.  
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B.          INTRODUCTION 
The liver often is the predominant organ for biotransformation of a precursor 
compound (i.e., prodrug) to active metabolite, which can influence therapeutic and/or 
toxicologic outcomes (Pang et al., 2008). Once formed, active metabolite can undergo 
further metabolism, excretion into the systemic circulation or bile, and/or intrahepatic 
sequestration. Therefore, accurate characterization of the systemic and hepatobiliary 
exposure of active metabolite is imperative for efficacy and risk assessment. Although 
physiologically relevant, in vivo studies are cumbersome, costly, and associated with a 
variety of extrahepatic variables, including metabolic and active uptake/efflux processes in 
the intestine and kidney. As an alternative methodology, in vitro or ex vivo hepatic models 
that have strong descriptive and predictive capabilities for the in vivo situation would offer 
significant advantages. 
Isolated perfused livers (IPLs) are considered the closest approximation to the 
hepatobiliary system in vivo due to maintenance of hepatic architecture, microcirculation, 
and bile production (Brouwer and Thurman, 1996). Biotransformation pathways, 
sinusoidal/biliary transport processes, mechanisms underlying drug-drug interactions, and 
alterations in physiology (blood flow or changes in protein binding that might be associated 
with disease) can be elucidated by manipulating experimental conditions, in the absence of 
extrahepatic influence. Despite these advantages, several shortcomings limit widespread 
use of IPLs, such as the delicate surgical techniques required, the relatively short 
experimental period in which viability is maintained (≤ 2h), and the time/labor-intensive 
nature of the procedure (Brouwer and Thurman, 1996).  
Sandwich-cultured hepatocytes (SCH) have emerged as an alternative in vitro model 
of the hepatobiliary system (Swift et al., 2009). Unlike conventional culture, hepatocytes 
cultured between layers of gelled collagen in a sandwich configuration establish cell polarity 
and form intact canalicular networks with appropriate localization, expression, and function 
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of transport proteins (LeCluyse et al., 1994; Liu et al., 1999a). Compared to IPLs, SCH 
represent a more cost-effective and high-throughput system, allowing for simultaneous 
monitoring of xenobiotics in both cells and culture medium over an extended period of time 
(up to 24 h). One limitation of SCH is that catalytic activity of cytochrome P450 enzymes 
declines with days in culture (Boess et al., 2003). A medium additive, dexamethasone (DEX), 
has been reported to induce the expression of certain phase I and II enzymes in SCH to 
levels that more closely approximate in vivo metabolic activity (LeCluyse, 2001; Hewitt et al., 
2007a; Hewitt et al., 2007b; Kienhuis et al., 2007).  
A large body of literature describes the hepatobiliary disposition of many xenobiotics 
using IPLs or SCH. However, a comparison of both sinusoidal/canalicular transport and 
metabolism between these two hepatic models has not been evaluated. In the current study, 
two antiparasitic prodrugs and derived metabolites were utilized as model drug/metabolite 
pairs to investigate this unaddressed issue. 
Human African trypanosomiasis (HAT), a neglected parasitic disease, consists of two 
stages. During first stage infection, parasites are restricted to the hemolymphatic system; 
second stage infection begins once parasites invade the central nervous system, causing 
serious neurologic dysfunction (Barrett, 2010). Without treatment, HAT is invariably fatal. 
Pafuramidine (Fig. 3.1), a prodrug of furamidine (Fig. 3.1), is the only orally-active agent that 
has shown efficacy in clinical trials for the treatment of first stage infection (Paine et al., 
2010). CPD-0868 (Fig. 3.1), a structural analog of pafuramidine and prodrug of CPD-0801 
(Fig. 3.1), demonstrated a higher cure rate compared to pafuramidine in a second stage 
mouse model (4/5 versus 1/5 at 50 mg/kg p.o. for 10 days) (Wenzler et al., 2009); systemic 
exposure to CPD-0801 was higher than that to furamidine in mice given the same dose of 
respective prodrugs (Wu et al., 2007). These encouraging observations warrant further 
evaluation of CPD-0868 as an orally-active agent for second stage HAT. 
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Both furamidine and CPD-0801 are formed in the liver via sequential oxidative O-
demethylation and reductive N-dehydroxylation reactions, producing four intermediate 
phase I metabolites (Fig. 3.1) (Zhou et al., 2004; Generaux, 2010). Once formed, active 
metabolites must be excreted from hepatocytes into the systemic circulation to exert 
antiparasitic activity. These observations led to the hypothesis that improved efficacy of the 
prodrug, CPD-0868, against second stage infection compared to pafuramidine reflects 
superior hepatobiliary disposition characteristics, including a greater extent of conversion to 
the active metabolite (CPD-0801) and/or more efficient efflux of CPD-0801 from hepatocytes 
into the systemic circulation. This hypothesis was addressed utilizing IPLs and SCH from 
rats, coupled with mathematical modeling, to elucidate mechanisms underlying the 
difference in systemic/hepatobiliary exposure of these two antiparasitic active metabolites. 
Results generated from SCH were compared with IPLs. 
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C.        MATERIALS AND METHODS 
Materials and Chemicals.  Dulbecco’s modified Eagle’s medium (DMEM) and insulin 
were purchased from Invitrogen/GIBCO (Carlsbad, CA). ITS+TM (insulin/transferring/selenium) 
culture supplement and MatrigelTM were purchased from BD Biosciences (Bedford, MA). 
Penicillin, streptomycin, fetal bovine serum (FBS), non-essential amino acids (NEAA), 
dexamethasone (DEX), Krebs-Henseleit buffer, Triton X-100, and taurocholate were purchased 
from Sigma-Aldrich (St. Louis, MO). The prodrugs pafuramidine and CPD-0868, the 
intermediate phase I metabolites (M1, M2, and M3) of pafuramidine and CPD-0868, the active 
metabolites furamidine and CPD-0801, and the internal standards (deuterium-labeled 
pafuramidine, CPD-0868, furamidine, and CPD-0801) were synthesized in the laboratory of Dr. 
David W. Boykin (Georgia State University, Atlanta, GA) (Boykin et al., 1996; Ismail et al., 2003; 
Ismail and Boykin, 2006). All other chemicals and reagents were of analytical grade and were 
used without further purification. 
Animals. Male Wistar rats (250–300 g) were purchased from Charles River Laboratories 
(Raleigh, NC) for liver perfusion and hepatocyte isolation. Animals had free access to water and 
food before surgery. All animal procedures were compliant with guidelines of the University of 
North Carolina Institutional Animal Care and Use Committee. 
Disposition of Prodrugs/Metabolites in Isolated Perfused Rat Livers. Recirculating 
IPLs from rats were prepared using standard techniques; perfusions were conducted ex situ 
over designated times (up to 2 h) in a temperature-controlled chamber with recirculating 
oxygenated Krebs-Henseleit buffer (80 ml) containing 20% (v/v) rat blood at a flow rate of 20 
ml/min (Brouwer and Thurman, 1996). Taurocholate was infused (30 µmol/h) into the perfusate 
reservoir to maintain bile flow. Prodrug (pafuramidine or CPD-0868) stock solution (80 µl; 10 
mM in DMSO) was added as a bolus to the perfusate reservoir to yield an initial concentration of 
10 µM (0.1% DMSO). Aliquots of perfusate (~400 µl) were collected from the IPL reservoir at 5-
min intervals from 0-40 min and at 10-min intervals thereafter up to 2 h during perfusion; bile 
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was collected at 10-min intervals; liver was harvested at the end of perfusion. Perfusate plasma, 
bile, and liver collections were stored at -80°C pending analysis for prodrug and derived 
metabolites by liquid chromatography with detection by tandem mass spectrometry (LC-
MS/MS). The prodrug concentration (10 µM) was based on solubility in perfusate and assay 
sensitivity to monitor prodrugs/metabolites in perfusate plasma, liver, and bile throughout the 2-
h experimental period. The absence-of-liver condition was used to assess nonspecific binding of 
prodrug and metabolites to the IPL apparatus. 
Determination of Unbound Fraction. Liver. Livers from IPL experiments (described 
above) were thawed and homogenized in three volumes (v/w) of 0.1 M phosphate buffered 
saline (PBS). The unbound fraction of formed active metabolite in liver homogenates was 
determined using rapid equilibrium dialysis devices (Pierce Biotechnology, ThermoFisher 
Scientific, Waltham, MA).  Liver homogenates (200 μl) and blank PBS (350 μl) were placed in 
tissue and buffer chambers, respectively, and incubated (37°C) for 6 h on a thermomixer (350 
rpm) (Eppendorf AG, Hamburg, Germany). Preliminary testing indicated that 6 h of incubation 
was sufficient to achieve equilibrium without significant compound degradation.  After 6 h, 
aliquots (100 µl) were collected from the tissue and buffer chambers and analyzed for total 
(bound+unbound) and unbound formed active metabolite, respectively, by LC-MS/MS. 
Perfusate/Plasma. Blank rat IPL perfusate (composed of 20% rat blood) and plasma were 
spiked with preformed active metabolite to yield a total concentration of 1 or 10 μM. Spiked 
perfusate/plasma (200 μl) and blank PBS (350 μl) were placed in corresponding dialysis 
chambers, incubated for 6 h, and analyzed for total (bound+unbound) and unbound preformed 
active metabolite,  respectively, by LC-MS/MS. 
Disposition of Prodrugs/Metabolites in Sandwich-Cultured Rat Hepatocytes. 
Freshly-isolated rat hepatocytes were seeded at 1.75 x 106 cells/well onto 6-well BioCoatTM 
collagen plates (BD Biosciences, Bedford, MA) in seeding medium (DMEM containing 5% (v/v) 
FBS, 10 μM insulin, 1 μM DEX, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units penicillin G 
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sodium, and 100 μg streptomycin sulfate). Approximately 24 hours after seeding (Day 1), cells 
were overlaid with 0.25 mg/ml MatrigelTM in ice-cold culture medium (DMEM supplemented with 
1% (v/v) ITS+TM, 1 μM DEX, 2 mM L-glutamine, 1% (v/v) NEAA, 100 units penicillin G sodium, 
and 100 μg/ml streptomycin sulfate). Thereafter, culture medium was changed every 24 h for 
two days. On Day 4, cells were incubated with culture medium (1.5 ml) containing pafuramidine 
or CPD-0868 at a concentration identical to that used for the IPL experiments (10 µM, 0.1% 
DMSO). At designated times up to 24 h, aliquots of medium (500 µl) were collected, and cells 
were washed twice and incubated at 37°C for 5 min with HBSS with Ca2+ (to maintain bile 
canalicular networks; cells+bile) or without Ca2+ (to open bile canalicular spaces; cells) (Lee et 
al., 2010). After incubation, buffer was removed, and cells were lysed with ice-cold 
methanol/water (7:1 v/v) containing 0.1% (v/v) trifluoroacetic acid (TFA). Media, cell lysates, and 
cells+bile lysates were stored at -80°C pending analysis for prodrug and derived metabolites by 
LC-MS/MS. The absence-of-cell condition was used to assess nonspecific binding of prodrug 
and metabolites to Matrigel-overlaid BioCoatTM collagen plates. 
Determination of Hepatocyte Viability. Effect of prodrugs/metabolites on hepatocyte 
viability was assessed by monitoring lactate dehydrogenase (LDH) release to the culture 
medium using a cytotoxicity detection kit (Roche, Indianapolis, IN) according to the 
manufacturer’s instructions.  Briefly, aliquots (25 µl) of medium from vehicle- (0.1% DMSO) and 
prodrug-treated SCH were collected at 0.5, 2, 4, 8, and 24 h. The degree of LDH release was 
expressed as percentage of the maximum cellular LDH release, which was measured by adding 
2% detergent, Triton X-100, to SCH (Lee et al., 2008). 
LC-MS/MS Analysis for Prodrugs and Derived Metabolites.  The concentration of 
prodrug and derived metabolites in perfusate/plasma or medium, liver homogenates or cell 
lysates, bile, and PBS from IPL or SCH studies (described above) was quantified by LC-MS/MS 
using a method modified from Wang et al. (2006). Briefly, analytes were extracted by adding 
methanol/H2O (7:1) with 0.1% TFA containing 600 nM internal standards, followed by vigorous 
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mixing and centrifugation at 1800 g for 10 min. The supernatant (100 µl) was transferred to 
HPLC vials and quantified for prodrug and metabolite using multiple reaction monitoring via an 
API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) equipped 
with a Turbo IonSpray interface (MDS Sciex, San Francisco, CA). Analytes were separated on 
an Aquasil C18 HPLC column (2.1 mm × 50 mm, 5 µm) (Thermo Electron, Waltham, MA) with a 
high-pressure linear gradient program consisting of 0.1% formic acid in HPLC-grade water (A) 
and 0.1% formic acid in HPLC-grade methanol (B) delivered by a Shimadzu pumping system 
(Shimadzu, Kyoto, Japan) at a flow rate of 0.75 ml/min as follows: after a 0.5-min initial hold at 
10% B, mobile phase composition was increased from 10% to 90% B over 3.5 min, and held at 
90% B for 0.5 min; the column was re-equilibrated for 0.5 min before the next injection. For all 
studies except liver binding, prodrugs and metabolites were quantified with calibration standards 
(1-10,000 nM) prepared in the appropriate matrix; for the liver binding study, both active 
metabolites were quantified with calibration standards prepared in liver homogenates (0.5-50 
µM) and PBS (1-10,000 nM). All calibration curves were linear over the respective range (R2 > 
0.98).  Intra- and Inter-day coefficients of variation were <15%.  
Pharmacokinetic Modeling. Stepwise nonlinear least-squares regression analysis 
(WinNonlin 5.0.1, Pharsight Corp., Mountain View, CA) was used to fit a compartmental model 
(Fig. 3.2, Model 1) to the hepatobiliary disposition of prodrug and derived metabolites mass 
versus time data obtained from IPLs and SCH. Model 2 (Fig. 3.2) incorporates the unbound 
fraction of active metabolite in the liver to emphasize the importance of hepatic binding in 
governing the systemic exposure of these compounds. Goodness of fit was based on 
randomness of residuals, correlation matrices, standard errors of parameter estimates, and 
visual comparison of predicted mass/concentration-time profiles with observed data.  Because 
the batch of synthesized pafuramidine standard contained impurities largely as the intermediate 
metabolite, M3, an initial value of 10% of pafuramidine in the dosing compartment (perfusate for 
IPLs; medium for SCH) was utilized to describe M3 disposition in IPLs and SCH. Some 
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intermediate metabolites (specifically, M1 and M2 of pafuramidine and M2 of CPD-0868) were 
not included in the model if concentrations in the perfusate/medium, liver/cells, and bile were 
below the limit of quantification (BLQ), or if pure synthesized standards (M4 of pafuramidine and 
CPD-0868) were not available. 
Data Analysis. The hepatic clearance (ml/min) and extraction ratio of prodrug in IPLs 
were calculated as follows: 
Total hepatic clearance (ClH) = dose / AUCperfusate,0-∞, where AUCperfusate,0-∞ was calculated 
as the area under the perfusate concentration-time curve from time 0 to infinity using the 
trapezoidal method. 
Biliary clearance (Clb) = massbile,0-120min / AUCperfusate,0-120min, where massbile,0-120min was 
calculated as the cumulative amount of compound excreted into bile over 120 min. 
Metabolic clearance (Clm) = ClH - Clb 
Hepatic extraction ratio (EH) = ClH / Q, where Q represents total perfusate flow rate (20 
ml/min). The blood-to-plasma ratio for both prodrugs is 1 (GZY, KLRB, MFP, unpublished 
observations). 
With both IPLs and SCH, hepatic accumulation was calculated as the amount of active 
metabolite recovered in the liver or cells as a percentage of the total amount formed over time. 
Extent of formation of active metabolite was determined as the total amount of active metabolite 
recovered in perfusate, liver and bile as a percentage of the initial amount of prodrug added to 
the perfusate reservoir (IPLs) or the total amount of active metabolite recovered in medium, 
cells and bile as a percentage of the initial amount of prodrug added to the culture medium 
(SCH).  
Data showed that distribution of furamidine/CPD-0801 between liver and perfusate in 
IPLs, and between cells and medium in SCH, reached equilibrium from 100 min and 16 h 
onward, respectively. Therefore, furamidine/CPD-0801 liver-to-perfusate (IPLs) or cell-to-
medium (SCH) partition coefficients (Kp,IPLs and Kp,SCH, respectively) were calculated as the ratio 
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of concentration in liver (CL) to that in perfusate (CPer) at the end of the perfusion (120 min), or 
the ratio of concentration in cells (CC) to that in medium (CM) at the end of the incubation (24 h). 
The hepatocellular volumes used to calculate CL and CC were 0.6 ml/g rat liver (Pang et al., 
1988) and 6.2 ×10-6 µl/hepatocyte (Swift et al., 2009) for IPLs and SCH, respectively. 
A two-tailed Student’s t-test was used to compare disposition properties between 
furamidine and CPD-0801 in IPLs and SCH. A p-value < 0.05 was considered statistically 
significant. 
 72
D.        RESULTS 
Nonspecific Binding of Prodrugs/Metabolites. Nonspecific binding of both prodrugs 
and all metabolites to collagen-coated culture plates, and to the perfusion tubing and apparatus, 
was <10% of the initial mass of starting material.  Accordingly, nonspecific binding was 
assumed to be negligible. 
Disposition of Prodrugs/Metabolites in Isolated Perfused Rat Livers. Both prodrugs 
were taken up and metabolized rapidly, as reflected by the prompt appearance of intermediate 
metabolites in perfusate (Fig. 3.3). Both prodrugs were eliminated in rat liver primarily by 
metabolism; biliary excretion was negligible (Table 3.1). Pafuramidine had a higher hepatic 
extraction ratio than CPD-0868 (Table 3.1). Recovery of M1 and M2 metabolites of 
pafuramidine in perfusate, liver, and bile was BLQ. The M3 metabolite of pafuramidine 
appeared in the perfusate immediately (Fig. 3.3A), reflecting M3 as an impurity in this batch of 
synthesized standard of pafuramidine, and then decreased slightly due to uptake into 
hepatocytes; at ~10 min, M3 began to increase slightly due to efflux of M3 formed from M1. The 
M1 metabolite of CPD-0868 in perfusate was maximal at ~15 min (Fig. 3.3B), then decreased 
rapidly, due to reuptake into hepatocytes and further metabolism.  The M3 metabolite of CPD-
0868 in perfusate was maximal at ~40 min (Fig. 3.3B), then decreased due to reuptake into 
hepatocytes and further metabolism.  The rate constants associated with both basolateral 
reuptake (kM3_reuptake) and efflux (kM3_efflux) of the M3 metabolite were comparable between 
prodrugs (Table 3.2).  kM3_reuptake was more than 40-fold higher than kM3_efflux for the M3 
metabolite of both prodrugs (Table 3.2). The rate constant associated with biliary excretion of 
the M3 metabolite (kM3_bile) of CPD-0868 was 4-fold higher than that of the M3 metabolite of 
pafuramidine (Table 3.2). The rate constant associated with conversion from M3 to the active 
metabolite (kM3→A) of CPD-0868 was 3.5-fold higher than that of pafuramidine (Table 3.2).  
The extent of formation of furamidine in rat IPLs was at least half that of CPD-0801 (Fig. 
3.4A). Perfusate exposure to CPD-0801 was much higher compared to furamidine. The area 
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under the perfusate concentration-time curve (AUC) PD-0801 was 10-fold higher than that for 
furamidine (Table 3.3). Pharmacokinetic modeling (Model 1, Fig. 3.2) revealed that the rate 
constant associated with net basolateral efflux (kA_net efflux) of CPD-0801 was 6-fold higher than 
that of furamidine (Table 3.2).  
Hepatic accumulation of both active metabolites in rat IPLs was extensive (Table 3.3). 
The liver-to-perfusate partition coefficient (Kp,IPLs) of furamidine at 2 h was 3700 and was 
approximately 5-fold higher than that of CPD-0801 (Table 3.3). The unbound fractions of both 
active metabolites in plasma/perfusate were similar at 1 and 10 µM. The unbound fraction of 
each active metabolite in rat liver (fu,L) was ≥24-fold lower than that in plasma (fu,P) and 
perfusate (composed of 20% rat blood; fu,Per) (Table 3.3). The fu,L of CPD-0801 was 
approximately 5-fold higher than that of furamidine (Table 3.3). Assuming that only unbound 
drug can translocate out of hepatocytes into blood and bile, fu,L was incorporated into the 
pharmacokinetic model (Model 2, Fig. 3.2) to evaluate further the hepatic excretion of derived 
active metabolite. Based on Model 2, the rate constant for biliary excretion (kA_bile,u) was 9-fold 
higher than that of basolateral efflux (kA_net efflux,u) for unbound furamidine, whereas kA_bile,u and 
kA_net efflux,u for CPD-0801 were more comparable than those for furamidine (Table 3.4). After 
incorporating fu,L, the kA_net efflux,u of furamidine became comparable to that of CPD-0801 (Table 
3.4). 
Disposition of Prodrugs/Metabolites in Day-4 Sandwich-Cultured Rat Hepatocytes. 
The disposition profiles of prodrugs and derived metabolites in SCH (Fig. 3.5) were similar to 
those for rat IPLs (Fig. 3.3), although the time-course in SCH was longer than that in IPLs (24 
versus 2 h). As shown in IPLs, the recovery of M1 and M2 metabolites of pafuramidine in 
medium, cells, and bile was BLQ; the M3 metabolite of pafuramidine appeared in medium 
immediately (Fig. 3.5A), reflecting M3 as an impurity. The M1 metabolite of CPD-0868 in 
medium was maximal at 2 h (Fig. 3.5B), and then decreased rapidly due to subsequent 
reuptake into hepatocytes and metabolism.  The M3 metabolite of CPD-0868 in medium was 
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maximal at 8 h (Fig. 3.5B), then decreased due to reuptake into hepatocytes and further 
metabolism.  The rate constant associated with conversion from M3 to the active metabolite 
(kM3→A) of CPD-0868 was 1.4-fold higher than that of pafuramidine (Table 3.5). Only the M3 
metabolite of CPD-0868 was recovered in bile (Table 3.5). 
The extent of conversion of CPD-0868 to CPD-0801 was consistently higher than that of 
pafuramidine to furamidine in SCH over 24 h (Fig. 3.4B). Medium exposure to CPD-0801 was 
higher compared to furamidine. The area under the medium concentration-time curve (Jin et al.) 
for CPD-0801 was 7-fold higher than that for furamidine (Table 3.3). As shown in IPLs, kA_net efflux 
of CPD-0801 was 6-fold greater than that of furamidine. Model 1 adequately described the 
disposition of furamidine in medium and hepatocytes (solid and dashed lines in Fig 3.5A); the 
large variability in the parameter estimate for kA_net efflux of furamidine may be due to the marked 
difference between the amount of furamidine recovered in the medium and that recovered in 
hepatocytes (>2 orders of magnitude). Hepatocellular accumulation of furamidine and CPD-
0801 over 24 hr was extensive (Table 3.3). The cell-to-medium partition coefficients of both 
active metabolites measured in SCH (Kp,SCH) was 6- to 7-fold higher than liver-to-perfusate 
partition coefficients measured in IPLs (Kp,IPLs); similar to IPL results, Kp,SCH of furamidine was 
approximately 5- to 6-fold higher than that of CPD-0801 (Table 3.3).  
Effect of Prodrugs/Metabolites on Hepatocyte Viability. In rat SCH treated with 
vehicle (0.1% DMSO) or prodrug (pafuramidine or CPD-0868), an elevation in LDH release was 
not observed over 24 h compared to untreated SCH (data not shown).  These data suggested 
that membrane integrity remained intact as a function of prodrug treatment and time.  
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E.         DISCUSSION 
 SCH have been used previously to investigate the hepatobiliary disposition of 
drug/metabolite pairs, including terfenadine and fexofenadine (Turncliff et al., 2006). The 
current work represents the first systematic comparison of two established hepatic models, 
IPLs and SCH, to understand mechanisms governing the systemic and hepatobiliary 
exposure of two antiparasitic active metabolites.  Rat IPLs and SCH showed similar 
disposition profiles of prodrugs and derived metabolites (Fig. 3.3 versus Fig. 3.5). The extent 
of formation and AUC in perfusate (IPLs) or medium (SCH) of CPD-0801 was consistently 
higher than that of furamidine (Table 3.3). A stepwise pharmacokinetic modeling approach 
was utilized to differentiate, quantitatively, between the contribution of hepatic metabolism 
and transport to the enhanced perfusate/medium AUC of CPD-0801 compared to furamidine. 
Model 1 described adequately the disposition of both prodrugs and derived metabolites (Fig. 
3.3 and Fig. 3.5; Supplemental Fig. 3.S1 and Fig. 3.S2) and predicted a net basolateral 
efflux rate constant (kA_net efflux) for CPD-0801 that was 6-fold higher than that for furamidine 
in both IPLs (Table 3.2) and SCH (Table 3.5). The extent of formation of CPD-0801 was 
only ≤2.5-fold higher than that of furamidine (Fig. 3.4A and Fig. 3.4B; Table 3.3).  These 
observations indicated that net basolateral efflux predominated over metabolism in 
governing perfusate/medium exposure to active metabolite.  
The fu,L of CPD-0801 was ~5-fold higher than that of furamidine. Based on Model 2 
(Fig. 3.2), the ratio of biliary excretion (kA_bile,u) to basolateral efflux (kA_net efflux,u) rate 
constants for furamidine was 9 (Table 3.4), suggesting that once formed in liver, the 
predominant process that determines furamidine elimination is excretion into bile, whereas 
biliary and basolateral excretory processes contribute approximately equally to CPD-0801 
hepatic excretion (Table 3.4). Incorporation of fu,L in Model 2 (Fig. 3.2) resulted in a 
comparable kA_net efflux,u of both active metabolites (Table 3.4), indicating that the 6-fold 
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difference in the rate constant for net basolateral efflux of total formed active metabolite 
(kA_net efflux) could be attributed largely to the 5-fold difference in hepatic binding.  
During an expanded phase I safety study in indigenous African volunteers, 
pafuramidine demonstrated transiently elevated liver transaminases, a known class effect of 
diamidines (Paine et al., 2010). In rats administered a single oral dose of pafuramidine (10 
mg/kg), liver-to-plasma partitioning (Kp) of furamidine was as high as 1300 (Midgley et al., 
2007). As shown in the current study, hepatic accumulation of furamidine was extensive, 
and the unbound fraction of furamidine in liver was at least 80-fold lower than that in plasma 
and perfusate (Table 3.3). Thus, binding sites in liver may act as an “intracellular sink” that 
limit systemic exposure to furamidine. Previous subcellular fractionation studies 
demonstrated that furamidine accumulated primarily in the mitochondrial fraction of liver 
tissue (Midgley et al., 2007). Consistent with these observations, preliminary fractionation 
studies with rat IPLs revealed that furamidine was localized primarily in the mitochondrial 
fraction (43%); CPD-0801 was localized primarily in the cytosolic fraction (45%), with 
negligible mitochondrial accumulation (≤1%) (GZY, KLRB, MFP, unpublished observations). 
Extensive accumulation of furamidine in mitochondria could cause mitochondrial dysfunction 
and trigger liver signal elevations (Pessayre et al., 1999).  Significant hepatic accumulation 
of furamidine is consistent with previous in vivo data (Midgley et al., 2007) suggesting that 
hepatocellular sequestration may limit systemic exposure of furamidine and predispose the 
liver to elevated signals. In contrast, a significantly higher hepatic unbound fraction and less 
mitochondrial accumulation of CPD-0801, compared to furamidine, could enhance systemic 
exposure to CPD-0801 and reduce hepatic signals. 
Utilizing appropriate preclinical hepatic models to estimate liver-to-plasma 
partitioning of potential hepatotoxicants has been a topic of interest in toxicologic risk 
assessment. In the current study, the liver-to-perfusate partition coefficient (Kp,IPLs) of 
furamidine measured in IPLs was 3700, about 2.8-fold higher than the in vivo Kp (1300) 
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measured in rats. This discrepancy can be explained by the 2-fold difference in the extent of 
protein binding of furamidine in perfusate (composed of 20% blood) versus plasma (Table 
3.3). If basolateral membrane barriers are absent, liver-to-plasma partitioning can be 
estimated as the ratio of the unbound fraction of furamidine in plasma to that in liver (i.e., Kp 
= fu,P/fu,L = 24/0.3 = 80), assuming the liver is a well-stirred organ (Rowland, 1985). Similarly, 
Kp,IPLs = fu,Per/fu,L = 44/0.3 = 147. Both estimated Kp and Kp,IPLs values are much lower than 
observed values in IPLs and intact rats, suggesting that active transport may be involved in 
the increased hepatic partitioning of furamidine in the intact organ. Notably, cell-to-medium 
partition coefficients of furamidine/CPD-0801 measured in SCH (Kp,SCH) overestimated 
corresponding values measured in IPLs (Kp,IPLs) by approximately 6-fold. This discrepancy 
could be explained, in part, by the absence of serum in culture medium, which resulted in a 
higher fu in medium (approximately unity) than that in perfusate. Therefore, binding 
differences in transport buffer/medium and plasma need to be considered when using SCH 
to estimate liver-to-plasma partitioning. Nonetheless, both Kp,SCH and Kp,IPLs of furamidine 
were >5-fold higher than those of CPD-0801.  
The intermediate metabolite, M3, from both prodrugs was excreted extensively into 
bile in IPLs; M3 from CPD-0868 was the most extensively excreted compound in bile among 
all prodrugs and metabolites.  Both active metabolites also were recovered in bile, but to a 
20- to 50-fold lesser extent than M3 from CPD-0868 (Table 3.2). In contrast, only M3 from 
CPD-0868 was recovered in bile of SCH. Unlike in IPLs, biliary excretion in SCH was 
measured indirectly, by determining the difference in substrate accumulation between 
standard HBSS (cells+bile) and Ca2+-free HBSS (cells) (Liu et al., 1999b). As reported 
previously, SCH may under-predict in vivo biliary clearance of compounds due to less 
extensive canalicular network formation relative to whole liver (Liu et al., 1999b; Hoffmaster 
et al., 2005; Abe et al., 2008). To compare the biliary excretion in SCH and in IPLs, the 
intrinsic biliary clearance of M3 from CPD-0868 in SCH (ClM3_biliary, SCH) was estimated by 
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multiplying kM3_bile (Table 3.5) by the hepatocellular volume of 6.2 × 10-6 µl/hepatocyte (Swift 
et al., 2009), and then scaled up to l/h/g liver based on 110 × 106 hepatocytes/g rat liver (Ito 
and Houston, 2004) and 1 × 106 hepatocytes/well in 6-well plates. The intrinsic biliary 
clearance of M3 from CPD-0868 in IPLs (ClM3_biliary, IPLs) was estimated by multiplying kM3_bile 
(Table 3.2) by the hepatocellular volume of 0.6 ml/g rat liver (Pang et al., 1988). Scaled 
ClM3_biliary, SCH approximated ClM3_biliary, IPLs (3.4 × 10-5 versus 25 × 10-5 l/h/g liver) within an 
order of magnitude. As shown in rat IPLs, the fraction of total formed furamidine and CPD-
0801 excreted into bile at 2 h was ≤3% (calculated by subtraction of percent of hepatic 
accumulation from unity; Table 3.3); in addition, kA_bile of furamidine and CPD-0801 was 20- 
to 50-fold lower compared to M3 (kM3_bile) from CPD-0868 (Table 3.2). Therefore, biliary 
excretion of furamidine/CPD-0801 may be so small that the difference in substrate 
accumulation between standard and Ca2+-free HBSS was indistinguishable.  
A previous study showed that CYP4F2 and CYP4F3B were the major enzymes 
responsible for pafuramidine O-demethylation (M1 formation) in human liver microsomes 
(Wang et al., 2006).  The enzymes involved in this reaction in rats have not been identified. 
Cyp1a2, Cyp2d2, and Cyp4f1 were reported to catalyze CPD-0868 O-demethylation in rat 
liver microsomes (Generaux, 2010). In the current work, metabolic activity in rat SCH was 
maintained by supplementing the culture medium with 1 µM DEX, a standard concentration 
used in metabolism studies with SCH (Turncliff et al., 2006). Further studies are warranted 
to characterize the effect of DEX concentration on expression/activity of the enzymes 
involved in the biotransformation of both prodrugs.  
In summary, an integrated approach involving two rat hepatic systems (IPLs and 
SCH) and pharmacokinetic modeling provided a mechanistic understanding of the impact of 
hepatic binding on the systemic and hepatobiliary exposure of two antiparasitic active 
metabolites. As hypothesized, despite structural similarities, CPD-0868 had superior 
hepatobiliary disposition characteristics compared to pafuramidine, as reflected by more 
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extensive formation of the active metabolite, CPD-0801, together with higher hepatic 
basolateral efflux (due to a higher hepatic unbound fraction), compared with furamidine. The 
combined effect of both factors could explain, in part, the enhanced systemic exposure of 
CPD-0801. Although mechanism(s) of brain penetration for these active metabolites have 
not been elucidated, an increased systemic exposure of CPD-0801 could lead to improved 
brain exposure. Based on similar in vitro potencies of both active metabolites against 
various strains of trypanosomes (Wenzler et al., 2009), increased brain exposure of CPD-
0801 may enhance antitrypanosomal efficacy in the central nervous system relative to 
furamidine. The agreement between results from rat IPLs and SCH further substantiates 
SCH as a useful in vitro tool to characterize hepatobiliary disposition of xenobiotics. 
Because human IPLs are not feasible, human SCH could be utilized as a surrogate to 
predict hepatobiliary disposition of xenobiotics in humans. 
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F.       TABLES 
 
Table 3.1. Hepatic clearance and extraction ratio of prodrugs in rat isolated perfused livers. 
 
Hepatic Clearance (ml/min) Prodrug Total Metabolic Biliary EH 
Pafuramidine 17.6 17.6 < 0.1 0.88 
CPD-0868 12.4 12.4 < 0.1 0.62 
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Table 3.2. Kinetic parametersa, generated from Model 1, associated with the disposition of 
prodrugs (pafuramidine and CPD-0868) and derived metabolites in rat isolated perfused 
livers. 
 
Pafuramidine / Metabolites CPD-0868 / Metabolites 
Parameters  
Estimate  
(h-1) 
CV 
(%) 
Estimate 
(h-1) 
CV  
(%) 
kP_net uptake 58 88 13 23 
kP→M1 N.A.b N.A. 3.8 7 
kM1_reuptake N.A. N.A. 96 55 
kM1_efflux N.A. N.A. 330 62 
kP→M3 1.7 6 N.A. N.A. 
kM1→M3 N.A. N.A. 108 20 
kM3_reuptake 13 69 11 33 
kM3_efflux 0.31 72 0.20 29 
kM3_bile 0.096 11 0.42 14 
kM3→A 0.43 8 1.5 12 
kA_reuptake 2.7 >100 3.3 >100 
kA_efflux 0.0065 >100 0.028 >100 
kA_net effluxc 0.0021 14 0.012 51 
kA_bile 0.020 48 0.0084 61 
aDefined in the legend to Fig. 3.2. No discernable correlation between parameters was observed by 
evaluation of the correlation matrix (absolute correlation value ≤0.5).  See Supplemental Fig. 3.S1 for 
the plot of weighted residual versus time data. 
 
bNot applicable. 
cDue to the high variability associated with the parameter estimates for kA,reuptake and kA_efflux, Model 1 
was modified to include a net efflux term, kA_net efflux. 
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Table 3.3.  Comparison of hepatic disposition of active metabolites in isolated perfused 
livers (IPLs) and day-4 sandwich-cultured hepatocytes (SCH) from rats. 
 
Rat IPLs Rat SCH 
Measurea 
Furamidine CPD-0801 Furamidine CPD-0801 
Hepatic Accumulation (%) 99 ± 1 97 ± 1 99 ± 0 95 ± 1* 
Extent of Formationb (%) 31 ± 6 72 ± 14* 49 ± 2 61 ± 11 
Perfusate or Medium 
AUC (µM•h)c 0.006 ± 0.002 0.06 ± 0.01* 0.6 ± 0.1 4.2 ± 0.3* 
Liver-to-perfusate or  
cell-to-medium  
partition coefficient  
3,700 800 27,000 4,700 
fu,Ld (%) 0.3 ± 0.1 1.6 ± 0.3* N.A.
e N.A. 
fu,Per f (%) 44 ± 5 70 ± 6* N.A. N.A. 
fu,P f (%) 24 ± 2 38 ± 3* N.A. N.A. 
aComparisons between furamidine and CPD-0801 for all outcomes were made using the two-tailed 
Student’s t-test. *p<0.05 versus furamidine. Values denote mean ± SD. 
 
bMeasured at the end of the perfusion for IPLs (120 min) and at the end of the incubation for SCH (24 
h). 
 
cCalculated as the area under the respective concentration-time curves from 0 to 2 h (IPL) and from 0 
to 24 h (SCH), respectively. 
 
dUnbound fraction of formed active metabolite in liver. 
 
eNot applicable. 
 
fUnbound fractions of preformed active metabolite added to perfusate or plasma at 1 µM. 
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Table 3.4. Kinetic parametersa, generated from Model 2, associated with the hepatic 
excretion of unbound active metabolites in rat isolated perfused livers. 
 
kA_net efflux,u kA_bile,u Unbound Active 
Metabolite Estimate (h-1) 
CV 
(%) 
Estimate 
(h-1) 
CV 
(%) 
Furamidine 0.66 16 6.0 19 
CPD-0801 0.60 42 0.74 40 
aDefined in the legend to Fig. 3.2. 
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Table 3.5. Kinetic parametersa, generated from Model 1, associated with disposition of 
prodrugs (pafuramidine and CPD-0868) and derived metabolites in Day-4 sandwich-cultured 
rat hepatocytes. 
 
Pafuramidine / Metabolites CPD-0868 / Metabolites 
Parameters 
Estimate  
(h-1) 
CV 
(%) 
Estimate 
(h-1) 
CV  
(%) 
kP_net uptake 0.30 7 0.40 4 
kP→M1 N.A.b N.A. 67 37 
kM1_reuptake N.A. N.A. 3.5 29 
kM1_efflux N.A. N.A. 71 42 
kP→M3 1.3 26 N.A. N.A. 
kM1→M3 N.A. N.A. 12 40 
kM3_reuptake 0.080 90 0.15 30 
kM3_efflux N.A. N.A. 0.35 27 
kM3_bile N.A. N.A. 0.050 55 
kM3→A 0.46 16 0.66 15 
kA_reuptake 0.83 >100 0.27 >100 
kA_efflux 0.0080 >100 0.015 >100 
kA_net effluxc 0.00076 >100 0.0046 27 
kA_bile N.A. N.A. N.A. N.A. 
aDefined in the legend to Fig. 3.2. No discernable correlation between parameters was observed by 
evaluation of the correlation matrix (absolute correlation value ≤0.5).  See Supplemental Fig. 3.S2 for 
the plot of weighted residual versus time data. 
 
bNot applicable. 
 
cDue to the high variability associated with the parameter estimates for kA,reuptake and kA_efflux, Model 1 
was modified to include a net efflux term, kA_net efflux. 
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G.        FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Biotransformation of prodrug to active metabolite and corresponding chemical 
structures. 
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Figure 3.2. Model schemes depicting disposition of prodrugs/metabolites in rat IPLs and 
SCH (Model 1) and hepatic excretion of unbound active metabolite in rat IPLs (Model 2). 
kP_net uptake represents the first-order rate constant for net hepatic uptake of prodrug; kP→M1 
represents the first-order rate constant for metabolic conversion from prodrug to 
intermediate metabolite M1; kM1_efflux and kM1_reuptake represent the first-order rate constants 
for hepatic basolateral efflux and reuptake of M1; kP→M3 represents the first-order rate 
constant for metabolic conversion from prodrug (pafuramidine only) to intermediate 
metabolite M3; kM1→M3 represents the first-order rate constant for metabolic conversion from 
M1 to M3; kM3_efflux, kM3_reuptake and kM3_bile represent the first-order rate constants for hepatic 
basolateral efflux, reuptake and biliary excretion of M3; kM3→A represents the first-order rate 
constant for metabolic conversion from M3 to active metabolite; kA_efflux, kA_reuptake, kA_net effulx 
and kA_bile represent the first-order rate constants for hepatic basolateral efflux, reuptake, net 
basolateral efflux and biliary excretion of active metabolite; fu,L represents hepatic unbound 
fraction of active metabolite; kA_net efflux,u and kA_bile,u represent first-order rate constants for 
hepatic basolateral net efflux and biliary excretion of unbound active metabolite. 
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Figure 3.3. Disposition of prodrugs, pafuramidine (A) and CPD-0868 (B), and corresponding 
metabolites over 120 min in rat isolated perfused livers. Prodrug (10 µM) was administered 
as a bolus to the perfusion reservoir, which contained 80 ml of 20% (v/v) rat blood. , 
prodrug; , M1; , M3; , active metabolite. Symbols and error bars for perfusate 
concentrations denote means and SDs, respectively, of n=5 livers. Symbols and error bars 
for liver mass denote means and SDs, respectively, of n=5 livers, using a destructive 
sampling strategy. Solid lines represent perfusate concentration-time profile of prodrug and 
derived metabolites. Dashed lines represent liver amount-time profile of active metabolite. 
Solid and dashed Lines represent the computer-generated best fit of the pharmacokinetic 
scheme depicted in Fig. 3.2 (Model 1) to the data. Note: pafuramidine contained 5-10% 
impurities, largely as M3; M1 from pafuramidine is not included in (A) because of low 
recovery in perfusate, as described in Results.   
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Figure 3.4.  Extent of formation of active metabolites represented as total amount of active 
metabolite recovered in perfusate, liver and bile as a percentage of the initial amount of 
prodrug added to the perfusate reservoir from isolated perfused rat liver experiments (A; 
mean ± SD, n=5 livers), and total amount of active metabolite recovered in medium, cells 
and bile as a percentage of the initial amount of prodrug added to the culture medium from 
sandwich-cultured rat hepatocyte experiments (B; mean ± SD, n=2 livers in duplicate). 
*p<0.05 versus furamidine (two-tailed Student’s t test). 
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Figure 3.5. Disposition of prodrugs, pafuramidine (A) and CPD-0868 (B) and corresponding 
metabolites over 24 h in day-4 sandwich-cultured rat hepatocytes. Prodrug (10 µM) was 
administered as a bolus to each well, which contained 1.5 ml culture medium. , prodrug; 
, M1; , M3; , active metabolite. Symbols and error bars denote means and SDs, 
respectively, of n=2 livers in duplicate. Solid lines represent medium concentration-time 
profile of prodrug and derived metabolites. Dashed lines represent hepatocyte amount-time 
profile of active metabolite. Solid and dashed lines represent the computer-generated best 
fit of the pharmacokinetic model depicted in Fig. 3.2 (Model 1) to the data. Note: 
pafuramidine contained 5-10% impurities, primarily M3; M1 from pafuramidine is not 
included in (A) because of low recovery in medium, as described in Results. 
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Supplemental Fig. S1. Plot of the weighted residual versus time data from the computer-
generated best fit of Model 1 to the rat isolated perfused liver data depicted in Fig. 3.3.  
Pafuramidine/metabolites (A) and CPD-0868/metabolites (B) are denoted as follows: , 
prodrug in perfusate; , M1 in perfusate; , M3 in perfusate; , active metabolite in 
perfusate; , active metabolite in liver. A weighting factor of 1/y2 was applied. 
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Supplemental Fig. 3.S2. Plot of the weighted residual versus time data from the computer-
generated best fit of Model 1 to the rat sandwich-cultured hepatocyte data depicted in Fig. 
3.5.  Pafuramidine/metabolites (A) and CPD-0868/metabolites (B) are denoted as follows: , 
prodrug in medium; , M1 in medium; , M3 in medium; , active metabolite in medium; 
, active metabolite in hepatocytes. A weighting factor of 1/y2 was applied. 
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A.        ABSTRACT 
Dose selection during antiparasitic drug development in animal models and humans 
traditionally has relied on correlations between plasma concentrations obtained at or below 
maximally tolerated doses that are efficacious. The objective of this study was to improve 
the understanding of the relationship between dose and plasma/tissue exposure of the 
model antiparasitic agent, pafuramidine, using a semi-physiologically-based 
pharmacokinetic (PBPK) modeling approach.  Preclinical and clinical data generated during 
the development of pafuramidine, a prodrug of the active metabolite, furamidine, were 
utilized. A whole-body semi-PBPK model for rats was developed based on a whole-liver 
semi-PBPK model using rat isolated perfused liver data.  A whole-body semi-PBPK model 
for humans was developed based on the whole-body rat model.  Scaling factors were 
calculated using metabolic and transport clearance data generated from rat and human 
sandwich-cultured hepatocytes. Both whole-body models described pafuramidine and 
furamidine disposition in plasma and predicted furamidine tissue (liver, kidney) exposure 
and excretion profiles (biliary, renal). The whole-body models predicted that the intestine 
contributes significantly (30-40%) to first-pass furamidine formation in both rats and humans.  
The predicted terminal elimination half-life of furamidine in plasma was three- to four-fold 
longer than that of pafuramidine in rats (170 versus 47 h) and humans (64 versus 19 h). The 
dose-plasma/tissue exposure relationship for the prodrug/active metabolite pair was 
determined using the whole-body models.  The human model proposed a dose regimen of 
pafuramidine (40 mg once daily) based on a pre-defined efficacy-safety index. A similar 
strategy could be used to guide dose-ranging studies in humans for next-in-class 
compounds.  
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B.        INTRODUCTION 
The primary goal of preclinical drug development is to identify compounds with 
optimal efficacy and safety profiles and desirable pharmacokinetic properties to advance to 
clinical trials. The design of safe and effective dosage regimens that are compatible with the 
target patient population and disease remains a major challenge. Suboptimal dose selection 
can adversely influence progression of a drug development program, resulting in additional 
time and expense for the dose-ranging study (dose too low), or a poor understanding of 
risk/benefit, causing unnecessary early termination of promising drug candidates (dose too 
high).   
Human African trypanosomiasis (HAT), a life-threatening parasitic disease, afflicts 
the world’s poorest populations (Barrett, 2010). HAT is characterized by a first stage, when 
parasites proliferate in the hemolymphatic system, and a second stage, when parasites 
cross the blood brain barrier and invade the central nervous system.  The disease is fatal if 
untreated. All current chemotherapies are unsatisfactory due to toxicity and/or inconvenient 
parenteral administration regimens (Barrett, 2010). Pafuramidine, a prodrug of furamidine, is 
the only orally-active agent that has shown efficacy in clinical trials for treatment of first 
stage infection (Paine et al., 2010). However, clinical development of pafuramidine was 
placed on hold due to transiently elevated liver transaminases observed in an expanded 
Phase I safety trial (www.immtechpharma.com/documents/news_022208.pdf) (Paine et al., 
2010). Bioconversion of pafuramidine to furamidine is believed to occur primarily in the liver.  
The metabolic pathway involves sequential oxidative and reductive reactions, producing four 
intermediate metabolites (Zhou et al., 2004). Following a single oral dose of 14C-
pafuramidine (10 mg/kg) to rats, tissue retention of total radioactivity, predominately as 
furamidine, was extensive (Midgley et al., 2007). The highest concentration of radioactivity 
was detected in liver, which was three orders of magnitude higher than that measured in 
plasma 24 h post-administration; radioactivity was still detectable in liver after seven days.  
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Unlike with animal models, collection of liver tissue from human subjects over a prolonged 
period of time is impossible due to obvious ethical reasons. Alternatively, a semi-
physiologically-based pharmacokinetic (PBPK) modeling approach could be used to predict 
the furamidine hepatic exposure-time profile in humans, permitting an improved 
understanding of the relationship between the dose of pafuramidine and plasma/hepatic 
exposure of furamidine. 
Hepatic clearance is a fundamental PBPK model parameter. Several approaches 
have been developed to predict human hepatic clearance, including 1) empirical allometric 
scaling; 2) physiologically-based direct scaling of in vitro human clearance; and 3) 
normalized scaling of in vivo animal clearance based on in vitro animal and human data 
(Luttringer et al., 2003; Ito and Houston, 2005). Empirical allometric scaling, a conventional 
technique based on body weight, frequently fails when drug disposition demonstrates large 
species differences (Lave et al., 1999). With physiologically-based direct scaling, intrinsic 
clearance, determined from human hepatocytes or liver microsomes, is corrected by a 
physiologically-based scaling factor, and subsequently scaled up based on a liver model 
(well-stirred or parallel-tube) (Ito and Houston, 2004). Although preferred to empirical 
allometric scaling, physiologically-based direct scaling consistently underestimates human 
clearance due to decreased enzyme activity or incomplete enzyme composition associated 
with in vitro systems (Ito and Houston, 2005). Normalized scaling, via integration of in vivo 
and in vitro data, represents an alternative approach to predict human pharmacokinetics 
(Lave et al., 1997; Luttringer et al., 2003). Application of these approaches has been limited 
primarily to the estimation of metabolic clearance of parent compounds; interspecies 
extrapolation of both metabolic and transport clearance values are reported rarely for 
metabolites (Pang et al., 2008). In the current work, normalized scaling was applied to 
isolated perfused rat liver (IPL) and rat/human sandwich-cultured hepatocyte (SCH) data to 
predict the metabolic/transport clearance of pafuramidine/furamidine. The following 
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modeling strategy was used: 1) develop a whole-liver PBPK model using rat IPL data; 2) 
develop and validate a whole-body PBPK model for rats based on the IPL model; 3) develop 
a whole-body PBPK model for humans to predict furamidine plasma and tissue exposure 
under various multiple-dose scenarios of pafuramidine. This strategy could be used to guide 
dose-ranging human studies for next-in-class compounds. 
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C.         MATERIALS AND METHODS 
Materials and Chemicals.  Dulbecco’s modified Eagle’s medium (DMEM) was 
purchased from Invitrogen/GIBCO (Carlsbad, CA). ITS+TM (insulin/transferring/selenium) 
culture supplement and MatrigelTM were obtained from BD Biosciences (Bedford, MA). 
Penicillin, streptomycin, non-essential amino acids (NEAA), dexamethasone (DEX), Hanks’ 
balanced salt solution (HBSS), modified HBSS (HBSS without Ca2+ and Mg2+, with 0.38 g/l 
EGTA), and phosphate buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis, 
MO). Human plasma was obtained from Biological Specialty Corporation (Colmar, PA). 
Pafuramidine, furamidine, and internal standards (d8-pafuramidine and d8-furamidine) were 
synthesized in the laboratory of Dr. David W. Boykin (Georgia State University, Atlanta, GA) 
as described (Boykin et al., 1996). All other chemicals and reagents were of analytical grade 
and were used without further purification. 
Animals. Male Wistar and Sprague-Dawley (SD) rats (250-300 g) were purchased 
from Charles River Laboratories (Raleigh, NC). Animals had free access to water and food 
before surgery. All animal procedures were compliant with guidelines of the University of 
North Carolina Institutional Animal Care and Use Committee. 
Disposition of Pafuramidine and Furamidine in Isolated Perfused Livers (IPLs) 
from Rats. Data were obtained from a previous recirculating rat IPL study, in which 
pafuramidine was added as a bolus to the perfusate reservoir to yield an initial concentration 
of 10 µM (Yan et al., 2011). In brief, perfusions were conducted ex situ over designated 
times (up to 2 h) in a temperature-controlled chamber. Aliquots of perfusate (~400 µl) were 
collected from the IPL reservoir at 5-min intervals from 0-40 min and at 10-min intervals 
thereafter, and bile was collected at 10-min intervals; the liver was harvested at the end of 
perfusion. 
Determination of Unbound Fraction. The unbound fractions of furamidine in liver 
and perfusate from rat IPL experiments and rat plasma, determined using rapid equilibrium 
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dialysis devices (Pierce Biotechnology, ThermoFisher Scientific, Waltham, MA), were 
provided from a previous study (Yan et al., 2011). In the present study, the unbound 
fractions of pafuramidine in liver and perfusate from rat IPL experiments and rat plasma, as 
well as unbound fractions of pafuramidine and furamidine in human plasma, were 
determined using the same method. In brief, pafuramidine or furamidine was added to 
thawed rat liver homogenates/perfusate/plasma to yield a concentration of 1 µM, and a 200-
μl aliquot, and 350 μl of 0.1 M PBS, was placed in tissue and buffer chambers, respectively, 
and incubated (37°C) on a thermomixer (350 rpm) (Eppendorf AG, Hamburg, Germany). 
After 6 h, aliquots (100 µl) were collected from the sample and buffer chambers and 
analyzed for total (bound+unbound) and unbound pafuramidine or furamidine, respectively, 
by LC-MS/MS.  
Determination of Blood-to-Plasma (B/P) Ratio in Rats. The B/P ratios of 
pafuramidine and furamidine in rats were determined using an in vitro method described 
previously (Berry et al., 2010). In brief, pafuramidine or furamidine was added to pre-
warmed fresh rat blood and reference (blank) plasma to yield a concentration of 0.1 µM. 
After incubation at 37 °C for 1 h in a humidified and oxygenated incubator, compound-
treated rat blood was centrifuged at 1500 g for 10 min, and plasma was separated from 
blood cells. Plasma was analyzed for pafuramidine and furamidine by LC-MS/MS. The B/P 
ratios were calculated by dividing the peak area observed in the reference plasma 
(representing nominal blood concentration) by the peak area observed in the compound-
treated plasma (representing plasma concentration).  
Disposition of Pafuramidine and Furamidine in Rat and Human Sandwich-
Cultured Hepatocytes (SCH).  Rat SCH data were obtained from a previous study (Yan et 
al., 2011). Freshly-isolated suspended human hepatocytes, provided by Invitrogen (Durham, 
NC), were seeded at 1.5 x 106 cells/well onto 6-well plates and overlaid with MatrigelTM in 
the same manner as described for rat hepatocytes (Yan et al., 2011). The liver donors were 
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reported as Caucasian (two women and one man; 50, 56, and 57 years old, respectively). 
Culture medium (DMEM supplemented with 1% (v/v) ITS+TM, 1 µM DEX, 2 mM L-glutamine, 
1% (v/v) NEAA, 100 units penicillin G sodium, and 100 µg/ml streptomycin sulfate) was 
changed daily for 5-7 days until extensive canalicular networks were formed. On the day of 
experimentation, SCH were incubated with culture medium (1.5 ml) containing pafuramidine 
at the same concentration (10 µM) as that used in rat SCH experiments (Yan et al., 2011). 
At designated times up to 24 h, aliquots of medium (500 µl) were collected, and cells were 
washed twice and incubated at 37°C for 5 min with 2 ml standard HBSS (to maintain bile 
canalicular networks; cells+bile) or Ca2+-free HBSS (to open bile canalicular spaces; cells) 
(Turncliff et al., 2006). After incubation, buffer was removed, and cells were washed three 
times with 2 ml ice-cold standard HBSS and lysed with 1 ml ice-cold methanol/water (7:1 
v/v) containing 0.1% (v/v) trifluoroacetic acid (TFA). Media and cell lysates were stored at -
80°C pending analysis for pafuramidine and furamidine by LC-MS/MS.  
In Vivo Studies  
Rats. Data were provided from a previous study, in which four Sprague Dawley rats 
were administered a single dose of pafuramidine (7.5 μmol/kg) by oral gavage (Generaux, 
2010). Pafuramidine was prepared as a suspension in acidified water (pH = 3)/70% Tween 
80 in ethanol (7:3 v/v). Blood (0.2 ml) was collected via a jugular vein cannula over 24 h 
after pafuramidine administration. Plasma was separated from blood cells by centrifugation 
(1500 g for 10 min) and analyzed for pafuramidine and furamidine by LC-MS/MS. 
Humans. Data were provided from a previous clinical study (Olson, 2008). 
The Institutional Review Board reviewed and approved the study protocol. In brief, male 
Caucasian volunteers (n=6) were administered a single oral dose of 14C-pafuramidine (100 mg). 
The dose was prepared in capsule form, containing 0.7 MBq (19 µCi) of radioactivity, and 
administered following a high fat meal to facilitate absorption. After administration of 14C-
pafuramidine, blood was collected at designated times over 168 h. Urine and feces were 
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collected for up to 14 and 21 days, respectively, post pafuramidine administration.  Total 
radioactivity was measured in whole blood, plasma, urine, and feces by high performance liquid 
radiochromatography; pafuramidine and furamidine concentrations in plasma were measured by 
LC-MS/MS. 
LC-MS/MS Analysis. In vitro samples and rat plasma. Pafuramidine and furamidine 
were quantified using an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, 
Foster City, CA) equipped with a Turbo IonSpray interface (MDS Sciex, San Francisco, CA). 
The sample preparation procedure and LC-MS/MS conditions for the quantification of 
pafuramidine and furamidine were detailed previously (Yan et al., 2011). Briefly, 
pafuramidine/furamidine and internal standards (d8-pafuramidine/d8-furamidine) were separated 
on an Aquasil C18 HPLC column (2.1 mm × 50 mm, 5 µm) (Thermo Electron, Waltham, MA) 
with a high-pressure linear gradient program.  Calibration curves were prepared in appropriate 
matrices (0.05-5 µM in liver homogenates; 1-10,000 nM in perfusate, medium, cell lysates, 
human plasma, and PBS) and were linear over the respective ranges (R2 > 0.98).  The limit of 
quantification was 5 nM for both compounds. Human plasma. Quantification of pafuramidine 
and furamidine was carried out by Tandem Labs (Salt Lake City, UT). The stock solutions of 
analytes (pafuramidine and furamidine) and internal standards (d8-pafuramidine and d8-
furamidine) were prepared in 100% methanol to yield concentrations of 0.37, 0.41, 0.21, and 0.3 
mg/ml, respectively. Stock solutions of pafuramidine and furamidine were diluted in blank 
human plasma to yield working concentrations of 5000 and 2000 ng/ml for preparation of 
calibration standards and quality controls, respectively. Calibration standards (0.25-250 ng/ml) 
and quality controls (0.75, 75, and 200 ng/ml) for pafuramidine and furamidine were prepared by 
serial dilution of the corresponding working solution with blank human plasma. The working 
internal standards (100 ng/ml for d8-pafuramidine and d8-furamidine) were prepared by diluting 
the respective stock solution with 0.05% TFA in water:methanol (5:5 v/v); 50 µl of the diluted 
stock solution and 500 µl of 50 nM ammonium acetate buffer (pH = 3) were added to 100 µl of 
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human plasma, standards, and quality controls. After vortex-mixing, all samples were loaded 
onto Polycrom B1000 1cc, 20-mg extraction cartridges (Cera, Inc., Baldwin Park, CA), followed 
by serial washing of the solid phase with 300 µl of 50 mM ammonium acetate buffer (pH 3), 
followed by 300 µl of 50 mM ammonium acetate buffer (pH = 3):methanol (8:2 v/v). Analytes 
were eluted with 300 µl of acetonitrile, followed by 300 µl of 0.1% hydrochloric acid in methanol. 
After evaporation at 45°C (TurboVap®; Zymark Corp., Hopkinton, MA), samples were 
reconstituted with 50 µl of 0.05% TFA in water:acetonitrile (9:1 v/v) and transferred to HPLC 
vials.  Pafuramidine and furamidine were quantified on an API 3000 triple quadrupole mass 
spectrometer (PE Sciex, Concord, Ontario). Analytes were separated on a BDS Hypersil Phenyl 
HPLC column (2 mm x 50 mm, 5 µm) at 35°C with a high-pressure linear gradient program 
consisting of 0.05% TFA in HPLC-grade water (A) and HPLC-grade acetonitrile (B) delivered by 
a Hewlett Packard HP 1100 pumping system (Hewlett Packard, Palo Alto, CA) at a flow rate of 
300 µl/min.  Mobile phase composition was increased from 10% to 70% B from 0 to 3.5 min, 
and then decreased to 10% B from 3.5 to 3.6 min; the column was re-equilibrated for 2 min 
before the next injection. Calibration curves for pafuramidine and furamidine were linear from 
0.25-250 ng/ml (R2 > 0.99). Intra- and Inter-day precision (expressed as CV%) and accuracy 
(expressed as bias%) of quality controls for both compounds were <15%. The mass 
spectrometers were operated in positive ion mode using multiple reaction monitoring: 
pafuramidine, 365.1→334.1 m/z; furamidine, 305.3→288.1 m/z; d8-pafuramidine, 373.1→242.0 
m/z; d8-furamidine, 313.3→296.1 m/z. 
Semi-Physiologically-Based Pharmacokinetic (PBPK) Modeling 
Modeling Strategy 
Kinetic parameters associated with hepatic disposition of pafuramidine and 
furamidine were generated from the whole-liver semi-PBPK model and utilized to develop 
the whole-body rat semi-PBPK model. Preclinical data on preformed furamidine kidney-to-
plasma partitioning and renal excretion were incorporated to predict formed furamidine 
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disposition in rats. In vivo rat data were used to develop the semi-PBPK model structure and 
associated parameters. Kinetic parameters for humans (see model parameterization) were 
utilized to predict the disposition of pafuramidine and furamidine and, ultimately, to predict 
the relationship between dose and plasma or tissue exposure. 
Model Structure   
Rats. Whole-liver. Pafuramidine and furamidine submodels were linked by 
pafuramidine metabolism in the liver (Fig. 4.1A). The pafuramidine submodel for rat IPLs 
was composed of two compartments: perfusate reservoir and liver (Fig. 4.1A).  The 
furamidine submodel was composed of three compartments: perfusate reservoir, liver, and 
bile. Pafuramidine is highly lipophilic (Log DpH_7 = 4.3) (Zhou et al., 2002) and poorly-soluble, 
qualifying as a class II compound according to the Biopharmaceutics Classification System 
(BCS) (Wu and Benet, 2005).  As such, pafuramidine was assumed to diffuse passively 
through the hepatic basolateral membrane. In contrast to pafuramidine, furamidine is 
hydrophilic (Log DpH_7 = -3) (Zhou et al., 2002). Furamidine basolateral reuptake and efflux 
clearances (ClF_up, u and ClF_eff, u; Table 4.1) estimated by the whole-liver model (Fig. 4.1A) 
were at least two-fold lower than perfusate flow rate (4 l/h/kg), suggesting that diffusional 
barriers exist for furamidine.  Therefore, distribution of pafuramidine and furamidine in liver 
was assumed to be flow- and diffusion-limited, respectively (Fig. 4.1A). 
Whole-body. The whole-liver rat model was expanded into a whole-body rat model 
by substituting the perfusion reservoir with the blood compartment (Fig. 4.1B).  Based on the 
high lipophilicity of pafuramidine, fat was added as a storage organ in the pafuramidine 
submodel. The kidney was incorporated as an additional storage organ in the furamidine 
submodel based on the significant kidney retention of furamidine (Midgley et al., 2007; 
Goldsmith, 2011); all other tissues were grouped together as “rest of body” in both 
submodels to maintain mass balance (Fig. 4.1B). Pafuramidine distribution into the liver was 
assumed to be flow-limited, whereas furamidine distribution into the liver was assumed to be 
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diffusion-limited. To avoid over-parameterization, distribution of both compounds into all 
other organs was assumed to be flow-limited (Fig. 4.1B).  
Based on the high hepatic extraction ratio calculated from IPL data (EH = 0.88) (Yan 
et al., 2011), pafuramidine was assumed to be cleared from the body primarily via hepatic 
metabolism.  Based on in vivo data, furamidine was assumed to be eliminated via both 
biliary and renal excretion (Midgley et al., 2007; Goldsmith, 2011). To simulate pafuramidine 
and furamidine plasma concentration-time profiles, the model incorporated a single gut 
compartment for pafuramidine absorption following oral administration. Absorption of 
pafuramidine from gut to liver was assumed to be a first-order process. Because the initial 
model failed to describe the prompt appearance of furamidine in plasma, the model was 
modified to include the gut as a site of furamidine formation during pafuramidine absorption.  
Humans. The final whole-body rat model was utilized initially to predict the 
disposition of pafuramidine/furamidine in humans. However, model predictions failed to 
describe the delayed absorption of pafuramidine observed in humans, which may be 
attributed to the capsule formulation and concurrent administration of a high fat meal. 
Therefore, three consecutive transit compartments were added between the site of 
administration (oral route) and site of absorption (gut) in the pafuramidine submodel (Fig. 
4.1B) to represent dissolution from the dosage form (capsule), stomach emptying, and/or 
partitioning from the fat components of the concomitant high fat meal. 
Model Parameterization 
Absorption and Metabolism in the Gut. Absorption and metabolism of 
pafuramidine/furamidine in the gut have not been characterized extensively in rats and 
humans.  Thus, the relevant kinetic parameters, including the fraction of the dose absorbed 
into enterocytes (fa), the rate constants associated with absorption of pafuramidine or 
furamidine (ka_P or ka_F), and the rate constant associated with metabolic conversion from 
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pafuramidine to furamidine in the gut (kG_P→F) were estimated by fitting the semi-PBPK 
models (Fig. 4.1B) to in vivo rat and human data. 
Tissue Distribution. Tissue-to-perfusate/plasma partition coefficients were 
optimized by fitting relevant PBPK models (Fig. 4.1A and 4.1B) to IPL and in vivo rat data. 
The pafuramidine liver-to-plasma partition coefficient in rats was calculated based on the 
liver-to-perfusate partition coefficient generated from the rat IPL data after correction for the 
5-fold difference in unbound fraction between plasma and perfusate (Table 4.1). Due to the 
lack of human tissue data, tissue partition coefficients and liver binding for 
pafuramidine/furamidine in humans were assumed to be equal to those in rats (Table 4.1).  
Clearances 
Hepatic. Rat hepatic clearance (Clrat_liver) values were derived by fitting the whole-
liver rat model to the rat IPL data. Clrat_liver, which represented metabolic and/or active 
transport capacities, was normalized by a scaling factor (SF) and corrected for liver weight 
(LW) to estimate the human hepatic clearance value: 
Clhuman_liver= Clrat_liver × SF × (LWhuman/LWrat)), 
where SF = Clhuman SCH / Clrat SCH or khuman SCH / krat SCH 
Because biliary Cl of formed furamidine was too small to measure in both rat and human 
SCH, in vivo human biliary Cl was estimated by scaling in vivo rat biliary Cl based on liver 
weight. 
Renal. Furamidine unbound renal clearance from plasma in rat (ClR_rat,u) was 
calculated based on preclinical data in rats administered furamidine intravenously (10 
µmol/kg) (Goldsmith, 2011). In brief, rats (n = 3-7) were sacrificed at designated timepoints 
up to 16 days post furamidine administration, after which kidneys were harvested and 
homogenized; urine was collected at 0-3, 3-6, 6-12, and 12-24 h intervals post furamidine 
administration. ClR_rat,u was calculated by dividing the total amount of furamidine recovered 
in urine from 0-24 h by the area under the concentration-time curve (AUC) in plasma within 
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the same time interval, and was corrected by the unbound fraction of furamidine in plasma 
(Table 4.1). The unbound renal clearance of furamidine from plasma in humans (ClR_human,u; 
l/h/kg) was estimated by the “glomerular filtration rate (GFR) ratio approach” (Lin, 1998): 
ClR_human,u = ClR_rat,u / GFR ratio, where the GFR ratio between rats and humans is 4.8.  
PBPK Modeling and Simulation  
Pharmacokinetic Analysis. PBPK modeling and simulation were performed with 
Berkeley Madonna (v 8.0.2, University of California, Berkeley, CA), a differential equation-
based modeling software program used extensively in the development of PBPK models 
(Rowland et al., 2004). The goodness-of-fit of model simulations was assessed based on 
visual comparison of predicted mass/concentration-time profiles and observed in vivo rat 
and human data. Observed and predicted plasma/tissue concentration-time profiles were 
analyzed for plasma/tissue AUC values and terminal half-lives (t1/2,terminal) of 
pafuramidine/furamidine by non-compartmental analysis using WinNonlin (v 5.0.1, Pharsight 
Corp., Mountain View, CA).   
Prediction of Dose-Exposure Relationship.  Furamidine plasma concentration-
time profiles were simulated under different multiple-dose regimens based on the single-
dose human semi-PBPK model (Fig. 4.1B). The efficacy and safety indices of furamidine 
were defined by a minimum effective concentration (Ceff,min) and a hypothetical no 
observable adverse effect level (NOAEL), respectively. Selection of an optimal multiple-dose 
regimen of pafuramidine was based on the assumption that furamidine concentrations in 
plasma must be above Ceff,min at least 80% of the time during the dosing interval, whereas 
the average steady-state and maximum concentrations in plasma (Css,ave and Css,max) must 
be less than the NOAEL. Ceff,min was determined based on an in vitro 50% inhibitory 
concentration (IC50; 1 ng/ml ≈ 3 nM) of furamidine against the Trypanosoma brucei 
rhodesiense strain, STIB900 (Wenzler et al., 2009). This trypanosome strain is used 
routinely at the Swiss Tropical and Public Health Institute to assess in vitro and in vivo 
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activity of diamidine compounds (Ismail et al., 2005). The IC50, determined with culture 
medium containing 15% heat-inactivated horse serum, was converted to Ceff,min based on 
the following assumptions: 1) no species differences in plasma binding (fu,p_F = 25%, Table 
4.1); 2) binding in 15% horse serum (fu,ser_F) approximated that in rat perfusate (fu,per_F), 
which consisted of 20% rat blood; that is, fu,ser_F = fu,per_F = 44% (Table 4.1). Ceff,min for total 
(bound+unbound) furamidine in plasma was corrected to 5 nM (Ceff,min = IC50 x fu,ser_F / fu,p_F = 
3 nM x 44% / 25% = 5 nM). The NOAEL has not been determined for furamidine. A 
concentration of 100 nM, which is 20% less than the predicted Css,ave under the dosage 
regimen used in the expanded Phase I safety study (100 mg twice daily for 14 days), was 
selected to define the NOAEL.  Dose safety was evaluated by comparing the furamidine 
concentrations in plasma with the hypothetical NOAEL, and comparing furamidine exposure 
in liver between the clinically-used and semi-PBPK model-predicted dosage regimens. 
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D.        RESULTS 
Whole-Liver Rat PBPK Model Prediction. The disposition of pafuramidine and 
furamidine in rat IPLs was characterized in a previous study (Yan et al., 2011). In summary, 
pafuramidine was taken up by IPLs and eliminated primarily by metabolism, with negligible 
biliary excretion; at the end of the 2-h perfusion, >98% of total formed furamidine was 
recovered in the liver.  Pafuramidine distribution between perfusate and liver reached 
equilibrium after ~20 min. The liver-to-perfusate partition coefficient for pafuramidine, 
generated based on the whole-liver model (Fig. 4.1A), was 70 (Table 4.1). Pafuramidine 
was highly bound to proteins in plasma, perfusate (composed of 20% blood), and liver tissue 
(Table 4.1), whereas furamidine was highly bound only to liver tissue.  The unbound fraction 
of furamidine in liver (fu,L_F) was at least 80-fold lower than that in plasma (fu,p_F) and 
perfusate (fu,per_F) (Table 4.1). The hepatic unbound intrinsic formation clearance of 
furamidine (ClL_P→F, u) accounted for approximately one-third of total hepatic unbound 
intrinsic clearance of pafuramidine (ClL_P→F, u + ClL_P→M, u) (Table 4.1). The unbound intrinsic 
clearance for furamidine hepatic basolateral reuptake (ClF_up, u) was 24-fold higher than that 
for basolateral efflux (ClF_eff, u) (Table 4.1), whereas the unbound intrinsic clearance for 
furamidine biliary excretion (ClF_bile, u) was similar to ClF_eff, u (Table 4.1).  
Disposition of Pafuramidine and Furamidine in Rat and Human Sandwich-
Cultured Hepatocytes. The disappearance of pafuramidine from medium was faster in 
human compared to rat SCH (Fig. 4.2), as reflected by the 3-fold higher intrinsic clearance 
of pafuramidine in human compared to rat SCH (Table 4.2). Disposition profiles of formed 
furamidine were similar between rat and human SCH (Fig. 4.2). The kinetic parameters 
associated with pafuramidine and furamidine hepatic disposition in rat and human SCH 
were derived from a previously developed compartmental model (Yan et al., 2011). The rate 
constants for furamidine basolateral efflux were similar between rats and humans, whereas 
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the rate constant for furamidine basolateral reuptake in human SCH was three-fourths of 
that in rat SCH (Table 4.2). Furamidine was not detected in bile in both rat and human SCH. 
Disposition of Pafuramidine and Furamidine in Rats. Pafuramidine was absorbed 
and metabolized to furamidine rapidly after oral administration; both compounds in plasma 
reached a maximum concentration at ~1 h and declined approximately in parallel for up to 
12 h (Fig. 4.3A, inset). The apparent terminal half-life (t1/2,app) of pafuramidine, based on the 
0-12 h plasma concentration-time profile, was similar to that of furamidine (4 h).  
Whole-Body Rat Semi-PBPK Model Prediction. Physiologic and pafuramidine- 
and furamidine-specific parameters (Table 4.1) were utilized to develop the rat semi-PBPK 
model (Fig. 4.1B). Pafuramidine and furamidine hepatic disposition parameters were 
obtained from the rat whole-liver model (Fig. 4.1A). The partition coefficient of pafuramidine 
in fat was much higher than that in other tissues, which could be due to the high lipophilicity 
(Zhou et al., 2002; Andersen et al., 2008). Based on previous data from rats administered 
preformed furamidine intravenously, the furamidine kidney-to-plasma partition coefficient 
was estimated to be as high as 4000 (Table 4.1); the renal clearance of furamidine from 
plasma (ClF_renal,u) in rats was approximately 3-fold less than GFR (Table 4.1) (Goldsmith, 
2011). The rate constant for pafuramidine absorption (ka_P) was 7-fold higher than that for 
metabolic conversion of pafuramidine to furamidine in the gut (kG_P→F). The overall fraction 
of furamidine formed from pafuramidine in the rat was about 40%, of which the liver 
contributed approximately twice as much as the gut (Table 4.3). The semi-PBPK model (Fig. 
4.1B) adequately described pafuramidine/furamidine disposition observed in plasma up to 
12 h (Fig. 4.3A, inset). Based on model predictions through 360 h, the terminal elimination 
half-lives (t1/2,terminal) of both pafuramidine and furamidine were at least 10-fold longer than 
those measured from the 0-12 h observed in vivo data (t1/2,app); t1/2,terminal of furamidine was 
~4-fold longer than that of pafuramidine (170 versus 47 h) (Fig. 4.3A). The semi-PBPK 
model predicted that liver and kidney accumulation of furamidine was extensive, accounting 
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for 63 and 32% of total formed at 12 h, respectively; ~1% of furamidine was recovered in 
plasma at 12 h. Furamidine exposure in liver and kidney reached a maximum at ~24 h (Fig. 
4.3B), and then declined in parallel with that in plasma (Fig. 4.3A). Furamidine was 
eliminated in rat primarily by biliary excretion; renal excretion was <10% (Table 4.3 and Fig. 
4.3B).  
Disposition of Pafuramidine and Furamidine in Humans. Following oral 
administration, pafuramidine was detected in plasma at 0.5 h in five of the six subjects. 
Pafuramidine concentrations increased to maximum values between 1.5-4 h (median Tmax = 2.8 
h). Pafuramidine concentrations declined, with apparent terminal half-lives of 4-46 h (harmonic 
mean t1/2,app = 11.5 h). Furamidine was not consistently detected in plasma until 2 h after 
pafuramidine administration and increased to a maximum concentration between 4-10 h 
(median Tmax = 6 h).  Furamidine concentrations declined, with a harmonic mean half-life (t1/2,app) 
of 14.5 h. Both pafuramidine and furamidine were above the limit of quantification (BLQ) in 
plasma of all subjects up to 24 h post-administration. Within 168 h of dosing (during which 
complete collections of excreta were available), the major route of elimination of radioactivity 
was via feces (a mean of 36% of the dose, primarily as furamidine, and one of the intermediate 
metabolites, M3), with a mean of 13% of the dose eliminated in urine (primarily as M3). 
Extrapolations of the data available after 168 h indicated that about 13% and 39% of the dose (a 
total of 52%) would be eliminated in urine and feces, respectively.  
Whole-Body Human Semi-PBPK Model Prediction. Physiologic and 
pafuramidine/furamidine-specific parameters (Table 4.1) were utilized to develop the human 
semi-PBPK model. No significant difference in plasma binding of pafuramidine and 
furamidine was observed between rats and humans (Table 4.1). Pafuramidine/furamidine 
hepatic clearance values in humans were predicted by scaling the corresponding in vivo rat 
values normalized by scaling factors derived from rat and human SCH studies, as described 
in Materials and Methods. Similar to rats, the renal clearance of furamidine from plasma 
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(ClF_renal,u), estimated by the GFR approach, was approximately 3-fold less than GFR (Table 
4.1). Because a one-compartment oral absorption model failed to predict the delayed 
absorption of pafuramidine, transit compartments were added to the human semi-PBPK 
model (Fig. 4.1B).  The rate constants for pafuramidine absorption along the transit 
compartments (kP_12, kP_23, kP_3g) were similar (Table 4.1); the rate constant for pafuramidine 
absorption from gut to liver (ka_P) was comparable to kP_12, kP_23, and kP_3g, but was 5-fold 
higher than that for furamidine absorption (ka_F) (Table 4.1); the rate constant for metabolic 
conversion of pafuramidine to furamidine in the gut (kG_P→F) was approximately 4-fold lower 
than ka_P (Table 4.1). The overall fraction of furamidine generated from pafuramidine in the 
gut and liver was about 50%; similar to rats, the contribution by the liver was higher than that 
by the gut (Table 4.3). Model predictions, based on the scheme depicted in Fig. 4.1B, 
adequately described pafuramidine and furamidine disposition observed in plasma up to 24 
h (Fig 4.4A, inset). Prolonged (up to 240 h) predictions indicated that the t1/2,terminal of both 
pafuramidine and furamidine were 1.5- and 4-fold longer, respectively, than those measured 
from the 24-h observed in vivo data; the t1/2,terminal of furamidine was ~3-fold longer than that 
of pafuramidine (64 versus 19 h) (Fig. 4.4A). Similar to rats, the semi-PBPK model for 
human disposition predicted that the liver and kidney are the major organs for furamidine 
accumulation. Furamidine distribution between tissues (liver, kidney) and plasma reached 
equilibrium after ~36 h, as reflected by the parallel terminal plasma concentration- and 
tissue mass-time profiles (Fig. 4.4A and 4.4B). Furamidine was eliminated in humans 
primarily by biliary excretion; renal excretion was negligible (Table 4.3 and Fig. 4.4B).  
Prediction of Dose-Exposure Relationship.  The human semi-PBPK model (Fig. 
4.1B) was used to simulate plasma- and liver-time profiles associated with various 
pafuramidine oral dosing regimens. Based on the pre-defined hypothetical efficacy and 
safety indices, a regimen (40 mg once daily for 14 days) that maintained furamidine plasma 
concentrations above the Ceff,min for ~99% of the time throughout the 14 days was selected 
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(Fig. 4.5). Based on the predicted plasma t1/2,terminal of furamidine, plasma concentrations of 
furamidine reached steady-state at approximately 12-13 days; Css,ave  was approximately 4-
fold higher than the Ceff,min and was 4-fold lower than the hypothetical NOAEL (Fig. 4.5). 
Predicted furamidine liver exposure, expressed as the area under the liver concentration-
time curve (AUC0-14 d), was 5-fold lower with this alternate dosage regimen compared to the 
dosage regimen administered in the expanded Phase I safety study (100 mg twice daily for 
14 days) (Fig. 4.5). 
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E.        DISCUSSION 
Accurate prediction of the pharmacokinetics of generated active metabolites in 
humans is essential in the selection of appropriate prodrug doses prior to clinical trials.  
Pafuramidine is a prodrug of the antiparasitic agent, furamidine, that demonstrated efficacy 
in animal models of first stage human African trypanosomiasis (Mdachi et al., 2009; Wenzler 
et al., 2009). Dose selection for antiparasitic drug development traditionally has relied on 
achieving efficacious plasma drug concentrations in humans that correlate with those in 
animal models.  A similar strategy was applied to pafuramidine, only plasma concentrations 
of furamidine were correlated between species.  The current work represents the first 
attempt to optimize this prodrug dose-selection strategy using whole-body semi-PBPK 
models for rats and humans to predict plasma and tissue exposure and excretion profiles of 
the active metabolite. Preclinical and clinical data generated during pafuramidine 
development were used as a training set to demonstrate the utility of PBPK modeling to 
examine the relationship between pafuramidine dose and furamidine plasma/tissue 
exposure, which could be used to guide clinical dose-ranging studies of next-in-class 
compounds.  
The final model structure and pafuramidine absorption characteristics in rats were 
used initially to predict pafuramidine and furamidine disposition in humans. However, the 
model prediction underestimated the Cmax and Tmax of pafuramidine and furamidine, which 
possibly could be attributed to differences in dosage formulation (suspension versus 
capsule) and/or concomitant diet (standard versus high fat meal) between rats and humans. 
Either or both of these factors could extend the Tmax of pafuramidine in humans. As such, 
three transit compartments were added sequentially to the pafuramidine human submodel to 
describe the dissociation of pafuramidine from the dosage form and the high fat meal before 
reaching the absorption site (gut). Pafuramidine is a BCS class II compound (Zhou et al., 
2002); the high fat meal was administered intentionally to facilitate pafuramidine absorption 
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(Wu and Benet, 2005). This food effect was substantiated by the enhanced fa estimated 
from the human compared to the rat semi-PBPK model (Table 4.1). These observations 
emphasized that formulation/diet may be significant determinants of 
pafuramidine/furamidine disposition. 
Tissue-to-plasma partitioning (Kp) is another factor that influences the disposition of 
compounds in the body. The in vivo Kp values for pafuramidine and furamidine were not 
available for human tissues. Unbound Kp values in rats and humans were assumed to be 
similar (Kp,u,rat = Kp,u,human) (Arundel, 1997). Because no significant species difference in 
plasma binding of pafuramidine/furamidine was observed (Table 4.1), Kp values derived from 
the rat model were applied to describe the distribution of pafuramidine/furamidine in humans.  
Extrapolation of metabolite kinetics from animals to humans remains a major 
challenge in PBPK modeling. Disposition of furamidine in the liver involves formation from 
pafuramidine, hepatocellular binding, basolateral efflux/reuptake, and biliary excretion. 
Empirical allometric scaling and physiologically-based direct scaling were not utilized for the 
following reasons: 1) marked species differences in pafuramidine metabolism (Table 4.2); 2) 
physiologically-based direct scaling using rat SCH underestimated metabolic Cl of 
pafuramidine in rat IPLs; and 3) in vitro biliary Cl of furamidine was too small to measure in 
rat and human SCH (Table 4.2) (Yan et al., 2011). Normalized scaling via integration of IPL 
and SCH data was utilized in the current work, as this method successfully predicted hepatic 
metabolic Cl of ten extensively metabolized drugs in humans (Lave et al., 1997). In addition, 
incorporation of Cl, predicted by normalized scaling using conventionally-cultured 
hepatocytes, into the PBPK model of an antimalarial drug, epiroprim, provided more 
accurate predictions of epiroprim disposition in humans (Luttringer et al., 2003). SCH, rather 
than conventionally-cultured hepatocytes, were utilized in the current study due to the ability 
to characterize both sinusoidal/biliary transport and metabolism (Swift et al., 2009). The 
human semi-PBPK model, based on these scaled parameters, adequately described 
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pafuramidine/furamidine concentration-time profiles in human plasma and predicted the 
dose-plasma/tissue exposure relationship and excretion profiles (Fig. 4.4). To the authors’ 
knowledge, the current work represents the first effort to extrapolate metabolism/transport 
clearance from rats to humans for a prodrug/active metabolite pair. 
Previous studies in rats and monkeys indicated that pafuramidine has a low oral 
bioavailability (10-20%) (Midgley et al., 2007), suggesting that pafuramidine could undergo 
extensive first-pass biotransformation in the gut, as well as in the liver. One report examined 
pafuramidine metabolism in the gut; the intrinsic formation clearance of the first intermediate 
metabolite (M1) from pafuramidine in human intestinal microsomes was at least 10-fold 
lower than that in human liver microsomes (Wang et al., 2007).  As such, the liver was 
assumed initially to be the sole site of furamidine formation.  However, in vivo studies 
showed a near-simultaneous appearance of furamidine with pafuramidine in plasma in both 
rats and humans (Fig. 4.3A and 4.4A, insets). Initial model predictions showed a marked 
delay in the appearance of furamidine relative to pafuramidine. This discrepancy suggested 
that furamidine may be formed during pafuramidine absorption through the gut before 
entering the liver. Bioconversion from pafuramidine to furamidine involves sequential 
oxidative and reductive reactions mediated by cytochrome P450 enzymes and cytochrome 
b5/NADH cytochrome b5 reductases (Saulter et al., 2005; Wang et al., 2006). These 
enzymes are expressed in both the liver and gut. Previous studies demonstrated that 
CYP4F, a major catalyst of M1 formation, represented a significant portion of the human 
intestinal P450 “pie” (Wang et al., 2007). These observations prompted incorporation of a 
gut compartment, representing furamidine formation during pafuramidine absorption, in the 
furamidine rat/human submodel (Fig. 4.1B). The model described furamidine plasma 
disposition adequately (Fig. 4.3A and 4.4A, insets). Concordant with in vivo observations, 
the model predicted that, once absorbed, pafuramidine was converted efficiently to 
furamidine in rats and humans, as reflected by nearly 50% conversion from pafuramidine; 
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the gut contributed approximately 30-40% to furamidine formation in both species (Table 
4.3). These data suggested that the gut contributes significantly to furamidine formation after 
pafuramidine administration, and substantiated the value of PBPK modeling to uncover 
potentially important biologic determinants of drug disposition. Further studies are warranted 
to confirm that the gut is a major pre-systemic site of furamidine formation following oral 
administration of pafuramidine. 
In rats and humans administered a single oral dose of pafuramidine, the apparent 
terminal half-life (t1/2,app) of furamidine was approximately 4 and 14.5 h, respectively, similar 
to pafuramidine (Fig. 4.3A and 4.4A, insets). However, one week after 14C-pafuramidine 
administration, a considerable amount of radioactivity was retained in rats (Midgley et al., 
2007) and humans (CAO, unpublished observations), largely as furamidine. Due to LC-
MS/MS assay sensitivity limitations in the current study, furamidine was BLQ in plasma 
beyond 8 and 24 h after pafuramidine administration to rats and humans, respectively.  As 
such, the observed plasma profile of furamidine (Fig. 4.3A and 4.4A insets) represents the 
distribution phase.  In the absence of a more sensitive assay, the “true” terminal half-life 
(t1/2,terminal) of furamidine  was predicted using semi-PBPK modeling.  The model predicted 
that furamidine t1/2,terminal in rats was approximately 40-fold longer than t1/2,app (7 d versus 4 h). 
After intravenous administration of preformed furamidine (10 µmol/kg) to rats, furamidine 
was detected in the kidney for up to 16 days. The corresponding kidney t1/2,terminal was 
estimated to be 7 d (Goldsmith, 2011). The human plasma and tissue t1/2,terminal of furamidine 
was predicted to be 64 h (~2.5 d), demonstrating the utility of PBPK modeling to estimate 
long-term plasma and tissue exposure, which may not be possible to measure directly in 
vivo due to analytical sensitivity and/or inaccessibility to sampling sites such as the liver.  
A semi-PBPK modeling approach was used in the current work to examine the 
relationship between dose and plasma/tissue exposure for an antiparasitic prodrug/active 
metabolite pair in humans. The model predicted that the Css,ave of the active metabolite, 
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furamidine, was 25-fold higher than the estimated Ceff,min in plasma (Fig. 4.5) based on the 
dose administered (100 mg twice daily) in the expanded Phase I safety study. An alternate 
dosage regimen (40 mg once daily) was predicted to maintain furamidine plasma 
concentrations half-way between the pre-defined hypothetical efficacy and safety indices 
~99% of the time throughout the entire 14-day dosing period (Fig. 4.5), while reducing 
furamidine hepatic exposure (Fig. 4.5). Model predictions suggested that, if a patient were to 
inadvertently miss or double the projected dose, only modest fluctuations in plasma 
furamidine concentrations within the efficacy-safety range would result. Next-in-class 
compounds in development for both stages of HAT are under investigation (Wenzler et al., 
2009).  This PBPK modeling-based strategy, which requires estimated or known efficacy 
(e.g., Ceff,min) and safety (e.g., NOAEL) indices,  could be applied to next-in-class 
compounds to predict plasma/tissue disposition and guide dose-ranging studies in humans. 
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F.        APPENDIX 
MODEL PARAMETER ABBREVIATIONS 
Doral: oral dose; 
Atissue/compartment: amount in whole organ or compartment; 
AA: amount in arterial blood; 
CA: arterial blood concentration; 
CV: venous blood concentration; 
CVP: venous plasma concentration; 
B/P: blood-to-plasma ratio; 
CVtissue: vascular tissue concentration; 
Ctissue: tissue concentration; 
CO: cardiac output; 
Qtissue: tissue blood flow; 
Vtissue: tissue volume; 
Kp,tissue: tissue-to-plasma partition coefficient 
kP_12, kP_23, kP_3g: first-order rate constants for pafuramidine distribution along the transit 
compartments of gut; 
ka_P and ka_F: first-order rate constants for the movement from gut to liver of pafuramidine 
and formed furamidine, respectively; 
kG_P→F: first-order rate constant for metabolic conversion from pafuramidine to furamidine in 
the gut;   
fu,L, and fu,p: unbound fractions in liver and plasma, respectively; 
ClL_P→F, u: hepatic unbound intrinsic clearance for the formation of furamidine from 
pafuramidine; ClL_P→M, u: hepatic unbound intrinsic clearance for metabolic conversion from 
pafuramidine to other metabolites;  
ClF_up, u: unbound intrinsic clearance for hepatic basolateral uptake of furamidine;  
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ClF_eff, u: unbound intrinsic clearance for hepatic basolateral efflux of furamidine;  
ClF_bile, u: unbound intrinsic clearance for biliary excretion of furamidine;  
ClF_renal, u: unbound renal clearance of furamidine from plasma;  
Rabs_P: rate of pafuramidine movement from gut to liver  
Rabs_F: rate of intestinally-formed furamidine movement from gut to liver 
Rgut formation_F: rate of furamidine formation in the gut; 
Rliver formation_F: rate of furamidine formation in the liver; 
Rliver formation_M: rate of other metabolite formation in the liver; 
Rrenal_F: rate of furamidine renal excretion; 
Rbile_F: rate of furamidine biliary excretion; 
Brown et al., 1997P, pafuramidine; M, other metabolites; F, furamidine. 
Note: The volume of tissue and vascular blood in the liver represents 95% and 5%, 
respectively, of total liver volume (Nong et al., 2008). 
 
HUMAN SEMI-PBPK MODEL EQUATIONS 
Pafuramidine 
Disposition in the gut: 
1) Amount in transit compartment 1 (T1): 
     Single-dose: dAT1/dt = -(kp_12 × AT1) + Doral (t = 0); 
     Multiple-dose: dAT1/dt = -(kp_12 × AT1) + Doral (at the beginning of each dosing 
interval)  
2) Amount in transit compartment 2 (T2): 
      dAT2/dt = (kp_12 × AT1) – (kp_23 × AT2)  
3) Amount in transit compartment 3 (T3): 
      dAT3/dt = (kp_23 × AT2) – (kp_3g × AT3) 
4) Amount in the gut: 
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                 dAgut_P/dt =  (kp_3g × AT3) – Rabs_P – Rgut formation_F 
                 Rabs_P = ka_P × Agut_P 
     Rgut formation_F = kG_P→F × Agut_P 
Disposition in the liver (flow-limited): 
dAliver_P/dt = Qliver × (CAP – CVliver_P) – Rliver formation_F – Rliver formation_M + Rabs_P 
Cliver_P = Aliver_P/Vliver 
CVliver_P = Cliver_P /Kp_liver_P 
Rliver formation_F = Cliver_P × fu,L_P × ClL_P→F, u 
Rliver formation_M = Cliver_P × fu,L_P × ClL_P→M, u 
Disposition in the fat (flow limited): 
            dAfat_P/dt = Qfat × (CAP – CVfat_P)    
Cfat_P = Afat_P/Vfat 
CVfat_P = Cfat_P/Kp_fat_P 
Disposition in the rest of body (rest) (flow limited): 
            dArest_P/dt = Qrest × (CAP – CVrest_P)    
Crest_P = Arest_P/Vrest 
CVrest_P = Crest_P/Kp_rest_P 
Blood and plasma concentration: 
1) Venous blood concentration:  
CVP = (Qliver × CVliver_P + Qfat × CVfat_P + Qrest × CVrest_P)/CO  
            2) Venous plasma concentration: 
                 CVPP = CVP/(B/PP) 
3) Arterial blood concentration:    
dAAP/dt = QC × (CVP – CAP) 
CAP = AAP/Vblood 
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Furamidine 
Disposition in the gut: 
                 dAgut_F/dt =  Rgut formation_F – Rabs_F 
                 Rabs_F = ka_F × Agut_F 
Disposition in the liver (diffusion-limited): 
            1) Liver blood: 
                  dAVliver_F/dt = Qliver × (CAF – CVliver_F) + Rabs_P – Ruptake_F + Refflux_F  
                  CVliver_F = AVliver_F/(0.05 × Vliver)  
             2) Liver tissue: 
dAliver_F/dt = Rliver formation_F + Ruptake_F – Refflux_F – Rbile_F 
Cliver_F = Aliver_F/(0.95 × Vliver) 
Ruptake_F = CVliver_F × fu,p_F × ClF_up, u  
Refflux_F = Cliver_F × fu,L_F × ClF_eff, u 
                  Rbile_F = Cliver_F × fu,L_F × ClF_bile, u 
Disposition in the kidney (flow limited): 
            dAkidney_F/dt = Qkidney × (CAF – CVkidney_F)    
Ckidney_F = Akidney_F/Vkidney 
CVkidney_F = Ckidney_F/Kp,kidney_F 
Disposition in the rest of body (rest) (flow limited): 
            dArest_F/dt = Qrest × (CAF – CVrest_F)    
Crest_F = Arest_F/Vrest 
CVrest_F = Crest_F/Kp,rest_F 
Blood and plasma concentration: 
1) Venous blood concentration:  
CVF = (Qliver × CVliver_F + Qkidney × CVkidney_F + Qrest × CVrest_F)/CO 
            2) Venous plasma concentration: 
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                 CVPF = CVF/(B/PF) 
3) Arterial blood concentration:    
dAAF/dt = QC × (CVF – CAF) – Rrenal_F 
Rrenal_F = CAF × fu,p_F × ClF_renal, u 
CAF = AAF/Vblood 
Urine: 
dAurine_F/dt = Rrenal_F 
            Feces:  
dAfeces_F/dt= Rbile_F 
 
 
  125
G.        TABLES 
Table 4.1. Semi-physiologically-based pharmacokinetic model parameters associated with 
the disposition of pafuramidine and furamidine in rats and humans. 
 
Value Parameters 
Rat Human 
Source 
Physiologic    
Body weight (kg) 0.3 70 Measured  
Cardiac output (l/h/kg) 14 5 Brown et al., 1997 
Blood and tissue volumesa    
Blood 0.074 0.077 Brown et al., 1997 
Fat 0.07 0.2 Brown et al., 1997 
Liver 0.03 0.03 Brown et al., 1997 
Kidney 0.007 0.004 Brown et al., 1997 
Tissue blood flowsa   Brown et al., 1997 
Fat 0.07 0.05 Brown et al., 1997 
Liver 0.17 0.25 Brown et al., 1997 
Kidney 0.14 0.19 Brown et al., 1997 
Rest of body 0.62 0.51 Calculated 
Chemical specific    
Pafuramidine    
Unbound fractions (%)    
Liver (fu,L_P)b 0.07 ± 0.02 Same as rats Measured 
Perfusate (fu,per_P) 1.1 ± 0.1 N.A.c Measured 
Plasma (fu,p_P) 0.2 ± 0.02 0.2 ± 0.01 Measured 
Liver-to-perfusate partition coefficient 70 N.A. Fitted 
Tissue-to-plasma partition coefficients    
Liver  14 Same as rats Calculated 
Fat 260 Same as rats Fitted 
Rest of body  2 Same as rats Fitted 
Blood-to-plasma (B/P) ratiod 1.1 ± 0.1 Same as rats Measured 
Fraction of dose absorbed into 
enterocytes (fa) 
0.3 1 Fitted 
Gastrointestinal rate constants (h-1)e    
kP_12, kP_23, kP_3g  N.A. 1.1 Fitted 
ka_P  0.5 1.1 Fitted 
kG_P→F  0.07 0.3 Fitted 
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Hepatic clearance (l/h/kg BW)f    
ClL_ P→M, u 70 124 
Fitted (Rat) 
Scaled (human) 
ClL_ P→F, u 40 71 
Fitted (Rat) 
Scaled (human) 
Furamidine    
Unbound fractions (%)    
Liver (fu,L_F)b 0.3 ± 0.1 Same as rats Measured 
Perfusate (fu,per_F) 44 ± 5 N.A. Measured 
Plasma (fu,p_F) 24 ± 2 25 ± 3 Measured 
Tissue-to-plasma partition coefficients     
Kidney  4000 Same as rats Fitted 
Rest of body  1 Same as rats Fitted 
Blood-to-plasma (B/P) ratiod 0.9 ± 0.1 Same as rats Measured 
Gastrointestinal rate constants (h-1)e     
ka_F  2.4 0.2 Fitted 
Hepatic and renal clearances (l/h/kg 
BW)e    
ClF_up, u 1.9 1 
Fitted (Rat) 
Scaled (human) 
ClF_eff, u 0.08 0.05 
Fitted (Rat) 
Scaled (human) 
ClF_bile, u 0.08 0.05 
Fitted (Rat) 
Scaled (human) 
ClF_renal, u 0.12 0.024 Calculated 
GFRg  0.4 0.08 Lin, 1998 
aTissue volumes and blood flows denote fractions of total body weight and cardiac output, 
respectively.  
 
bLiver unbound fractions in humans were assumed equal to those in rats. 
cNot applicable. 
 
dB/P ratio of pafuramidine or furamidine at 0.1 µM in rat blood (see Materials and Methods). 
 
eRate constants associated with pafuramidine and furamidine absorption and metabolism in the gut 
are defined in the legend to Fig. 4.1 and were optimized by fitting the semi-PBPK model (schemed 
depicted in Fig. 4.1B) to in vivo rat and human data. 
 
fClearance values associated with the disposition of both pafuramidine and furamidine in rat livers are 
defined in the legend to Fig. 4.1 and were optimized by fitting the semi-PBPK model (schemed 
depicted in Fig. 4.1A) to rat IPL data; corresponding hepatic clearances in humans were calculated as 
described in Methods; furamidine renal clearance in rats was calculated based on in vivo rat data; 
human renal clearance was estimated using a ‘GFR ratio approach’ proposed by Lin, 1998 (see 
Materials and Methods). 
 
gGFR, glomerular filtration rate, was obtained from Lin,1998. 
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Table 4.2. Kinetic parameters associated with disposition of pafuramidine and furamidine in 
rat and human sandwich-cultured hepatocytes (SCH). 
 
Parametera Rat SCH Human SCH Scaling Factorb 
ClL_P→M 0.0047 0.013 3 
ClL_P→F 0.0023 0.0067 3 
kF_up 0.8  0.6 0.75 
kF_eff 0.008  0.008 1 
kF_bilec N.A.d N.A. N.A. 
aClL_P→M and ClL_P→F represent in vitro intrinsic clearance (ml/min/106 cells) for the metabolic 
conversion of pafuramidine to other metabolites and furamidine, respectively. kF_up, kF_eff, and kF_bile 
represent first-order rate constants (h-1) for furamidine hepatic basolateral uptake, efflux and biliary 
excretion, respectively. SCH values denote mean data from n = 3 separate livers. 
 
bDetermined by the ratio of rat-to-human hepatic clearances or rate constants determined with SCH. 
The scaling factor was used to normalize in vivo clearance values from rats prior to scaling to human 
clearance values (see Materials and Methods). 
 
cFuramidine biliary excretion  was undetectable in both rat and human SCH. 
dNot applicable. 
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Table 4.3. PBPK Model prediction of furamidine formation and excretion in rats and humans 
after administration of a single oral dose of pafuramidine (7.5 µmol/kg and 100mg, 
respectively). 
 
Measure Rat Human 
fm (%)a 40 52 
Formation (%)b   
Gut 30 40 
Liver 70 60 
Excretion (%)c   
Bile 93 96 
Urine 7 4 
afm represents the total fraction of pafuramidine converted to furamidine in gut and liver. 
 
bFormation (%) represents percent contribution of gut or liver in furamidine formation. 
 
cPercent excretion was calculated based on the cumulative amount of furamidine excreted in bile or 
urine up to time infinity. 
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Figure 4.1. Semi-PBPK model schemes depicting disposition of pafuramidine and 
furamidine in rat IPLs (A) and in vivo in rats and humans (B). Distinct PBPK structures were 
developed for the prodrug, pafuramidine, and the derived active metabolite, furamidine, and 
linked by liver (and gut) metabolism. Pafuramidine distribution in all tissue compartments 
was assumed to be flow-limited. Furamidine distribution in the liver was described as 
diffusion-limited, as depicted by the dashed line in the liver compartment; furamidine 
distribution in all other tissue compartments was assumed to be flow-limited. Compartments 
T1, T2, and T3 in the dashed square represent three consecutive transit compartments for 
pafuramidine before reaching the absorption site in the gut after oral administration in 
humans, where kP_12, kP_23, kP_3g represent the first-order rate constants for pafuramidine 
distribution along the transit compartments and gut. kG_P→F represents the first-order rate 
constant for metabolic conversion from pafuramidine to furamidine in the gut;  ka_P and ka_F 
represent the first-order rate constants for the movement from gut to liver of pafuramidine 
and formed furamidine, respectively. ClL_P→F, u represents hepatic unbound intrinsic 
clearance for the formation of furamidine from pafuramidine; ClL_P→M, u represents hepatic 
unbound intrinsic clearance for metabolic conversion from pafuramidine to other metabolites; 
ClF_up, u represents unbound intrinsic clearance for hepatic basolateral uptake of furamidine; 
ClF_eff, u represents unbound intrinsic clearance for hepatic basolateral efflux of furamidine; 
ClF_bile, u represents unbound intrinsic clearance for biliary excretion of furamidine; ClF_renal, u 
represents unbound renal clearance of furamidine from plasma. P, pafuramidine; M, other 
metabolites; F, furamidine. 
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Figure 4.2. Disposition of pafuramidine (diamonds) and furamidine (triangles) over 24 h in 
sandwich-cultured hepatocytes (SCH) from (A) rats and (B) humans. Rat SCH data were 
obtained from a previous study (Yan et al., 2011); human SCH data were obtained using a 
similar study design. Pafuramidine (10 µM) was administered as a bolus to each well, which 
contained 1.5 ml culture medium. Symbols and error bars denote mean values and SDs, 
respectively of n=3 livers. Lines represent the computer-generated best fit of a previously 
developed pharmacokinetic model  (Yan et al., 2011) to the data.  
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Figure 4.3.  Disposition of pafuramidine (diamonds) and furamidine (triangles) in rats 
administered a single oral dose of pafuramidine (7.5 µmol/kg). (A) Comparison of observed 
(symbols) and semi-PBPK model-predicted (scheme depicted in Fig. 4.1B) plasma 
concentration-time profiles of pafuramidine and furamidine over 12 h (inset) and 360 h. 
Symbols and error bars denote mean values and SD, respectively, of 4 rats. (B) Semi-PBPK 
model-predicted (scheme depicted in Fig. 4.1B) amount-time profiles of furamidine in 
liver/kidney (solid lines) and bile/urine (dashed lines) over 360 h.  
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Figure 4.4. Disposition of pafuramidine (diamonds) and furamidine (triangles) in healthy 
male subjects administered a single oral dose of 14C-pafuramidine (100 mg, equivalent to 
274 µmol) in capsule form.  (A) Comparison of observed (symbols) and semi-PBPK model-
predicted (scheme depicted in Fig. 4.1B) (lines) plasma concentration-time profiles of 
pafuramidine and furamidine over 24 h (inset) and 240 h.  Symbols and error bars denote 
mean values and SD, respectively, of 6 subjects. (B) Semi-PBPK model-predicted (scheme 
depicted in Fig. 4.1B) amount versus time profiles of furamidine in liver/kidney (solid lines) 
and bile/urine (dashed lines) over 240 h. 
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Figure 4.5. Semi-PBPK model-predicted (scheme depicted in Fig. 4.1B) plasma and liver 
concentration-time profiles of furamidine in humans following oral administration of 100 mg 
pafuramidine twice daily (gray lines) and 40 mg pafuramidine once daily (black lines). Dotted 
and dashed lines represent safety and efficacy indices defined by a hypothetical no-
observable-adverse-effect-level (NOAEL) and a minimum effective concentration (Ceff,min) of 
furamidine in plasma, respectively. NOAEL and Ceff,min were determined as described in 
Materials and Methods. Time > Ceff,min denotes the time that furamidine concentrations in 
plasma were above the Ceff,min as a percentage of the entire dosing period (14 days); Css,ave 
denotes average plasma concentration of furamidine at steady-state; “AUC0-14d ↓ 5x” 
denotes liver exposure of furamidine, expressed as the area under the liver concentration-
time curve (AUC0-14 d), which was 5-fold lower with the modified pafuramidine dosage 
regimen (40 mg once daily) compared to the dosage regimen administered in the expanded 
Phase I safety study (100 mg twice daily). 
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A. SUMMARY AND DISCUSSION 
An important objective in drug development is to identify the concentration/exposure 
range that provides the optimal benefit-to-risk ratio. An inadequate dose will result in 
ineffective therapy; an excessive dose will lead to unacceptable toxicity, which may prevent 
further development of a promising drug candidate. The clinical response (pharmacological 
and toxic effects) is a function of the dose.  Thus, selection of appropriate dosage regimens 
for clinical trials is the key to successful transition of preclinical drug candidates to clinical 
drug development (Reigner and Blesch, 2002). Accurate prediction of an efficacious and 
safe dose for humans relies on integration of pharmacokinetic/pharmacodynamic data from 
multiple sources, both in vitro and in vivo from animals and humans, using a variety of 
methods and approaches. For this reason, proper selection of validated preclinical models is 
imperative. 
Human African trypanosomiasis (HAT), also called sleeping sickness, is a parasitic 
disease caused by Trypanosoma brucei species; the disease is endemic throughout tropical 
Africa (Barrett, 2010). Almost all of the current chemotherapies for treatment of both first 
(hemolymphatic infection) and second (central nervous system infection) stages of HAT 
were introduced more than half a century ago and require complicated treatment regimens 
via parenteral administration (Fairlamb, 2003). An orally-active agent with a convenient 
dosing regimen would be beneficial in resource-constrained areas of Africa.  
Diamidine prodrugs have exhibited satisfactory oral activity against both stages of 
HAT (Paine et al., 2010). Pafuramidine and CPD-0868 are bis-O-methylamidoxime prodrugs 
of pentamidine analogs, furamidine and CPD-0801, respectively. To date, pafuramidine is 
the first and only orally-active agent that has entered clinical trials (phase I-III) for the 
treatment of first stage infection. However, during an expanded phase I safety study, 
transient elevation of liver transaminases was observed in 25% of subjects five days post 
completion of the dosage regimen of pafuramidine (100 mg twice daily for 14 days), which 
  140
placed pafuramidine program on clinical hold 
(http://www.immtechpharma.com/documents/news_022208.pdf) (Paine et al., 2010). 
Although pafuramidine is no longer under development, lessons learned from pafuramidine 
highlighted the need for an improved understanding of the dose-exposure relationship of 
these orally-active antiparasitic prodrugs. Preclinical studies showed that furamidine 
accumulated extensively in the liver and remained in this organ for a prolonged time 
following a single oral dose of pafuramidine; furamidine concentrations in plasma were lower 
by three orders of magnitude than those in the liver (Midgley et al., 2007). Both pafuramidine 
and furamidine were ineffective in a second stage (CNS) mouse model (Wenzler et al., 
2009). Structural analogs of pafuramidine/furamidine were synthesized and screened in vitro 
and in vivo to identify clinical candidates for the treatment of second stage HAT. To date, the 
most potent analog is CPD-0868, a prodrug of CPD-0801. Despite the structural similarity, 
CPD-0868 demonstrated superior efficacy against second stage infection (Wenzler et al., 
2009), and the systemic exposure of CPD-0801 was higher than that of furamidine in mice 
given the same dose of respective prodrug (Wu et al., 2007).  
Prior to this dissertation research, the mechanism responsible for the large 
differences in tissue and plasma exposure of furamidine, the reason for the improved 
systemic exposure of CPD-0801 compared to furamidine, and the relationship between 
dose of pafuramdine and plasma or tissue exposure of furamidine were unknown. In 
addition, pafuramidine preclinical and clinical studies in pharmacokinetics, efficacy, and 
safety were carried out by different researchers from various laboratories and institutes 
within the Consortium for Parasitic Drug Development (CPDD). Given the large body of 
experimental data obtained from a variety of sources, there was no quantitative strategy for 
leveraging prior knowledge to inform the dose selection of antiparasitic prodrugs. These 
unaddressed but important questions and issues guided the direction of this dissertation 
project. A variety of in vitro, ex vivo, and in vivo models, together with comprehensive 
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pharmacokinetic modeling approaches were utilized to address the following objectives: 1) 
gain a mechanistic understanding of the overall disposition of these antiparasitic prodrugs 
and metabolites; 2) develop a quantitative strategy that allows preclinical data to be 
integrated and combined with historical information from clinical studies to predict the dose-
plasma/exposure relationship in humans. 
 
A.1.    Characterization and Comparison of the Intestinal and Hepatobiliary 
Disposition of Pafuramidine and CPD-0868 and Derived Metabolites in Preclinical 
Models. 
Using a well-established human intestine-derived absorption model, Caco-2 cell 
monolayers, absorption of pafuramidine and CPD-0868 through the intestinal epithelium 
was elucidated. In the absence of serum in the incubation medium, A→B and B→A 
translocation profiles of both pafuramidine and CPD-0868 were nearly superimposable (Fig. 
2.3), corresponding permeability coefficients of both prodrugs in both directions of transport 
were not significantly different, and efflux ratios were near unity (Table 2.1). These 
observations indicated that both prodrugs cross the intestinal epithelium by passive diffusion, 
without involvement of efflux transporters, which was consistent with previous results with 
pafuramidine using a different Caco-2 cell source (Zhou et al., 2002).  
To examine further the difference in the extent of absorption between the two 
prodrugs, the basolateral compartment (representing the blood side) was supplemented with 
4% bovine serum albumin (BSA), to mimic plasma protein binding. Under this more 
physiologically-relevant condition, absorptive (A→B) permeability of pafuramidine increased 
greatly, whereas that of CPD-0868 remained unchanged (Table 2.1). As a consequence, the 
Papp,A→B values of both prodrugs become comparable (Table 2.1). These findings were 
consistent with published observations that the presence of BSA increased the absorptive 
permeability of only highly lipophilic (logP > 3.0) and extensively protein bound (fu < 5%) 
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compounds (Aungst et al., 2000). Regardless of structural similarity, pafuramidine is more 
lipophilic than CPD-0868, as reflected by a 2-fold higher logP (4.0 versus 2.2) and 35-fold 
lower fu in human plasma (0.2 versus 7%).  The results from Chapter 2 suggested that 
plasma protein binding may have a much greater impact on pafuramidine absorption in vivo. 
In addition, comparable permeability coefficients of both prodrugs under “sink” conditions 
suggested that the extent of absorption between pafuramidine and CPD-0868 may be 
similar in vivo. Results presented in Chapter 2 further substantiated Caco-2 cells as a 
valuable screening tool to assess absorption properties of compounds across the intestinal 
epithelium, as well as emphasized the need of application of BSA in the basolateral 
compartment to evaluate more accurately the intestinal permeability of highly lipophilic 
compounds. Moreover, results from this study suggested that the enhanced systemic 
exposure of CPD-0801 compared to furamidine was not due to a higher intestinal 
permeability of the prodrug CPD-0868 compared to pafuramidine. The mechanisms 
underlying the difference in the systemic exposure of respective active metabolites were, 
therefore, investigated further in two well-established hepatic models, isolated perfused 
livers (IPLs) and sandwich-cultured hepatocytes (SCH) from rats, to characterize and 
compare the hepatic disposition of pafuramidine/CPD-0868 and derived metabolites.  
In both rat IPLs and SCH, the disposition profiles of both prodrugs and respective 
derived metabolites were similar (Fig. 3.3 and 3.5), whereas the extent of formation and 
AUC of CPD-0801 in perfusate (IPLs) or medium (SCH) were consistently higher compared 
to furamidine (Fig. 3.4 and Table 3.3). Initial compartmental modeling showed that the net 
basolateral efflux (6-fold difference) played a more important role than metabolism (2-fold 
difference) in the enhanced perfusate/medium exposure of CPD-0801 compared to 
furamidine (Table 3.2, 3.3 and 3.5). In addition, both active metabolites accumulated in the 
liver and hepatocytes at substantially higher concentrations compared to perfusate and 
medium (Fig. 3.3 and 3.5). Nevertheless, in both IPL and SCH, CPD-0801 exhibited less 
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hepatic retention compared to furamidine, as reflected by the 5- to 6-fold lower liver-to-
perfusate and hepatocyte-to-medium partition coefficients (Table 3.3), which substantiated 
SCH as a valuable in vitro tool to predict in vivo liver-to-plasma partitioning. Limited 
perfusate/medium exposure of both active metabolites, relative to liver, led to a subsequent 
investigation of the plasma/perfusate and liver binding properties of these compounds. The 
unbound fractions (fu) of both active metabolites in the liver were much lower (≥24-fold) than 
those in the plasma and perfusate; fu of CPD-0801 in the liver was >5-fold higher than that of 
furamidine (Table 3.3). Assuming that only unbound compound can translocate out of cells 
to the perfusate and bile, liver fu was, therefore, incorporated into the model (scheme 
displayed in Fig. 3.2B), which resulted in comparable rate constants associated with the net 
basolateral efflux of unbound active metabolites. These results provided further evidence 
that the enhanced perfusate/medium exposure of CPD-0801 was attributed largely to the 5-
fold lower hepatic binding compared to furamidine.  
The integrated approach involving two rat hepatic systems (IPLs and SCH) and 
pharmacokinetic modeling provided an improved mechanistic understanding of the impact of 
hepatic binding on the systemic and hepatobiliary exposure of these two antiparasitic active 
metabolites. A higher extent of formation and lower hepatic binding of CPD-0801, compared 
to furamidine (Table 3.3), at least in part, explained the enhanced systemic exposure of 
CPD-0801 (≥2-fold) observed in vivo. In addition, a ~2-fold higher fu in plasma (Table 3.3) 
can result in a further increase (~4-fold) in the systemic exposure of unbound CPD-0801 
compared to furamidine. Assuming only unbound compound can cross the blood brain 
barrier and both active metabolites have the similar membrane permeability, a higher 
systemic exposure of unbound CPD-0801 could lead to an increased brain exposure (~4-
fold) compared to furamidine. Tissue binding studies showed that CPD-0801 has a 
consistently higher fu (≥5-fold) in both liver and kidney than furamidine (Goldsmith, 2011; 
Yan et al., 2011). If the similar trend holds in brain, a much greater (≥one order of magnitude) 
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brain exposure of unbound CPD-0801 can be expected. In vitro studies showed that CPD-
0801 and furamidine had similar trypanocidal potency (Wenzler et al., 2009). Assuming that 
only unbound compound can be taken up by the parasites and both active metabolites have 
similar uptake properties, higher unbound concentrations of CPD-0801 in the brain could 
lead to an enhanced antitrypanosomal effect in the CNS.  The insights gained from this 
study not only supported CPD-0868 as a hopeful orally-active agent for treatment of second 
stage HAT, but also substantiated SCH as a useful tool to study hepatobiliary disposition of 
xenobiotics in preclinical species, and highlighted the potential application of this hepatic 
model in human studies. 
 
A.2.       Prediction of the Dose-Exposure Relationship via Semi-PBPK Modeling 
PBPK modeling takes into account the physiologic, metabolic, and chemical-specific 
parameters to simulate quantitatively the absorption, distribution, metabolism, and excretion 
of a compound under different dosing scenarios (Poulin and Theil, 2002). For this reason, a 
systematic strategy combining preclinical/clinical data and semi-PBPK modeling was 
developed to improve the understanding of the relationship between prodrug dose and 
plasma/tissue exposure of active metabolite using pafuramidine/furamidine as model 
compounds (Chapter 4). Because a large body of in vitro and in vivo data on pafuramidine 
and furamidine disposition was available for rats, the model strategy began with 
development of a whole-body rat semi-PBPK model. The liver is a major site of furamidine 
formation/accumulation in rats.  Thus, a whole-liver semi-PBPK model (scheme depicted in 
Fig. 4.1A) was developed first using the data generated from the rat IPL study (Yan et al., 
2011) to estimate parameters associated with the hepatic disposition of 
pafuramidine/furamidine in rats. The whole-body rat semi-PBPK model (scheme depicted in 
Fig. 4.1B) was developed based on the liver model, with addition of major organs of 
absorption, storage, and elimination for pafuramidine/furamidine. In vivo rat pharmacokinetic 
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data generated in a previous study (Generaux, 2010) were utilized to validate and refine the 
model structure and to optimize associated parameters.  
The whole-body rat semi-PBPK model adequately described the disposition of 
pafuramidine and furamidine in the plasma (Fig. 4.3A), and predicted furamidine disposition 
in key organs (liver and kidney) and excretion profiles (biliary and renal) (Fig. 4.3B). 
Consistent with in vivo results (Midgley et al., 2007; Generaux, 2010), predicted furamidine 
exposure in liver and kidney was much higher than that in plasma by 2-3 orders of 
magnitude (Fig. 4.3A and 4.3B); furamidine was cleared predominately by biliary excretion, 
accounting for >90% of the total excreted, whereas renal excretion played a minor role in 
furamidine elimination (<10%) (Table 4.3 and Fig. 4.3B).  
Upon development of the rat model, efforts focused on building a whole-body human 
semi-PBPK model. Without prior knowledge of pafuramidine/furamidine disposition in 
humans, the same model structure and pafuramidine absorption properties (fa and ka) for 
rats were applied initially to the human model. However, model predictions underestimated 
both Tmax and Cmax of pafuramidine in humans, which may be attributed to the differences in 
the dosage form of pafuramidine (suspension versus capsule), and concomitant diet (regular 
versus high fat meal) between rats and humans. Pafuramidine is a poorly water-soluble 
compound, for this reason, the dosage forms used in the animal studies were often 
prepared as a suspension in DMSO or acidified ethanol containing Tween 80 (Midgley et al., 
2007; Wenzler et al., 2009). The capsules used in human studies may delay the absorption 
of pafuramidine while passing through the intestine due to dissolution from the dosage form, 
causing an increased Tmax. It has been well documented that food and gastrointestinal (GI) 
motility can affect drug absorption (Welling, 1977; Evans, 2000; Jamei et al., 2009). As such, 
patient instructions for drug administration often include a direction to either take with food 
or on an empty stomach. Previous studies showed that food can delay gastric emptying and 
therefore delays absorption of antimicrobial agents, tetracyclines and penicillins (Welling 
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and Tse, 1982).  The extent of absorption of poorly water-soluble but highly lipophilic 
antimicrobial agents, such  as  spironotactone and griseofulvin, was enhanced when 
administered together with a fat-containing meal as compared to with water or in the fasting 
state (Palma et al., 1986). Based on these results, the concomitant high-fat meal also could 
have a significant impact on the rate and extent of absorption of the highly lipophilic 
antiparasitic agent, pafuramidine. 
To account for the formulation and food effect on the absorption of pafuramidine in 
humans, a three transit compartments were added sequentially between site of 
administration (oral route) and absorption (gut) into the pafuramidine human submodel (Fig. 
4.1B), which could represent dissolution from the capsule, gastric emptying, and/or 
partitioning from the fat components of accompanying meal. Model predictions showed that 
addition of these compartments was adequate to describe the delayed appearance of both 
pafuramidine and furamidine in the plasma (Fig. 4.4A). Consistent with previous 
observations on the other lipophilic antimicrobial agents, fa of pafuramidine predicted by the 
semi-PBPK model was near 100% in humans, which was much higher than that in rats 
(~30%). These results highlighted the importance of formulation/diet in the disposition of 
these antiparasitic prodrugs and active metabolites.  
The disposition profiles of pafuramidine/furamidine in SCH from rats and humans 
were similar between these two species. However, pafuramidine was metabolized in human 
SCH more quickly than in rat SCH, as reflected by a 3-fold higher intrinsic clearance (Table 
4.2) and faster appearance of furamidine in the hepatocytes (Fig. 4.2). The rate constant 
associated with reuptake of furamidine in human SCH was 25% lower than that in rat SCH 
(Table 4.2), which resulted in a decreased hepatocyte-to-medium partitioning of furamidine 
(Fig. 4.2). These observations suggested a species difference in the hepatic disposition of 
pafuramidine/furamidine between rats and humans. Traditionally, human clearance values 
have been predicted using empirical allometric scaling and physiologically-based direct 
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scaling from in vitro-derived intrinsic clearance values (Ito and Houston, 2004; Jones et al., 
2006). Allometric scaling, which is empirical in nature, fails to account for differences in 
pharmacokinetics across species (Mahmood, 2000).   Physiologically-based direct scaling 
from in vitro-derived intrinsic clearance values offers a more physiological rationale by 
incorporating blood flow and plasma protein binding, however, this method relies on an 
assumption of liver models (well-stirred, parallel tube, and/or dispersion) selected in the 
scaling process to relate the clearances obtained in vitro to in vivo conditions (Ito and 
Houston, 2004; Ito and Houston, 2005). In addition, scaling directly from in vitro derived 
metabolic clearance often underestimates in vivo values due to decreased enzyme activity 
associated with the in vitro systems (Ito and Houston, 2005). To balance between these two 
methods, normalized scaling, rat clearance determined from IPL data corrected with in vitro 
derived scaling factors, was utilized to account for species differences in the hepatic 
disposition of pafuramidine/furamidine between rats and humans (Fig. 4.2 and Table 4.2). 
To authors’ knowledge, prior to this dissertation project, there have been no reports utilizing 
this approach to extrapolate metabolic and transport clearance values for both parent and 
metabolites from rats to humans. SCH offer significant advantages over conventionally-
cultured hepatocytes, including the ability to characterize both metabolic and 
sinusoidal/biliary transport processes in a single cellular system (Turncliff et al., 2006; Swift 
et al., 2009), and in particular, the ability to predict the biliary clearance (Clbiliary) in humans, 
which remains a challenge in drug development (Abe et al., 2008). The biliary clearance of 
furamidine was too low to measure in rat and human SCH (Table 4.2); however, for 
compounds that exhibit large interspecies differences in biliary excretion, scaling of rat in 
vivo Clbiliary corrected by a scaling factor derived from rat and human SCH could be utilized 
for interspecies extrapolation of Clbiliary. 
Insights from the rat and human semi-PBPK models revealed two major findings: 1) 
the gut may play an important role in pre-systemic furamidine formation. The contribution of 
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the GI tract to the first-pass metabolism of pafuramidine, and the overall formation of 
furamidine, has not been characterized extensively. To date, only one report showed that 
the intrinsic formation clearance for the first intermediate metabolite (M1) from pafuramidine 
in human intestinal microsomes was at least 10-fold lower than that in human liver 
microsomes (Wang et al., 2007). PBPK models, for the first time, predicted that the intestine 
may contribute 30-40% of total furamidine formation from pafuramidine in both rats and 
humans. Corresponding confirmation experiments using appropriate intestinal models are 
warranted and represent a major focus for future studies. 2) The “true” terminal half-life of 
furamidine may be days, rather than hours (Fig. 4.3A and 4.4A). The terminal half-life of 
compounds is an important factor that determines the frequency of dosage regimens.  
However, due to the limitation of analytical assays, plasma concentrations of furamidine 
were not measurable 12 and 24 hours post oral administration of pafuramidine in rats and 
humans, respectively.  Thus, previous studies failed to identify the “true” elimination phase 
of furamidine, resulting in an underestimation of the “true” terminal half-life (t1/2,terminal). The 
semi-PBPK model-predicted plasma t1/2,terminal was verified further based on the measured 
tissue (kidney) t1/2,terminal in rats following IV administration of preformed furamidine, 
assuming the pharmacokinetic behavior did not differ between preformed and generated 
furamidine. The approach demonstrated the ability of PBPK modeling to predict drug 
disposition in plasma and tissue over a prolonged period of time without conducting the 
actual long-term in vivo experiments.  
Previous studies showed that the exposure time may contribute to the more 
pronounced inhibitory effect of another diamidine, pentamidine, against T. b. gambiense in 
vivo, whereas peak concentrations (Cmax) of short duration may be less important (Miezan et 
al., 1994).  As a pentamidine analog, furamidine may exhibit the antiparasitic effect in a 
similar time-dependent manner. The mechanism of pafuramidine-induced transiently 
elevated hepatic transaminases in humans is not known. If hepatic accumulation of 
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furamidine is the cause of this adverse effect, the elevated hepatic signals could be either 
concentration- or time-dependent, or a combination of both. Based on these assumptions, 
the following criteria were utilized in the dose selection for pafuramidine: 1) plasma 
concentrations of furamidine must be above a hypothetical therapeutic index (Ceff,min) >80% 
of the time throughout the dosing period (14 days); 2) average steady-state concentrations 
(Css,ave)  of furamidine must be below a hypothetical safety index (NOAEL). Hepatic 
exposure of furamidine was estimated by the human PBPK model and compared with the 
dosage regimen of 100 mg twice daily used in the expanded safety study. Accordingly, a 
modified dosage regimen of pafuramidine, 40 mg once daily, was predicted via model 
simulations of plasma and tissue concentration-time profiles of furamidine (Fig. 4.5). With 
this alternative daily regimen, plasma concentrations of furamidine could be maintained 
within the pre-defined hypothetical therapeutic-safety window while the hepatic exposure of 
furamidine was reduced by ~5-fold.  
In rats infected with T. b. brucei, furamidine systemic exposure increased markedly 
(up to 3-fold) compared to control animals administered the same oral dose of pafuramidine 
(Generaux, 2010). Simulations based on the IPL compartmental model described in Chapter 
3 (scheme depicted in Fig. 3.2B) showed that the perfusate exposure of furamidine was 
most sensitive to the rate constant associated with net basolateral efflux (a combination 
effect of basolateral uptake and efflux) and liver fu. Furamidine is a potent substrate for an 
uptake transporter, human OCT1, which is localized primarily on the sinusoidal membrane 
of hepatocytes (Ming et al., 2009). Nitric oxide, an inflammatory mediator of immunity, can 
down-regulate OCT1 expression during inflammation and infection (Heemskerk et al., 2008). 
Compromised activity of OCT1 could decrease the reuptake of furamidine after excretion 
from liver to blood, hence, increase systemic exposure of furamidine. As shown in Chapter 3, 
furamidine was highly bound to liver tissues from rats, as reflected by a much lower fu 
compared to plasma (Table 3.3). Based on model simulations, perturbation in tissue binding 
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that leads to a higher fu of furamidine in the liver can cause a proportional increase in 
systemic exposure. Whether infection can decrease the binding capacity of furamidine in the 
liver currently is unknown. However, with the aid of the developed tissue/plasma binding 
assay in this dissertation project, this issue can be addressed by measuring the fu in the liver 
from the infected animals and comparing with that from control animals (Table 3.3). Whether 
trypanosomal infection can alter the pharmacokinetics of pafuramidine/furamidine in humans 
remains unclear. If infection causes a similar effect on the systemic exposure of furamidine 
in humans, a further reduction in the amount and/or frequency of pafuramidine based on 
healthy individuals may be needed for infected patients. 
Significance: This dissertation project, via a quantitative integration of 
preclinical/clinical data with pharmacokinetic modeling/simulation, addressed key issues 
regarding the pharmacokinetics (including the absorption, metabolism, transport, 
plasma/tissue binding, biliary/renal excretion profiles) and the dose-exposure relationship of 
antiparasitic prodrugs and active metabolites. Future directions will include using these 
multifaceted tools and models, coupled with pharmacokinetic modeling/simulation, to predict 
the disposition profiles, and guide dose-ranging studies in humans for next-in-class 
compounds for oral treatment of HAT.  
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B.         FUTURE DIRECTIONS  
 
B.1.       Characterize the Intracellular localization of Active Metabolites in the Liver 
As noted in the current studies, extensive and prolonged hepatic accumulation of 
active metabolites, furamidine and CPD-0801, was observed in both IPLs and SCH from 
rats. Previous studies using centrifugal fractionation showed that furamidine was mainly 
localized in the mitochondrial fraction (Midgley et al., 2007). In the rat IPL study, subcellular 
fractions of liver homogenates (n=1 liver/compound) were collected using a differential 
centrifugation method described previously (Studenberg and Brouwer, 1993). Consistent 
with in vivo observations, furamidine was localized primarily in the mitochondrial fraction 
(43%) in rat IPLs; in contrast, CPD-0801 was localized primarily in the cytosolic fraction 
(45%), with negligible mitochondrial accumulation (≤1%) (Fig. 5.1). These observations 
suggested that the active metabolite formed inside the hepatocyte may not reside in a single 
homogeneous compartment, but may bind to certain intracellular compartments; moreover, 
the difference in intracellular localization could provide a potential mechanism for differences 
in the hepatobiliary disposition as well as hepatotoxic potential of these active metabolites.  
The subcellular localization of active metabolites showed in Fig. 5.1 was only based 
on one liver per compound. The reproducibility of these findings needs to be verified in 
future studies. It is worth noting that there are several concerns associated with the 
fractionation approach including: a) some degree of cross-contamination among isolated 
cellular fractions. Therefore, activity/content of specific organelle markers will need to be 
assessed to define the exact composition and purity of each fraction, i.e., ethidium bromide 
binding (nucleus) assays, marker enzymes of the main organelles, namely, lactate 
dehydrogenase (cytosol), inosine 5’-diphosphatase (plasma and endoplasmic reticulum 
membranes) and succinate dehydrogenase (mitochondria). If contamination is severe in 
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target organelles (e.g. mitochondria), alternative fractionation strategies will need to be 
employed: e.g. subfractionation of cytoplasmic organelles by isopycnic centrifugation in a 
sucrose gradient (Duvvuri et al., 2004); b) potential disruption of binding equilibrium between 
cellular compartments during fractionation procedures. This problem will be more evident for 
drugs that partition into cellular spaces and compartments is primarily via passive diffusion 
driven by the concentration gradient (Duvvuri et al., 2004). The cationic and hydrophilic 
properties of furamidine/CPD-0801, together with in vivo evidence of extensive and 
prolonged accumulation in cellular organelles, suggests that these active metabolites may 
bind to intracellular compartments with high affinity, therefore, the potential diffusion 
between cellular fractions during isolation would be expected to be negligible. 
These diamidine active metabolites are fluorescent compounds, which allows for 
monitoring of the hepatocellular trafficking by fluorescence microscopy. One advantage of 
SCH is that intracellular disposition of fluorescent substrates can be examined by confocal 
imaging (Bow et al., 2008). The experimental procedure is proposed as following: freshly 
isolated rat hepatocytes will be seeded onto collagen-coated 35-mm glass-bottomed culture 
dishes and cultured as described in Chapter 3. On day-4, cells will be incubated with either 
pafuramidine or CPD-0868 (10 µM) over 24 h. The real-time intracellular distribution of 
active metabolites will be imaged with a laser scanning confocal microscope at excitation 
and emission wavelengths of 359 nm and 461 nm, respectively. Using confocal imaging with 
SCH, the dynamic intracellular disposition of fluorescent active metabolites can be 
visualized, which will provide further evidence supporting the results from subcellular 
fractionation study. Furthermore, confocal imaging together with fractionation studies will 
improve our ability to investigate how changes in drug structure influence drug distribution 
within cellular compartments. An understanding of these structure-distribution relationships 
could lead to novel drug design for the treatment of HAT.  
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B.2.    Identify Transport Protein(s) Involved in the Hepatobiliary Disposition of 
Furamidine  
Once formed in the liver, furamidine needs to be excreted to the systemic circulation 
for antiparasitic effect and to the bile for elimination. Given the cationic and hydrophilic 
nature, it is likely that active transporters are involved in the translocation of furamidine from 
hepatocytes to the blood and bile. Pharmacokinetic modeling in both rat IPLs and SCH 
showed that the rate constant for basolateral reuptake were much higher that that for 
basolateral efflux, albeit the large variability associated with the parameter estimates (Fig. 
3.2 and 3.5), indicating that reuptake predominated over efflux in governing the basolateral 
transport of furamidine. Previous studies using stably-transfected Chinese hamster ovary 
(CHO) cells demonstrated that furamidine is a good substrate for human OCT1 (Ming et al., 
2009). OCT1, an uptake transporter localized mainly on the sinusoidal membrane of 
hepatocytes, could be involved in the basolateral reuptake of furamidine in humans. To date, 
little is known with regards to transporters involved in the basolateral and canalicular efflux 
of furamidine in the liver. Previous studies with Caco-2 cells showed that the efflux ratio of 
furamidine was 2.25, suggesting that furamidine may be a substrate for an efflux pump (e.g., 
P-gp) on the apical membrane of Caco-2 cells (Zhou et al., 2002). Ranitidine, also a cationic 
hydrophilic compound, was shown to be a substrate for P-gp and OCT1 (Bourdet et al., 
2005; Bourdet et al., 2006). Pentamidine, a structural analog of furamidine, demonstrated a 
significantly higher (up to 3-fold) brain exposure in P-gp knockout mice compared to control 
animals (Sanderson et al., 2009).  In the same study, coadministration of indomethacin, an 
inhibitor of MRP, increased pentamidine accumulation in choroid plexus of P-gp knockout 
mice; coadministration of adenosine, a nucleoside analog and a substrate for concentrative/ 
equilibrative nucleoside transporters (CNT and ENT) and MRP4/5 (Schuetz et al., 1999; 
Wijnholds et al., 2000; Molina-Arcas et al., 2009), also caused the similar effect (Sanderson 
et al., 2009). Previous studies showed that ENTs, but not CNTs, were expressed on the 
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basolateral membrane of human hepatocytes (Molina-Arcas et al., 2009; Fukuchi et al., 
2010), indicating that CNTs are unlikely to be involved in the furamidine uptake into 
hepatocytes. 4',6-diamidino-2-phenylindole (DAPI), another furamidine analog, was shown 
to be a substrate for hOCT1 and multidrug and toxin extrusion protein 1 (MATE1), which is 
an efflux transporter expressed mainly on the canalicular membrane of hepatocytes and the 
brush border of the renal epithelium (Yasujima et al., 2010). These candidate transporters 
could be responsible for the basolateral (MRP4/5, OCT1, and ENT) and canalicular (P-gp 
and MATE1) transport of furamidine in the liver. Future studies on identification of the role of 
these transporters in the hepatobiliary disposition of furamidine are warranted. Appropriate 
in vitro and in vivo models include, but are not limited to: stably-transfected cell lines (e.g., 
CHO), membrane vesicles, isolated perfused rat livers (in the presence or absence of 
inhibitors), and P-gp/MRP knockout animals.  
 
B.3.      Characterize First-Pass Metabolism of Prodrugs in the Gut 
The PBPK modeling study (Chapter 4) suggested that the gut may contribute 
significantly (30-40%) to furamidine formation in rats and humans following oral 
administration of pafuramidine (Table 4.3). These observations lead to a re-evaluation of the 
role of gut in the observed difference in the systemic exposure of furamidine and CPD-0801. 
Like liver, CPD-0801 may have a greater extent of formation during prodrug (CPD-0868) 
absorption in the gut compared to furamidine, which also could contribute to the enhanced 
systemic exposure of CPD-0801. Additional experiments would be needed to elucidate the 
differential role of the gut and liver in the first-pass metabolism of these prodrugs, and the 
overall formation of respective active metabolites.  
Previous studies showed that formation of a furamidine analog, CPD-0801, was 
negligible when the prodrug, CPD-0868, was incubated with liver microsomes, whereas 
CPD-0801 was detected readily in hepatocytes from both rats and humans (Generaux, 
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2010). In the current study (Chapter 3 and 4), both pafuramidine and CPD-0868 were 
biotransformed efficiently to the respective active metabolites, furamidine and CPD-0801, in 
rat and human SCH (Fig. 3.5 and Fig. 4.2). Phenotyping studies showed that 
biotransformation of pafuramidine/CPD-0868 to furamidine/CPD-0801 requires two enzyme 
systems: cytochrome P450s (CYP4F2/3B and possibly CYP3A4) and cytochrome b5/NADH 
cytochrome b5 reductases (Saulter et al., 2005; Wang et al., 2006). These reductases are 
essential in the final step of furamidine formation (Fig. 1.3) (Saulter et al., 2005).  
Cytochrome b5/NADH cytochrome b5 reductases are localized primarily in microsomes and 
other cellular organelles, including mitochondrial and cytosol (Saulter et al., 2005). In order 
to characterize the pre-systemic formation of furamidine and CPD-0801 in the gut, whole-
cell systems would be required, such as, 1α,25-(OH)2-D3-treated Caco-2 cells, Ussing 
chambers, single-pass perfused intestine from rats, or portal vein-cannulated rats (Fisher et 
al., 1999; Sinko et al., 2004; Masaki et al., 2007; Pang et al., 2008; Clarke, 2009). General 
experimental procedures for selected in vitro and in vivo studies are proposed as following:   
In 1α,25-(OH)2-D3-treated Caco-2 cells, midazolam, a probe substrate for CYP3A, 
showed similar absorption and metabolism characteristics as observed in vivo, which 
substantiated this modified Caco-2 cells as a suitable model system for studying drug 
absorption and first-pass intestinal metabolism (Fisher et al., 1999). For this reason, this 
modified system also could be useful to study the intestinal disposition of these antiparasitic 
prodrugs/active metabolites. Briefly, 1α,25-(OH)2-D3-treated Caco-2 cells will be incubated 
with pafuramidine or CPD-0868. At designated times, apical, cellular, and basolateral 
samples will be collected for quantification of prodrugs and active metabolites. A catenary 
model encompassing the apical, cellular, and basolateral compartments will be developed to 
quantitatively characterize and compare the distribution and intestinal metabolism of 
prodrugs/active metabolites (Fan et al., 2010).  
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For in vivo study, portal and jugular vein cannulated rats will be given a single dose 
of pafuramidine/CPD-0868 by oral gavage.  Blood will be sampled via the portal and jugular 
vein cannulas at designated times over 24 h. Intestine and liver will be harvested and 
homogenized at the end of experiment. Plasma and tissue samples will be analyzed for 
prodrug and derived active metabolites by LC-MS/MS. For prodrugs, portal vein 
concentrations represent the amount of prodrug absorbed across the gut, while 
concentrations in the jugular vein represent the amount of systemically available prodrug. 
Thus, the difference represents the extent of first-pass metabolism of prodrug in the liver. 
For active metabolites, portal vein concentrations represent the amount of active metabolite 
formed during prodrug absorption and escaped from the gut, while concentrations in the 
jugular vein represent the total amount of active metabolite formed and escaped from both 
formation sites (gut and liver). Tissue concentrations present the amount of generated active 
metabolites sequestered in the gut and liver over 24 h. Results from this study will provide 
mechanistic information on the relative contribution of gut and liver to the overall formation 
of these active metabolites.  
 
B.4.      Determine the Therapeutic-Safety Index of the Active Metabolites Furamidine 
and CPD-0801 
Due to the lack of knowledge regarding the dose-exposure relationships, the 
modified dosage regimen of pafuramidine (Chapter 4) was based on a hypothetical NOAEL 
(20% less than the Css,ave achieved with the dosage regimen that caused transiently elevated 
liver transaminases in the clinical trial Fig 4.5). The mechanism of elevated hepatic signals 
and the relationship with the dose of pafuramidine currently are being investigated in rodent 
models. The study results will provide a qualitative or semi-quantitative description of  
site(s), severity, and reversibility of this adverse effect, as well as the dose threshold 
associated with the NOAEL where no overt adverse effects can be observed. Once this 
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maximal-tolerated dose is determined, the rat PBPK model developed in the current study 
(Chapter 4, scheme depicted in Fig. 4.1B) can be utilized to predict the corresponding Css,ave 
of furamidine (NOAEL) via simulations, and hence, the safety margin of furamidine in rats. 
IC50 of furamidine against T.b. brucei strain was determined in the presence of 15% horse 
serum. Because the fu of furamidine in this matrix was unknown, the therapeutic index, 
Ceff,min, was corrected by the fu in perfusate (composed of 20% rat plasma) assuming the 
binding properties of furamidine were similar between the two matrices. In the future study, 
the fu of furamidine in 15% horse serum will need to be determined using the binding assay 
developed in this dissertation project (Chapter 3) to refine further the therapeutic-safety 
window. 
 
B.5.      Apply the PBPK Model-based Strategy to Future Drug Development 
Preclinical safety profiling is built on the assumption that similar drug exposures will 
result in similar preclinical and clinical outcomes. However, species-specific adverse events 
may not be realized until the results of preclinical and clinical studies are compared (Reigner 
and Blesch, 2002). Results from the expanded phase I safety study suggested that humans 
may be more sensitive to pafuramidine-induced elevated hepatic signals than rats and/or 
monkeys. As such, the human equivalent dose for safety will be considered to be the dose 
that leads to furamidine Css,ave similar to the NOAEL in rats corrected by a “sensitivity” factor, 
which adjusts for anticipated differences in sensitivity to pafuramidine between rats and 
humans. Empirically, the maximum starting dose for the first-in-human study is the smallest 
of the following three doses: 1/10 of the NOAEL dose in rodents, 1/6 of the NOAEL dose in 
dogs, or 1/3 of the NOAEL dose in monkeys (Boxenbaum and DiLea, 1995; Mahmood, 
2000). However, one rule cannot apply to all. A more rational and mechanistic approach is 
needed to determine the “sensitivity” factor in a compound-specific manner. Rat SCH have 
demonstrated success in prediction of the hepatotoxicity of trabectedin observed in vivo 
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using lactate dehydrogenase (LDH) as a biomarker (Lee et al., 2008). Similarly, differences 
in the LDH release measured in rat and human SCH could be utilized to estimate the 
“sensitivity” factor, and thus predict a safe dosage regimen for humans. 
In conclusion, the PBPK models developed and the studies proposed in this 
dissertation project can facilitate development of the therapeutic-safety index for future drug 
candidates in the treatment of HAT. With the aid of PBPK modeling, preclinical/clinical data 
on pharmacokinetics, efficacy, and safety can be leveraged quantitatively to guide dose-
ranging studies for next-in-class antiparasitic compounds. As new data from early clinical 
studies become available, the PBPK models can be updated and refined, and guide dose 
selection for later phase II/III trials, allowing for a more precise evaluation of toxicity and 
efficacy. 
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C.         FIGURES 
 
Furamidine CPD-0801
Nuclear, 18%
Mitochondrial, 
43%
Lysosomal, 15%
Microsomal, 4%
Cytosolic, 20% Nuclear, 20%
Mitochondrial, 
1%
Lysosomal, 32%
Microsomal, 2%
Cytosolic, 45%
 
Figure 5.1. Subcellular localization of generated active metabolites, furamidine and CPD-
0801, in rat isolated perfused livers. Prodrug, pafuramidine or CPD-0868 (10 µM) was 
administered as a bolus to the perfusion reservoir. 
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